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A B S T R A C T
Background
Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually
respond to antipsychotics but the cognitive andnegative symptomsof schizophrenia are difficult to treat with conventional antipsychotics
and significantly impact on quality of life and social outcomes. Selective noradrenaline reuptake inhibitors (NRIs) increase prefrontal
dopamine and noradrenaline levels without significantly affecting subcortical dopamine levels, making them an attractive candidate
for treating cognitive and negative symptoms.
Objectives
To investigate the effects of selective noradrenaline reuptake inhibitors (NRIs), compared with a placebo or control treatment, for
people with schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (up to 7 February 2017) which is based on regular searches of
MEDLINE, Embase, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries of clinical trials. There are no language, date,
document type, or publication status limitation for inclusion of records into the register. We inspected references of all included studies
for further relevant studies.
Selection criteria
We included randomised controlled trials (RCTs) comparingNRIswith either a control treatment or placebo for people with schizophre-
nia or related disorders (such as schizoaffective disorder) by any means of diagnosis. We included trials that met our selection criteria
and provided useable information.
Data collection and analysis
We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included
studies. For binary data we calculated risk ratio (RR), for continuous data we calculated mean difference (MD), and for cognitive
outcomes we derived standardised mean difference (SMD) effect sizes, all with 95% confidence intervals (CI) and using a random-
effects model. We assessed risk of bias for the included studies and used the GRADE approach to produce a ’Summary of findings’
table which included our prespecified main outcomes of interest.
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Main results
Searching identified 113 records. We obtained the full text of 48 of these records for closer inspection. Sixteen trials, randomising a
total of 919 participants are included. The majority of trials included adults with schizophrenia or similar illness who were inpatients,
and while they were poorly characterised, most appeared to include patients with a chronic presentation. The intervention NRI in nine
of the 16 trials was reboxetine, with atomoxetine and viloxazine used in the remaining trials. 14 trials compared NRIs with placebo.
Only two trials provided data to compare NRIs against an active control and both compared reboxetine to citalopram but at 4 weeks
and 24 weeks respectively so they could not be combined in a meta-analysis.
One trial was described as ’open’ and we considered it to be at high risk of bias for randomisation and blinding, three trials were at high
risk of bias for attrition, six for reporting, and two for other sources of bias. Our main outcomes of interest were significant response or
improvement in positive/negative mental state, global state and cognitive functioning, average cognitive functioning scores, significant
response or improvement in quality of life and incidence of nausea. All data for main outcomes were short term.
NRIs versus placebo
Mental state results showed significantly greater rates of improvement in negative symptoms scores (1 RCT, n = 50; RR 3.17, 95%
CI 1.52 to 6.58; very low quality evidence) with NRIs on the PANSS negative. No data were reported for significant response or
improvement in positive symptoms, but average endpoint PANSS positive scores were available and showed no difference between
NRIs and placebo (5 RCTs, n = 294; MD −0.16, 95% CI −0.96 to 0.63; low-quality evidence). Improvement in clinical global
status was similar between groups (1 RCT, n = 28; RR 0.99, 95% CI 0.45 to 2.20; very low quality evidence). Significant response
or improvement in cognitive functioning data were not reported. Average composite cognitive scores showed no difference between
NRIs and placebo (4 RCTs, n = 180; SMD 0.04, 95% CI −0.28 to 0.36; low-quality evidence). Significant response or improvement
in quality of life data were not reported, however average endpoint scores from the GQOLI-74 were reported. Those receiving NRIs
had better quality of life scores compared to placebo (1 RCT, n = 114; MD 9.36, 95% CI 7.89 to 10.83; very low quality evidence).
All-cause withdrawals did not differ between the treatment groups (8 RCTs, n = 401, RR 0.94 95% CI 0.63 to 1.39; moderate-quality
evidence). Rates of nausea were not greater with NRIs (3 RCTs, n = 176; RR 0.49, 95% CI 0.10 to 2.41; low-quality evidence).
Authors’ conclusions
Our results provide tentative very low quality evidence that compared to placebo, NRIs (specifically reboxetine) may have a benefit
on the negative symptoms of schizophrenia. Limited evidence also suggests that NRIs have no effect on the positive symptoms of
schizophrenia or cognitive functioning. NRIs appear generally well tolerated with no real differences in adverse effects such as nausea
noted between NRIs and placebo. However, these results are based on short-term follow-up and are poor quality - there is need for
more good-quality evidence. A large RCT of reboxetine over a longer period of time, focusing specifically on negative and cognitive
symptoms as well as more detailed and comprehensive reporting of outcomes, including adverse events, is required.
P L A I N L A N G U A G E S U M M A R Y
Using selective noradrenaline reuptake inhibitors (NRIs) to treat schizophrenia
Review question
Are selective noradrenaline reuptake inhibitors (NRIs) effective for treating the symptoms, particularly the negative symptoms, of
schizophrenia?
Background
People with schizophrenia often have positive symptoms such as hearing voices (hallucinations), bizarre beliefs (delusions), or unclear
thinking (formal thought disorder). These can be treated successfully with antipsychoticmedication. People with schizophrenia also have
negative symptoms such as social withdrawal or lack of motivation and cognitive symptoms such as difficulties making decisions and
problems with attention or memory. Negative symptoms often are long term and reduce quality of life. Unlike the positive symptoms,
there is a lack of effective medications to treat these negative symptoms.
Noradrenaline reuptake inhibitors (such as reboxetine or atomoxetine) are medicines that might help with the negative symptoms of
schizophrenia in particular. There have been trials investigating the effectiveness of NRIs for people with schizophrenia but results
found NRIs had little benefit. However, these were very small studies. We wanted to see whether combining results from all these trials
would provide better-quality evidence.
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Searching and study characteristics
The Information Specialist of Cochrane Schizophrenia searched their specialised register for relevant trials up to February 2017. We
found sixteen trials that could be included. These trials randomised 919 adults with schizophrenia to receive either an NRI, a placebo
(dummy treatment), or an antidepressant. All participants continued to receive the antipsychotic medications they were already taking.
Most trials included participants who were in hospital and who had had symptoms of schizophrenia for a long time.
Key results and quality of the evidence available
Our main areas of interest were the effect NRIs have on improving mental and global state, cognitive functioning and quality of life
for people with schizophrenia; and if NRIs cause unpleasant side-effects such as nausea.
We found that compared to placebo treatment, NRIs (reboxetine in particular) have an effect on improving negative symptoms.
However, we did not find evidence that NRIs have an effect on improving positive symptoms, cognitive functioning or incidence of
nausea. One trial reported a benefit of reboxetine on quality of life scores.
Conclusions
The results of our review should be viewed with caution as the quality of evidence available is very low due to the small size of studies
and poor quality of the trials. In order to make firm conclusions regarding the effectiveness of NRIs for people with schizophrenia we
need larger and better quality trials of NRIs. These should be long term and look particularly at negative and cognitive symptoms as
well as side-effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Select ive noradrenaline reuptake inhibitor (NRI) versus placebo in schizophrenia
Patient or population: adults with schizophrenia
Setting: inpat ient and outpat ient
Intervention: NRI
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with NRI
Mental state: signifi-
cant response or im-
provement in nega-
tive symptoms (PANSS
negative subscale, high
= worse) - short term
(12 weeks)
Study populat ion RR 3.17
(1.52 to 6.58)
50
(1 RCT)
⊕©©©
VERY LOW 12345
Addit ional information
f rom average negat ive
symptoms score was
equivocal
240 per 1000 761 per 1000
(365 to 1000)
Mental state: specific -
average positive symp-
toms score (PANSS
posit ive subscale, high
= worse) - short term (2
to 12 weeks)
- The mean PANSS pos-
it ive score in the inter-
vent ion group was 0.16
less (0.96 less to 0.63
more)
- 294
(5 RCTs)
⊕⊕©©
LOW 1,6
No data reported for our
prespecif ied outcome:
signif icant response or
improvement in posi-
t ive symptoms
SAPS and BPRS posi-
t ive subscale outcomes
showed sim ilar results
Clinical global re-
sponse: significant re-
sponse or improve-
ment in global status
(CGI-S, high = worse) -
short term (4 weeks)
Study populat ion RR 0.99
(0.45 to 2.20)
28
(1 RCT)
⊕©©©
VERY LOW 34579
Addit ional information
f rom average clinical
global status score
found a sim ilar lack of
ef fect
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467 per 1000 462 per 1000
(210 to 1000)
Cognitive functioning:
significant response or
improvement in cogni-
tive functioning
no data reported for this outcome
Cognitive functioning:
average compost ive
endpoint score (SMD,
low = favours NRI) -
short term (2 to 12
weeks)
The mean compos-
ite cognit ive funct ion-
ing SMD in the inter-
vent ion group was 0.
04 standard deviat ions
more (0.28 less to 0.36
more)
- 180
(4 RCTs)
⊕⊕©©
LOW 78
Quality of life: Average
endpoint score (GQOLI-
74, high = better) - short
term (2 to 12 weeks)
- The mean GQOLI-74
score in the interven-
t ion group was 9.36
more (7.89 more to 10.
83 more)
- 114
(1 RCT)
⊕©©©
VERY LOW 1,2,4,5,6
No data reported for
our prespecif ied out-
come of signif icant re-
sponse or improvement
in quality of lif e
Adverse effects: Nau-
sea - short term (2 to 12
weeks)
Study populat ion RR 0.49
(0.10 to 2.41)
176
(3 RCTs)
⊕⊕©©
LOW 5,7
148 per 1000 72 per 1000
(15 to 356)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io; SMD: Standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect5
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Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Imprecision: ’Serious’ - Small sample size - Downgraded by 1 level
2 Risk of bias: ’Serious’ - Methods of random sequence generat ion and allocat ion concealment are poorly described -
Downgraded by 1 level
3 Risk of bias: ’Serious’ - Evidence of select ive report ing bias - Downgraded by 1 level
4 Inconsistency: ’No’ - Only 1 study - Not downgraded
5 Publicat ion bias: ’Strongly suspected’ - Evidence of signif icant relevant unpublished or unusable results - Downgraded by 1
level
6 Indirectness: ’Serious’ - Outcome of interest was not reported so a related outcome was subst ituted as a surrogate -
Downgraded by 1 level
7 Imprecision: ’Serious’ - Small sample size, conf idence intervals include clinically signif icant benef its or harms - Downgraded
by 1 level
8 Risk of bias: ’Serious’ - Includes studies with high risk of attrit ion, report ing, and other sources of bias - Downgraded by 1
level
9 Indirectness: ’Serious’ - Part icipants recruited specif ically with depressive symptoms so unrepresentat ive of most pat ients
with schizophrenia - Downgraded by 1 level
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B A C K G R O U N D
Description of the condition
Schizophrenia is frequently a chronic and disabling illness (Prudo
1987) but it has a variable course and patients present with a het-
erogeneous range of symptoms. These have been grouped into
’positive’ and ’negative’ categories (Crow 1980). Positive symp-
toms include psychotic phenomena such as hallucinations and
delusions, and disorganised features including formal thought dis-
order, bizarre behaviour and inappropriate affect. Negative symp-
toms include affective flattening, lack of speech (alogia), lack of
motivation (avolition) and inability to experience pleasure (anhe-
donia). In addition to the diagnostic symptoms associated with
schizophrenia, it is now clear that it is also accompanied by cogni-
tive deficits, particularly in working memory and attention (Bilder
2000; Weickert 2000). Cognitive and negative symptoms are dif-
ficult to treat with conventional antipsychotics and significantly
impact on quality of life and social outcomes (Goldberg 2007;
Green 1996; Makinen 2008).
Description of the intervention
The selective noradrenaline reuptake inhibitors (NRIs) were orig-
inally designed to specifically inhibit noradrenaline reuptake as
part of the trend towards more selective targeting of antidepressant
action that started with the development of the selective serotonin
reuptake inhibitors (SSRIs) (Lopez-Munoz 2009). The pharma-
cology of NRIs differs from the SSRIs (e.g. fluoxetine) and sero-
tonin-noradrenaline reuptake inhibitors (e.g. venlafaxine) by hav-
ing minimal serotonergic effect.
The twomainNRIs are atomoxetine and reboxetine. Atomoxetine
(as tomoxetine) was originally trialled in the 1980s as an antide-
pressant but development was discontinued by Eli Lilly to focus
on its use in attention deficit hyperactivity disorder (ADHD) for
which it was licensed in the mid-1990s (Preti 2002). Evidence
for an antidepressant effect is largely negative (Fleurence 2009).
Conversely, reboxetine was successfully launched by Pfizer as an
antidepressant in the mid-1990s with claims for similar efficacy to
SSRIs. However, recently it has been suggested that it is in fact less
effective than other antidepressants (Cipriani 2009); and, when
unpublished trials are taken into account, may in fact be no better
(or even harmful) compared with placebo (Eyding 2010).
Reboxetine is used in two divided doses from 8 mg to 12 mg daily
(BNF 2016) with a half-life of around 13 hours and it is primarily
metabolised by the CYP3A4 isozyme of cytochrome P450 (Pfizer
2015). Atomoxetine is used in doses from 40 mg to 120 mg daily
(BNF 2016). It is metabolised by the CYP2D6 isozyme of cy-
tochrome P450 and has a half-life that ranges from 3.6 hours in
extensive metabolisers to 21 hours in poor metabolisers (Eli Lilly
2015). The main side-effects of reboxetine and atomoxetine are
loss of appetite, nausea, agitation, insomnia, dizziness, constipa-
tion, fatigue, dry mouth, sedation, sweating, and palpitations. Re-
boxetine is associated with postural hypotension and atomoxetine
with hypertension. Rare but more serious complications include
liver damage with atomoxetine and suicidal thoughts with both
(BNF 2016).
How the intervention might work
In contrast with other stimulant medication (such as am-
phetamines), NRIs increase prefrontal dopamine without sig-
nificantly affecting subcortical dopamine levels (Bymaster 2002;
Masana 2011; Marcus 2010), which leads to a substantially de-
creased abuse potential (Jasinski 2008). ThismakesNRIs an attrac-
tive candidate for treating schizophrenia, and particularly negative
and cognitive symptoms (Apud 2007b; Friedman 1999; Raedler
2004), since it is thought that subcortical dopamine excess under-
lies positive symptoms (hence the efficacy of dopamine receptor
blockade with antipsychotic medication; Seeman 1975) while rel-
ative prefrontal dopamine deficit is hypothesised to contribute to
negative symptoms and cognitive dysfunction (Knable 1997).
Meta-analyses have concluded that antidepressants used as add-
on therapy show a moderate beneficial effect on negative symp-
toms in schizophrenia (Rummel-Kluge 2006; Singh 2010). Am-
phetamines have potent dopaminergic and noradrenergic activ-
ity and there is some evidence for a beneficial effect on negative
and cognitive symptoms (Daniel 1991; Nolte 2004). In ADHD
(Chamberlain 2007; Faraone 2005) and in animal models (Seu
2009), atomoxetine has been associated with improved cognitive
function.
Why it is important to do this review
Current recommendations for pharmacological management of
negative symptoms in schizophrenia are limited and there are no
strategies recommended for the pharmacological treatment of cog-
nitive symptoms. While there is some evidence of a small benefit
of certain atypical antipsychotics over typical antipsychotics the
effect is small (e.g. an effect size of 0.3 for amisulpride) (Leucht
2009). Augmentation of clozapine can also give some additional
benefit (e.g. an effect size of 0.4 for lamotrigine) (Tiihonen 2009).
However, SSRIs ormirtazapine are usually recommended first-line
for negative symptoms (Barnes 2011; Maudsley 2015). The over-
all benefit of antidepressants on negative symptoms is still quite
small (an effect size of 0.5 overall, 0.4 for fluoxetine specifically)
(Singh 2010) with some evidence of a larger benefit with mirtaza-
pine and mianserin (an effect size of 0.8 to 0.9) (Hecht 2012;
Kishi 2014). The relatively larger benefit of mirtazapine and mi-
anserin is interesting as these drugs act as alpha-2 autoreceptor and
heteroreceptor antagonists promoting efflux of not only serotonin
but also noradrenaline.
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There have been a number of trials of NRIs, both atomoxetine and
reboxetine, as add-on therapy for schizophrenia, all largely negative
in their findings but each underpowered with small sample sizes.
We sought to combine the data from these trials to increase the
power and assess whether the totality of evidence favours the use of
NRIs in schizophrenia, given strong theoretical reasons to suspect
that they would be beneficial for negative and cognitive symptoms
in particular.
O B J E C T I V E S
To investigate the effects of selective noradrenaline reuptake in-
hibitors (NRIs), compared with a placebo or control treatment,
for people with schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. If a trial was described as
’double blind’ but implied randomisation, wewould have included
it in a sensitivity analysis. We excluded quasi-randomised studies,
such as those allocating by alternate days of theweek.Where people
were given additional treatments within a selective noradrenaline
reuptake inhibitor (NRI) trial, we only included data if the adjunct
treatment was evenly distributed between groups and it was only
the NRI treatment that was randomised.
Types of participants
Trials with a majority of participants (≥ 70%) with schizophre-
nia or related disorders (including schizophreniform disorder,
schizoaffective disorder, and delusional disorder, but excluding
bipolar disorder or psychotic depression) by any means of diagno-
sis.
Types of interventions
1. Selective noradrenaline reuptake inhibitor treatment
Defined as treatment with atomoxetine, reboxetine or other NRI
by any dose or mode of administration but for a minimum dura-
tion of one week; most likely as an augmentation strategy but not
excluding studies as monotherapy; excluding non-selective com-
pounds such as those also significantly affecting dopamine or sero-
tonin reuptake.
2. Placebo treatment
Defined as treatment with an inactive compound.
3. Active control treatment
Defined as treatmentwith an active compound other than anNRI.
Types of outcome measures
We grouped the outcomes into brief (less than two weeks), short-
term (two to 12 weeks), medium-term (13 to 26 weeks), and long-
term (over 26 weeks) durations. If outcomes were available for
multiple time-points within the same overall duration we used the
longest duration data (e.g. if there were outcomes for 2 weeks, 4
weeks, and 8 weeks, and 24 weeks then we used the data from
8 weeks when considering the short term and 24 weeks for the
medium term).
Primary outcomes
1. Mental state
Specific significant response or improvement in negative symp-
toms as defined by each study.
2. Cognitive functioning
Significant response or improvement in clinical scale of cognitive
functioning as defined by each study.
3. Quality of life
Significant response or improvement in quality of life as defined
by each study.
4. Clinical global response
Significant response or improvement in clinical global status as
defined by each study.
Secondary outcomes
1. Mental state
1.1 General: significant response or improvement in general/over-
all symptoms as defined by each study
1.2 General: average general/overall symptoms score
1.3 Specific: significant response or improvement in positive symp-
toms as defined by each study
1.4 Specific: average positive symptoms score
1.5 Specific: average negative symptoms score
1.6 Specific: significant response or improvement in mood as de-
fined by each study
8Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.7 Specific: average mood score
1.8 Specific: average score for other symptoms
2. Cognitive functioning
2.1 Average clinical scale of cognitive functioning score
2.2 Significant response or improvement in composite cognitive
functioning
2.3 Average composite cognitive functioning score
2.4 Significant response or improvement in working memory as
defined by each study
2.5 Average working memory score
2.6 Significant response or improvement in reasoning/problem
solving as defined by each study
2.7 Average reasoning/problem solving score
2.8 Significant response or improvement in speed of processing as
defined by each study
2.9 Average speed of processing score
2.10 Significant response or improvement in attention as defined
by each study
2.11 Average attention score
2.12Significant response or improvement in verbal learning/mem-
ory as defined by each study
2.13 Average verbal learning/memory score
2.14 Significant response or improvement in visual learning/mem-
ory as defined by each study
2.15 Average visual learning/memory score
3. Quality of life
3.1 Average quality of life score
4. Clinical global response
4.1 Average clinical global status score
4.2 Relapse as defined by each study
5. Service utilisation outcomes
5.1 Days in hospital
5.2 Admission to hospital
6. Leaving the study early
6.1 for any reason
6.2 due to specific event (e.g. adverse event)
7. Adverse effects
7.1 Death
7.2 General adverse events and side-effects
7.3 Significant extrapyramidal side-effects/movement disorder as
defined by each study
7.4 Average extrapyramidal side-effects/movement disorder score
7.5 Incidence of use of antiparkinson medication
7.6 Cumulative dosage of antiparkinson medication
7.7 Average weight gain
7.8 Significant weight gain as defined by each study
8. Satisfaction with treatment
8.1 Significant improvement in satisfaction with treatment as de-
fined by each study
8.2 Average satisfaction with treatment score
8.3 General impression of carer/other
9. Social or general functioning
9.1 Significant response or improvement in social functioning as
defined by each study
9.2 Average social functioning score
9.3 Occupational status
10. Economic outcomes
11. ’Summary of findings’ table
We have used the GRADE approach to interpret findings (
Schünemann 2008) and usedGRADE profiler (GRADE PRO) to
import data from Review Manager 5 (Review Manager) to create
’Summary of findings’ tables. These tables provide outcome-spe-
cific information concerning the overall quality of evidence from
each included study in the comparison, the magnitude of effect
of the interventions examined, and the sum of available data on
all outcomes we rate as important to patient-care and decision
making. We intended to select the following main outcomes for
inclusion in the ’Summary of findings’ table.
1. Mental state: Specific significant response or improvement
in negative symptoms as defined by each study
2. Mental state: Specific significant response or improvement
in positive symptoms as defined by each study
3. Clinical global response significant response or improvement in
clinical global status as defined by each study
4. Cognitive functioning significant response or improvement
in cognitive functioning as defined by each study
5. Cognitive functioning average composite cognitive function-
ing score
6. Quality of life significant response or improvement in quality
of life as defined by each study
7. Specific adverse effect incidence of nausea as defined by each
study
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Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group’s Trials Register
The Trials Search Coordinator (TSC) searched the Cochrane
Schizophrenia Group’s Registry of Trials (20 August 2014; 17
November 2015; 7 February 2017) using the following search
strategy:
(*atomoxetine* or *attentin* or *beloxepin* or *davedax* or
*edonax* or *edronax* or *esreboxetine* or *FCE 20124* or *FCE
21684* or *LY 139602 * or *LY 139603* or *nisoxetine* or *nore-
box* or *Org 4428* or *prolift* or *reboxetine* or *solvex* or
*SPN 812* or *strattera* or *talopram* or *talsupram* or *tomox-
etin* or *vestra* or *NRI* or *noradrenaline reuptake* or *nore-
pinephrine reuptake*) in Title, Abstract and Keyword Fields of
REFERENCE and Intervention Field of Study
In such study-based registers, searching themajor concept retrieves
all the synonyms and relevant studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics (Shokraneh 2017).
This register is compiled by systematic searches of major resources
(AMED, BIOSIS, CINAHL, ClinicalTrials.Gov, Embase, MED-
LINE, PsycINFO, PubMed, WHO ICTRP) and their monthly
updates; ProQuest Dissertations and Theses A&I and its quar-
terly update; Chinese databases (CBM, CNKI, andWanfang) and
their annual updates; handsearches; grey literature; and conference
proceedings (see Group’s Module). There are no language, date,
document type, or publication status limitations for inclusion of
records in the register.
For previous searches, see Appendix 1.
Searching other resources
1. Reference searching
We inspected references of all identified studies for further relevant
studies.
2. Personal contact
We attempted to contact the corresponding author of each in-
cluded study for information regarding unpublished trials.
Data collection and analysis
Selection of studies
Two authors (PM and JH) independently inspected citations from
the searches and identified relevant abstracts. We obtained full
reports of the abstracts meeting the review criteria or references/
abstracts that authors disagreed on; and both review authors in-
spected them.We would have contacted the authors of studies for
clarification if it had not been possible to resolve disagreement by
discussion.
Data extraction and management
1. Extraction
Two review authors (PM and MP) independently extracted data
from all included studies, discussed any disagreement and doc-
umented decisions. We extracted data presented only in graphs
and figures whenever possible, but included only if both review
authors independently had the same result. We made attempts to
contact authors through an open-ended request in order to ob-
tain missing information or for clarification whenever necessary.
If studies were multicentre we attempted to extract data relevant
to each component centre separately.
2. Management
2.1 Forms
We extracted data onto standard, simple forms. Information in-
cluded relevant study details including trial intervention (e.g. ato-
moxetine), participant numbers and diagnoses (including clinical
subgroups and illness duration), baseline symptom severity (and
differences between arms), demographics (age, sex), medication
(concomitant antipsychotic, NRI dosage), trial duration, outcome
measures, and trial quality. Baseline severity was estimated based
on Clinical Global Impression (CGI) descriptors (Guy 1976);
and utilising correlations between other measures and the CGI
when the latter was not reported (Leucht 2005b; Levine 2013;
Rabinowitz 2006).
2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument had not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly, and noted
in Description of studies if this was the case or not.
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2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint) which can be difficult in un-
stable and difficult-to-measure conditions such as schizophrenia.
We decided to preferentially use endpoint data if both endpoint
and change data were available, if the standard deviation (SD) of
end scores needed to be imputed but the SD for change scores was
available then we used the latter in order to minimise the use of
imputation. We combined endpoint and change data from differ-
ent trials in analyses using mean differences (MD) where possible.
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards
to relevant data before inclusion.
a) Standard deviations (SDs) andmeans were reported in the paper
or obtainable from the authors (this is not possible if the SD is
imputed).
b) When a scale starts from the finite number zero, the SD, when
multiplied by two, is less than the mean (as otherwise the mean is
unlikely to be an appropriate measure of the centre of the distri-
bution (Altman 1996)).
c) If a scale started from a positive value (such as the Positive and
Negative Syndrome Scale, PANSS, which can have values from
30 to 210), we modified the calculation described above to take
the scale starting point into account. In these cases skew is present
if 2SD > (S − Smin), where S is the mean score and Smin is the
minimum score. Endpoint scores on scales often have a finite start
and end point and these rules can be applied. When continuous
data are presented on a scale that includes a possibility of negative
values (such as change data), it is difficult to tell whether data are
skewed or not. Skewed data pose less of a problem when looking
at means if the sample size is large and would have been entered
into syntheses. We entered skewed endpoint data from studies of
less than 200 participants as Additional tables rather than into
analyses.
Although we could not determine whether change scores were
skewedwe attempted to calculate endpoint scores from thesewhere
possible and assessed these for evidence of skew. While using the
associated change scores rather than endpoint scores could correct
the skew it was not possible to test this so we performed a sensi-
tivity analysis where we excluded those change scores which were
associated with skewed endpoint scores.
2.5 Common measure
To facilitate comparison between trials, we converted variables that
could be reported in different metrics, such as days in hospital
(mean days per year, per week or per month) to a common metric
(e.g. mean days per month).
2.6 Conversion of continuous to binary
We made efforts to convert outcome measures to dichotomous
data where sufficient information was available. This can be done
by identifying cut-off points on rating scales and dividing par-
ticipants accordingly into ’clinically improved’ or ’not clinically
improved’. It is generally assumed that if there is a 50% reduc-
tion in a scale-derived score such as the Brief Psychiatric Rating
Scale (BPRS, Overall 1962) or the PANSS (Kay 1986), this could
be considered as a clinically significant response (Leucht 2005a;
Leucht 2005b). If data based on these thresholds were not avail-
able, we used the primary cut-off presented by the original au-
thors. We did not use methods to estimate dichotomous outcomes
directly from summary statistics (mean and SD) of continuous
data. Even if we had been able to convert continuous data to di-
chotomous data, we would also have analysed the continuous data
separately as it provides additional, complementary information
to dichotomous data.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
NRIs.Where keeping to this made it impossible to avoid outcome
titles with clumsy double-negatives (e.g. ’Not un-improved’) we
reported data where the left of the line indicates an unfavourable
outcome and noted this in the relevant graphs.
2.8 Composite cognitive scores
We used composite scores for cognitive functioning as defined in
each study. If composite scores were not reported directly then
we calculated these as the mean of the individual effect sizes of
outcomes presented in that study where possible (after Wykes
2011).
Assessment of risk of bias in included studies
Again, two review authors (PM and MP) worked independently
to assess risk of bias by using criteria described in the Cochrane
Handbook for Systematic Reviews of Interventions to assess trial qual-
ity (Higgins 2011). This set of criteria is based on evidence of
associations between overestimate of effect and high risk of bias of
the article such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
If the raters disagreed, they made the final rating decision by con-
sensus.Where inadequate details of randomisation and other char-
acteristics of trials were provided, we contacted authors of the stud-
ies in order to obtain further information. We report non-concur-
rence in quality assessment , but if disputes arose as to which cat-
egory a trial was to be allocated, again we resolved by discussion.
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The level of risk of bias is noted in both the text of the review and
in the Summary of findings for the main comparison.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive than odds ratios (Boissel 1999);
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). Further illustrative comparative risks are found in
the Summary of findings for the main comparison.
2. Continuous data
For continuous outcomes we estimatedmean difference (MD) be-
tween groups where possible. However, we were particularly inter-
ested in measures of cognitive function and traditionally a number
of different tests have been used tomeasure each cognitive domain.
Frequently these are only really interpretable, or meaningful, when
normalised. Therefore, we used effect size measures (standardised
mean difference, SMD) to combine all tests reported by a study
that measure the same cognitive domain and also to calculate an
overall composite cognitive score for that study.
We pooled the SMD effect size measures using generic inverse
variance. Themean effect size approach does not take into account
covariation and therefore leads to conservative estimates (Wykes
2011) and we included effect sizes calculated this way in a sensi-
tivity analysis. We have interpreted these estimates of composite
effect size cautiously and would have contrasted them with out-
comes derived from individual cognitive tests if available. When
effect sizes are relatively homogeneous (as would reasonably be as-
sumed for tests measuring the same cognitive domain), the simple
mean is a suitable estimate even without taking into account the
covariance structure (Marin-Martinez 1999).
We have drawn our cognitive domains of interest in schizophrenia
from the MATRICS-NIMH review and assigned cognitive tests
to domains as outlined in that paper (Nuechterlein 2004). For
cognitive function scores which are not covered in Nuechterlein
2004 we referred to the primary literature to assign the best fitting
cognitive domain (if any).We understand that there are significant
assumptions involved in combining different outcomes scales as
SMD (Higgins 2011); and we have interpreted this cautiously and
only used the SMDwhere there is not a substantial level of hetero-
geneity (see Subgroup analysis and investigation of heterogeneity).
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error whereby P values are spuriously low, confidence
intervals unduly narrow and statistical significance overestimated
(Divine 1992). This causes type I errors (Bland 1997; Gulliford
1999).
If clustering had not been accounted for in primary studies, we
would have presented data in a table, with a (*) symbol to indicate
the presence of a probable unit of analysis error. We would have
contacted first authors of studies to obtain intra-class correlation
coefficients (ICCs) for their clustered data and adjusted for this by
using accepted methods (Gulliford 1999). If clustering had been
incorporated into the analysis of primary studies, we would have
presented these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the ICC [Design effect = 1 + (m − 1)*ICC]
(Donner 2002). If the ICC is not reported, it will be assumed to
be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into ac-
count ICCs and relevant data had been documented in the report,
we would have been able to synthesise with other studies using the
generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (pharmacological, physiological or psychological)
of the treatment in the first phase is carried over to the second
phase. As a consequence, on entry to the second phase the par-
ticipants can differ systematically from their initial state despite a
wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, we would
have only used data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if relevant
we presented the additional treatment arms in comparisons. For
binary data we simply added and combined within the two-by-
two table. If data were continuous we would have combined data
following the formula in section 7.7.3.8 (Combining groups) of
the Cochrane Handbook for Systematic Reviews of Interventions. We
would not reproduce data that is not relevant to this review.
Dealing with missing data
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1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them within analyses, except for the outcome of
leaving the study early. If, however, more than 50% of those in
one arm of a study were lost, but the total loss was less than 50%,
we would mark such data with (*) to indicate that such a result
may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data are not clearly described, data are
presented on a ’once-randomised-always-analyse’ basis (an inten-
tion-to-treat analysis). Those leaving the study early are assumed
to have the ’worst case scenario’ (e.g. no clinical response). For the
outcomes of death and adverse effects we used the rate of those
who stayed in the study - in that particular arm of the trial - for
those who did not and undertook a sensitivity analysis comparing
’completer’ data only with the intention-to-treat analysis. Where
the denominator for withdrawals was not clear we included all
those in that arm of the study who did not withdraw for other
reasons.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50% and completer-only data were reported, we repro-
duced these.
3.2 Standard deviations
If SDs were not reported, we first tried to obtain the missing
values from the authors. If not available, where there were missing
measures of variance for continuous data, but an exact standard
error (SE) and CIs were available for group means, and either P
value or t value available for differences inmean, we could calculate
them according to the rules described in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). When only the
SE is reported, SDs are calculated by the formula SD = SE *
√
(n).
Chapters 7.7.3 and 16.1.3 of theCochraneHandbook for Systematic
Reviews of Interventions present detailed formulae for estimating
SDs from P values, t or F values, CIs, ranges or other statistics
(Higgins 2011). If these formulae did not apply, we calculated the
SDs according to an imputation method which is based on the
SDs of the other included studies (Furukawa 2006). An exception
to this was when we were imputing the SD for change scores
when we already had the SD for endpoint data from that study: in
this case we assumed a correlation between baseline and endpoint
scores of 0.5 used the formulae in the Cochrane Handbook for
Systematic Reviews of Interventions (after Singh 2010).We intended
to validate the use of a correlation of 0.5 by deriving estimates
from other studies where possible and including these empirical
estimates of correlation in a sensitivity analysis. For imputing the
SD for endpoint data where we have baseline and change scores we
used the baseline SD and examined this assumption in a sensitivity
analysis.
Although these imputation strategies can introduce error, the al-
ternative would be to exclude a given study’s outcome and thus
to lose information. We nevertheless examined the validity of the
imputations in a sensitivity analysis excluding imputed values.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results (Leucht 2007). Therefore, where LOCF data were used
in the trial, if less than 50% of the data had been assumed we
reproduced these data if completer-only data were not available,
and indicated that they were the product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We then simply in-
spected all studies for clearly outlying populations or situations
which we had not predicted would arise. When such situations or
participant groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose,
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
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3.2 Employing the I² statistic
We investigated heterogeneity between studies by considering the
I² statistic alongside the Chi² P value. The I² statistic provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
I² depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi² test, or a
confidence interval for I²). We interpreted an I² estimate greater
than or equal to 50% accompanied by a statistically significant
Chi² statistic as evidence of substantial levels of heterogeneity (Sec-
tion 9.5.2 Higgins 2011). When substantial levels of hetero-
geneity were found in the outcome, we explored some potential
reasons for heterogeneity (Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plotsmay be useful in investigating reporting biases but
are of limited power to detect small-study effects (Sterne 2011).
We did not use funnel plots for outcomes where there were 10
or fewer studies, or where all studies were of similar size. In other
cases, if funnel plots were possible we would have sought statistical
advice in their interpretation.
Where study protocols have been published, we compared these to
the reported results to look for outcome reporting bias. Otherwise
we looked for unreported outcome measures mentioned in the
’Methods’ section of the study.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We chose random-effects models for all analyses but we examined
the consequences of our choice in sensitivity analyses.
Subgroup analysis and investigation of heterogeneity
We only conducted formal subgroup or sensitivity analyses where
there were more than three trials available but we investigated all
outcomes for sources of heterogeneity.
1. Subgroup analyses
1.1 Individual noradrenaline reuptake inhibitors (NRIs)
As well as reporting findings from NRIs combined as a class, we
also analysed data from the two main NRIs (reboxetine and ato-
moxetine) separately.
1.2 Clinical state, stage or problem
We are interested in making sure that information is as relevant
to the current care of people with schizophrenia as possible so in-
tended to clearly highlight the current clinical state (acute, early
post-acute, partial remission, remission) as well as the stage (pro-
dromal, first episode, early illness, persistent) and as to whether
the studies primarily focused on people with particular problems
(for example, negative symptoms, treatment-resistant illnesses).
1.3 Participant age
We grouped each study by the age range of the majority of par-
ticipants included (under 18 years, 18 to 60 years, over 60 years)
and analysed separately. If the proportion within each age range
was not available then we allocated studies by mean age.
2. Investigation of heterogeneity
We reported if inconsistency was high. First, we investigated
whether data were entered correctly. Second, if data were correct,
we visually inspected the graph and removed outlying studies to
see if homogeneity was restored. If substantial heterogeneity re-
mained, we discussed this but did not perform further investi-
gation of potential causes of heterogeneity (e.g. meta-regression)
beyond our planned subgroup and sensitivity analyses.
When unanticipated clinical or methodological heterogeneity was
obvious, we simply stated hypotheses regarding these for future
reviews or versions of this review. We did not undertake analyses
relating to this.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. We included
these studies and if there was no substantive difference when the
implied randomised studies were added to those with better de-
scription of randomisation, then we used all relevant data from
these studies.
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2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to fol-
low-up (see Dealing with missing data), we compared our inten-
tion-to-treat assumptions with completer data only. If there was a
substantial difference, we reported results and discussed them but
continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation, allocation concealment, blinding and outcome reporting
for the meta-analysis. If the exclusion of trials at high risk of bias
did not substantially alter the direction of effect or the precision
of the effect estimates, then we entered relevant data from these
trials in the analysis.
4. Imputed values
We undertook a sensitivity analysis to assess the effects of includ-
ing data from trials where we used imputed values (see Dealing
with missing data). If we noted substantial differences in the di-
rection or precision of effect estimates in these sensitivity analyses
then we did not pool data from the imputed trials with the other
trials contributing to the outcome, but presented them separately.
Where imputed SDs depend on an assumption of 0.5 correlation
of baseline to endpoint scores, we attempted to derive an estimate
of this correlation coefficient empirically from included studies
and to compare this estimate with the assumption of 0.5 in a sen-
sitivity analysis.
5. Mean effect sizes for composite cognitive scores
Where we calculated mean effect sizes to create composite cog-
nitive scores, we attempted to examine the effect of including or
excluding these from other studies where composite scores were
reported directly.Where there were substantial differences, we pre-
sented these data separately.
6. Fixed-effect and random-effects
We synthesised all data using a random-effects model but we also
reported outcomes using a fixed-effect model to evaluate whether
the greater weights assigned to larger trials with greater event rates
altered the significance of the results compared with the more
evenly distributed weights in the random-effects model.
7. Skew
Where we used change scores, but these were associated with
skewed endpoint scores, we examined the effect of excluding these
change scores.
R E S U L T S
Description of studies
Results of the search
See Figure 1 for the search flow diagram. We identified 80 distinct
records from searches up to 2012, a further six records repeating
the search in 2014, a further three records in 2015, and a further 17
records in 2017. In addition we identified one further record when
the search criteriawere broadened in2015.We also identified three
records through handsearching citations, responses from authors
contacted, and other sources.
15Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Of the 110 distinct records identified 62 were excluded based on
the title and abstract alone as they did not meet the inclusion
criteria (i.e. they were not RCTs of NRIs). We obtained the full
text of 48 records. Of these, 16 distinct studies were included in
the review, representing 31 records. Eight distinct studies were
excluded as they did not meet the inclusion criteria, representing
11 records. There are two studies awaiting classification (see also
Characteristics of studies awaiting classification) , which represent
five records; and there is one ongoing study (see alsoCharacteristics
of ongoing studies). All records identified from sources other than
the main search were for studies also identified by records in the
main search.
In 2015 we broadened the search criteria to include further sub-
stanceswe identified as selective noradrenaline reuptake inhibitors,
including viloxazine which we had previously included in the
search under the name ’SPN-812’. We identified one study util-
ising viloxazine (Kurland 1981). Viloxazine is a selective nora-
drenaline reuptake inhibitor that was manufactured by ICI and
used as an antidepressant in Europe until being withdrawn in the
early 2000s. It has since been investigated by Supernus Pharma-
ceuticals as an antidepressant and treatment for ADHD as SPN-
809 and SPN-812 respectively.
Studies awaiting classification
We have identified one RCT of atomoxetine which has been ter-
minated (Shekhar 2005) and another RCT which has been com-
pleted (Tamminga 2009) but could find no further information
on the results. See Characteristics of studies awaiting classification.
Ongoing studies
We have identified one RCT of reboxetine started in 2006 for
which we have not been able to determine any further information
(Baranchik 2006). Therefore it is unclear if this trial is ongoing or
terminated. See Characteristics of ongoing studies.
Included studies
1.1 Methods
We included sixteen studies; details of individual studies are listed
in the Characteristics of included studies table. All were ran-
domised parallel trials and double-blind placebo controlled except
for one randomised open trial (Yu 2012); while two trails also
had a citalopram arm (Hinkelmann 2013; Usall 2014). All studies
were published in English except for three trials in Chinese (Li
2008; Yu 2012; Zhao 2013).
Most trials were of short duration with eleven lasting between two
and 12 weeks (Eli Lilly 2006; Friedman 2008; Hinkelmann 2013;
Kelly 2009; Kurland 1981; Li 2008; Poyurovsky 2003; Poyurovsky
2007; Sacco 2009; Schutz 2001; Shafti 2015); and the remaining
five weremedium term, lasting 13 to 26weeks (Ball 2011;Ganguli
2008; Usall 2014; Yu 2012; Zhao 2013).
1.2 Setting
Where reported, seven trials included only inpatients (Li 2008;
Poyurovsky 2003; Poyurovsky 2007; Schutz 2001; Shafti 2015;
Yu 2012; Zhao 2013); two only outpatients (Ball 2011; Friedman
2008); and one reported enrolling both (Kelly 2009).
1.3 Participants
Most studies included only patients diagnosed with schizophre-
nia (Eli Lilly 2006; Friedman 2008; Hinkelmann 2013; Kurland
1981; Schutz 2001; Shafti 2015; Usall 2014; Yu 2012; Zhao
2013) with some also including schizoaffective disorder (Ball
2011; Ganguli 2008; Kelly 2009; Sacco 2009) or schizophreni-
form disorder (Poyurovsky 2003; Poyurovsky 2007). Where re-
ported, all participants were adults aged 18 to 65 years with no
evidence of participants aged under 18 years or over 65 years being
enrolled in trials. All studies used the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) except
two using the Chinese Classification of Mental Disorders, Third
Edition (CCMD-3) (Li 2008; Yu 2012), one using the Interna-
tional Classification of Diseases, 10th Revision (ICD-10) (Zhao
2013), and one not reporting the criteria used (Kurland 1981).
Duration of illness ranged from 10 months (Yu 2012), one to six
years (Li 2008; Poyurovsky 2003; Poyurovsky 2007; Zhao 2013),
to over 10 years (Hinkelmann 2013; Kelly 2009; Usall 2014). Al-
though not reporting overall duration of illness two studies indi-
cated at least six months or two years of illness (Ball 2011 and
Shafti 2015 respectively). Three studies reported including stable
patients (Ball 2011; Sacco 2009; Zhao 2013); and three reported
including chronic patients (Li 2008; Schutz 2001; Shafti 2015).
The studies by Poyurovsky reported enrolling first episode patients
but themean duration of illness in these studies ranged from three
to six years (Poyurovsky 2003; Poyurovsky 2007). Seven studies
recruited patients specifically with negative symptoms (Ganguli
2008; Hinkelmann 2013; Li 2008; Shafti 2015; Usall 2014; Yu
2012; Zhao 2013); and one recruited participants with depressive
symptoms (Kurland 1981). Specific inclusion criteria included pa-
tients with metabolic syndrome (Zhao 2013) or with weight gain
(Ball 2011). Overall baseline severity (as rated by mean or esti-
mated CGI score) ranged from borderline mentally ill (Friedman
2008), mildly ill (Ball 2011; Ganguli 2008; Li 2008; Schutz 2001;
Usall 2014; Yu 2012; Zhao 2013), moderately ill (Poyurovsky
2003; Poyurovsky 2007), markedly ill (Hinkelmann 2013; Kelly
2009), to severely ill (Shafti 2015).
17Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Two studies involved only patients taking clozapine (Li 2008;
Zhao 2013), with two further studies including a mixture of
patients taking clozapine and other atypical antipsychotics (Ball
2011; Hinkelmann 2013). The majority of studies included par-
ticipants taking a variety of atypical antipsychotics (Eli Lilly 2006;
Friedman 2008; Kelly 2009; Poyurovsky 2003; Poyurovsky 2007;
Usall 2014; Yu 2012); while three studies included participants
taking only typical antipsychotics (Kurland 1981; Schutz 2001;
Shafti 2015).
1.4 Study size
There were 919 participants across all trials with 72 of these from
the two studies which were only included in the qualitative dis-
cussions due to a lack of useable data (Ganguli 2008; Sacco 2009);
and 39 from the citalopram arms of two trials (Hinkelmann 2013;
Usall 2014). Most studies were small: two studies had 20 partici-
pants or fewer (Friedman 2008; Sacco 2009); six studies had 21 to
50 participants (Ball 2011; Kelly 2009; Kurland 1981; Poyurovsky
2003; Schutz 2001; Shafti 2015); five had 51 to 100 participants
(Ganguli 2008; Hinkelmann 2013; Poyurovsky 2007; Usall 2014;
Yu 2012); and three had more than 100 participants (Eli Lilly
2006; Li 2008; Zhao 2013).
1.5 Interventions
1.5.1 Reboxetine
Nine studies used reboxetine as the intervention. Most used up
to 8 mg daily (Hinkelmann 2013; Li 2008; Schutz 2001; Usall
2014; Yu 2012; Zhao 2013) with the rest using up to 4 mg daily
(Poyurovsky 2003; Poyurovsky 2007; Shafti 2015).
1.5.2 Atomoxetine
Six studies used atomoxetine as the intervention. Most titrated up
to 80 mg daily (Eli Lilly 2006; Friedman 2008; Ganguli 2008;
Kelly 2009).One study used doses up to 120 mg daily (Ball 2011);
and there was one study with two arms which used 40 mg and 80
mg daily (Sacco 2009).
1.5.3 Other drug treatment arms
One study used viloxazine in doses up to 300 mg daily (Kurland
1981). In two studies, in addition to the reboxetine and placebo
arms, there was also a citalopram arm with one study using doses
up to 30 mg (Usall 2014) and one up to 40 mg daily (Hinkelmann
2013).
1.6 Funding
Four studies did not report their source of funding (Li 2008;
Schutz 2001; Yu 2012; Zhao 2013). Three studies were funded
partly or wholly by Eli Lilly (Ball 2011; Eli Lilly 2006; Friedman
2008). Eli Lilly also contributed study medication to a further
trial (Kelly 2009). Two studies received medication or assistance
fromother pharmaceutical companies (Kurland 1981; Poyurovsky
2003). Four studies were funded partly or wholly by US Govern-
ment agencies such as the National Institutes of Health (NIH)
(Ball 2011; Friedman 2008; Kelly 2009; Sacco 2009); and a fur-
ther two trials received funding fromother state sources outside the
US (Shafti 2015;Usall 2014). The StanleyMedical Research Insti-
tute provided funding for four trials (Ganguli 2008; Hinkelmann
2013; Kelly 2009; Poyurovsky 2007); and the National Alliance
for Research on Schizophrenia and Depression (NARSAD) con-
tributed funding to one study (Sacco 2009).
1.7 Outcomes
None of the included studies reported results for service utilisation,
satisfaction, or economic outcomes.
1.7.1 Mental state
1.7.1.1 Positive and Negative Syndrome Scale (PANSS)
The PANSS is a 30-item structured clinical interview producing
three subscales, positive (seven items), negative (seven items) and
general psychopathology (such as anxiety or depressed mood) (16
items) with individual items rated one to seven (Kay 1986).Higher
scores indicate more severe illness.
1.7.1.2 Brief Psychiatric Rating Scale (BPRS)
The BPRS is a clinician-rated instrument used to score 18 items
of psychopathology (such as hallucinations or depressed mood)
rated one to seven (Overall 1962). Higher scores indicate more
severe illness.
1.7.1.3 Scale for the Assessment of Negative Symptoms (SANS)
The SANS is a 26-item clinician-rated scale measuring negative
symptoms of schizophrenia across five domains (such as alogia
or avolition) and items are rated from zero to five. Higher scores
indicate more severe illness (Andreasen 1982).
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1.7.1.4 Scale for the Assessment of Positive Symptoms (SAPS)
The SAPS is a 34-item clinician-rated scale measuring positive
symptoms of schizophrenia across four domains (such as halluci-
nations or delusions) and items are rated from zero to five. Higher
scores indicate more severe illness (Andreasen 1984).
1.7.1.5 Hamilton Rating Scale for Depression (HRSD)
The HRSD is a semi-structured interview producing a 17-item
scale of depressive symptoms (such as depressed mood or feelings
of guilt) with each item rated from zero to two, three, or four
(depending on the item) for a maximum score of 53 (Hamilton
1980). Longer versions such as a 24-item scale have beendeveloped
but as far as we could determine all studies utilised the 17-item
scale. Higher scores indicate more severe illness.
1.7.2. Cognitive functioning
As predicted, a wide-range of cognitive tests were utilised in the
included studies. These have been classified according to the
MATRICS-NIMH domains (Nuechterlein 2004) and individual
tests are not discussed in detail.
1.7.3 Clinical global response
1.7.3.1 Clinical Global Impression (CGI)
1.7.3.1.1 Clinical Global Impression Severity (CGI-S)
The CGI-S is a clinician-rated scale where the severity of the pa-
tient’s illness is scored from one to seven based on clinical experi-
ence with higher scores indicating more severe illness (Guy 1976).
1.7.3.1.2 Clinical Global Impression Improvement (CGI-I)
The CGI-I is a clinician-rated scale where the deterioration or
improvement in the patient’s illness compared to baseline is scored
from one to seven where one indicates ’very much improved’ and
seven indicates ’very much worse’ so higher scores indicate more
severe illness (Guy 1976).
1.7.4 Quality of life
The General Quality of Life Inventory-74 (GQOLI-74) is based
on the World Health Organization’s Quality of Life Assessment
Instrument modified for use in a Chinese population (Lu 2007). It
is a 74-item inventory with 20 subscores in four domains. Higher
scores indicate better quality of life.
1.7.5 Social functioning
1.7.5.1 Scale of Social-skills for Psychiatric Inpatients (SSPI)
The SSPI is a published Chinese scale with ten factors of social
functioning each from three items scored 0 to 2 (Guo 1995).
Higher scores represent worse performance.
1.7.5.2 Specific Level of Function (SLOF)
The SLOF scale is a 43-item instrument administered to the pa-
tient’s caregiver to assess functional performance in six domains
(Schneider 1983). Items are scored on a five-point Likert scale.
Higher scores indicate better performance.
1.7.6 Adverse effects
1.7.6.1 Abnormal Involuntary Movement Scale (AIMS)
The AIMS is a clinician-rated scale to assess the severity of tardive
dyskinesia (Munetz 1988). The 12 items are scored zero to four
with a higher score indicating worse side-effects.
1.7.6.2 Simpson-Angus Scale (SAS)
The SAS is a clinician-rated scale to assesses parkinsonism in
schizophrenia (Simpson 1970). Ten items are scored zero to four,
higher scores indicate worse side-effects.
1.7.6.3 Barnes Akathisia Scale (BAS)
The BAS is a clinician-rated scale of drug-induced akathisia incor-
porating subjective and objective ratings scored from zero to three
with an additional six-point scale to assess global severity (Barnes
1989). Higher scores indicate worse side-effects.
Excluded studies
We excluded eight studies; details of individual studies are shown
in Characteristics of excluded studies. Three excluded studies were
of citalopram which is not a selective NRI and thus does not meet
the inclusion criteria (Barnes 2009; Hou 2007; Salokangas 1997).
The publication by Mueller 2005 reported on two randomised
placebo-controlled add-on trials of a COX2-inhibitor, one trial
examined patients with depression who were receiving reboxe-
tine and another examined patients with schizophrenia who were
receiving risperidone. Therefore it was not a trial of an NRI in
schizophrenia. Shafti 2004 reported trials ofmultiple psychotropic
medications including maprotiline.We did not regard any of these
compounds as selective NRIs; in particular we excluded maproti-
line due to its significant actions at multiple monoamine receptors
in addition to noradrenaline reuptake inhibition.
Amrami-Weizman 2013 combined data from Poyurovsky 2003
and Poyurovsky 2007 to report metabolic and hormonal mea-
sures which were not defined as outcomes of interest in this re-
view. Apud 2007a conducted a cross-over RCT of atomoxetine in
schizophrenia stratified by COMT genotype: only four patients
completed the trial and no data was collected. It was terminated
early due to slow recruitment and as a low scientific priority for
NIMH. Poyurovsky 2013 reported an RCT of the combination of
reboxetine and betahistine in schizophrenia; therefore betahistine
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use was not equally distributed across treatment and control arms
and the study did not meet inclusion criteria. This study found
a benefit of the reboxetine betahistine combination on reducing
weight gain from olanzapine but no effect on symptom outcome
measures such as the SANS.
Risk of bias in included studies
Information for risk of bias across the included studies is illustrated
in Figure 2 and Figure 3. There were three incidents of non-con-
currence in risk ratings: two for assessment of blinding (Friedman
2008; Kurland 1981); and one for assessment of selection bias
(Shafti 2015). All decisions were between ’unclear risk’ and ’low
risk’ and overall ratings of ’unclear risk’ were agreed in all three
cases. The overall value of a weighted kappa was high at 0.96 for
112 decisions across 16 trials.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies were described as randomised but only seven stud-
ies reported the method of randomisation and were rated as low
risk (Ball 2011; Hinkelmann 2013; Kelly 2009; Poyurovsky 2003;
Poyurovsky 2007; Schutz 2001; Usall 2014). One study was de-
scribed as open and was considered high risk for allocation (Yu
2012). The remaining studies were described as double-blind
and placebo-controlled although only five studies described the
method of allocation concealment in detail and were rated as low
risk (Ball 2011;Hinkelmann 2013;Kelly2009; Schutz 2001;Usall
2014). The remaining studies were rated as unclear risk.
Blinding
The majority of studies did not report blinding in detail but we
considered the one open study (Yu 2012) to be at high risk for
inadequate blinding. Seven studies described blinding of partici-
pants and we considered them low risk (Ball 2011; Kelly 2009; Li
2008; Poyurovsky 2007; Schutz 2001; Shafti 2015; Usall 2014).
Four studies described blinding of outcomes and we rated them as
low risk (Poyurovsky 2003; Poyurovsky 2007; Shafti 2015; Usall
2014). We rated the remaining studies as unclear risk.
Incomplete outcome data
Six studies accounted for incomplete data and we considered them
low risk (Friedman 2008; Kurland 1981; Li 2008; Poyurovsky
2003; Poyurovsky 2007; Shafti 2015); while three were classified
as high risk due to a very high rate of withdrawals (Ganguli 2008)
or an imbalance in withdrawals between arms (Ball 2011; Eli Lilly
2006). We rated the remaining studies as unclear risk.
Selective reporting
Eight studies appeared to report all relevant outcomes and were
rated as low risk (Friedman 2008; Kelly 2009; Poyurovsky 2003;
Poyurovsky 2007; Schutz 2001; Shafti 2015; Usall 2014; Zhao
2013). Six studies demonstrated selective reporting of outcomes
(Ball 2011; Eli Lilly 2006; Ganguli 2008; Kurland 1981; Sacco
2009; Yu 2012). The remaining studies were rated as unclear risk.
Other potential sources of bias
The majority of studies did not demonstrate evidence of other
sources of bias and we rated them as low risk.We gave two studies a
high risk of bias due to excluding participants after randomisation
(Kelly 2009), and evidence of methodological flaws (such as mean
PANSS total scores < 30) (Yu 2012). For four studies we rated
them as having an unclear risk of bias due to methodological flaws
as it was not clear that these would have a significant impact on
the results (Eli Lilly 2006; Ganguli 2008; Kurland 1981; Sacco
2009).
Effects of interventions
See: Summary of findings for the main comparison
Noradrenaline reuptake inhibitors versus placebo
Two studies did not report any outcomes that could be used in
the meta-analysis and are included in the narrative review only
(Ganguli 2008; Sacco 2009). As far as could be determined all
studies included patients with a duration of illness of six months
or more with the majority over one year, with many described as
stable or chronic; and as we did not perform sensitivity analysis
looking at duration or stage of illness except to consider studies
including participants taking clozapine or recruiting specifically
participants with prominent negative symptoms.
Under each heading of the Summary of findings for the main
comparison we included the analysis with the longest period of
follow-up (providing there weremore than three studies to include
for that time period), otherwise we used the duration which in-
cluded the most studies. Where there was more than one outcome
measure (e.g. PANSS and BPRS) for a time-point we used the
outcome with the most studies.
1. Comparison 1. NRI versus placebo
1.1 Primary outcome - A. Mental state: Specific - clinically
significant response or improvement in negative symptoms
(SANS, high = worse) - short term (12 weeks)
While all 16 studies included in the review utilised instruments
which could produce an indication of rates of improvement in
negative symptoms only one provided usable data. Shafti 2015
measured response rates at 12 weeks (defined as 20% reduction in
the SANS) and reported rates of 6/25 and 19/25 in the placebo
and reboxetine arms respectively indicating a significant benefit
of reboxetine (1 RCT, n = 50; RR 3.17, 95% CI 1.52 to 6.58;
Analysis 1.1).
1.2 Primary outcome - B. Clinical global response: clinically
significant response or improvement in global status (CGI-S,
high = worse) - short term (4 weeks)
Kurland 1981 reported non-specific improvement rates of 7/15
and 6/13 in the placebo and viloxazine arms respectively, show-
ing no difference (Analysis 1.2). Nine studies measured global re-
sponse using the CGI-I or CGI-S but none defined clinical im-
provement on these scales or reported dichotomous outcomes.
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1.3 Mental state: 1. General - clinically significant response
or improvement in general/overall symptoms as defined in
each study - short term (2 to 12 weeks)
Kurland 1981 reported non-specific improvement rates of 7/15
and 6/13 in the placebo and violoxazine arms respectively at 4
weeks (these data have also been included under the primary out-
come measure of clinical global response), while Schutz 2001 re-
ported response rates at 6 weeks (defined as 20% reduction in
PANSS total score) and we calculated ITT rates of 5/15 and 7/15
for placebo and reboxetine respectively. When combined (n = 58)
we found no significant benefit of NRIs (RR 1.15, 95% CI 0.64
to 2.09; Analysis 1.3).
1.4 Mental state: 2a. General: average general/overall
symptoms score (various scales, high = worse) - short term
(2 to 12 weeks)
Nine studies reported a useable overall clinical symptom scale or
general subscale score from either the PANSS or the BPRS.
Li 2008 reported PANSS total and general endpoint scores at 12
weeks. Yu 2012 reported PANSS total endpoint scores at 8 weeks.
Zhao 2013 reported PANSS total and general endpoint scores at
8 weeks. Friedman 2008 reported completer-only PANSS general
change scores at 8 weeks and we calculated LOCF PANSS gen-
eral endpoint scores with an estimated SD but these were skewed
and entered into Analysis 1.8. Hinkelmann 2013 reported LOCF
PANSS general endpoint scores at 4 weeks which were skewed
and entered into Analysis 1.8 and LOCF PANSS general change
scores were calculated with an estimated SD. Kelly 2009 reported
completer-only BPRS total scores at 8 weeks which were skewed
and entered into Analysis 1.8 and completer-only BPRS change
scores were calculatedwith an estimated SD. Schutz 2001 reported
PANSS total and general endpoint scores at 6 weeks which were
skewed and entered into Analysis 1.8 and we calculated change
scores and estimated the SD. Usall 2014 reported PANSS total
and general endpoint scores at 24 weeks which were skewed and
entered into Analysis 1.8 and we calculated change scores and es-
timated the SD.
1.4.1 BPRS total
Kelly 2009 reported BPRS total change scores and found no ben-
efit of atomoxetine at 8 weeks (MD 1.50, 95% CI−6.64 to 9.64;
Analysis 1.4).
1.4.2 PANSS general
Five studies had results for the PANSS general subscale (n = 294)
with a statistically significant benefit of NRIs (MD −2.17, 95%
CI −3.93 to −0.40; Analysis 1.4).
We performed subgroup and sensitivity analysis (see Table 1). The
only study of atomoxetine is Friedman 2008, which shows no ben-
efit; and excluding this to look only at reboxetine studies makes
little difference. The two studies looking at only patients on cloza-
pine were both positive (MD −2.8; 95% CI −4.87 to −0.72)
(Li 2008; Zhao 2013); and looking only at studies that included
patients taking clozapine, which were the studies that specifically
recruited patients with negative symptoms, made little difference
to the outcome (Hinkelmann 2013; Li 2008; Zhao 2013). The
change scores in Hinkelmann 2013 and Schutz 2001 have im-
puted SDs and excluding these slightly inflated the effect size (MD
−2.66, 95% CI −4.50 to −0.82). Excluding all change scores
associated with a skewed endscore (Friedman 2008; Hinkelmann
2013; Schutz 2001) left the two clozapine-only studies utilising
unskewed endpoint scores (Li 2008; Zhao 2013). A fixed-effect
model made little difference except to slightly inflate the effect size
and narrow the confidence intervals (MD−2.73, 95% CI−3.71
to −1.74). No studies were at high risk of bias for randomisa-
tion but only two studies described their method in any detail
(Hinkelmann 2013; Schutz 2001), and combining these showed
no benefit for NRIs (MD 0.89, 95% CI−3.60 to 5.37). No stud-
ies were at high risk of bias in any domain.
1.4.3 PANSS total
Four studies had short-term PANSS total score results (n = 309)
which showed a significant benefit of reboxetine (MD−2.84, 95%
CI −5.28 to −0.40; Analysis 1.4) and substantial heterogeneity
(I² = 72%).
We performed subgroup and sensitivity analysis (see Table 2). Vi-
sually there was no clear outlying trial contributing to heterogene-
ity but excluding the open study by Yu 2012 abolished the hetero-
geneity (I² = 0%) while magnifying the effect size (MD −4.20,
95% CI−5.82 to−2.58). The two studies of patients taking only
clozapine both showed a significant benefit of reboxetine (MD
−4.25, 95% CI −5.89 to −2.62) (Li 2008; Zhao 2013). Ex-
cluding Schutz 2001, the single study that did not specifically re-
cruit patients with negative symptoms, made little difference to
the overall effect. Schutz 2001 was also the only study using im-
puted SD. A fixed-effect model made marginal difference to the
overall outcome. No study was considered to be at high risk of bias
for randomisation but only Schutz 2001 described the method
of randomisation in detail. Yu 2012 was considered at high risk
of bias for allocation concealment, blinding of participants and
outcomes, selective reporting, and other sources of bias.
1.5 Mental state: 2b. General: average general/overall
symptoms score (various scales, high = worse) - medium
term (13 to 26 weeks)
Yu 2012 reported PANSS total endpoint scores at 16 weeks but we
considered these to be skewed, partially because the mean scores
were less than 30 which should not be possible with the PANSS
total scale, and this was entered into Analysis 1.9. We calculated
change scores at 16 weeks and estimated the SD. Zhao 2013 re-
ported PANSS total and general endpoint scores at 24 weeks. Ball
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2011 reported BPRS total endpoint scores at 24 weeks which were
skewed and are entered into Analysis 1.9 and not included in the
meta-analysis but change scores were calculated with an estimated
SD. Usall 2014 reported PANSS total and general endpoint scores
at 24 weeks which were skewed and entered into Analysis 1.9 and
we calculated change scores and estimated SD.
1.5.1 BPRS total
Ball 2011 reported BPRS total change scores and found no benefit
of atomoxetine at 24 weeks (MD−1.40, 95% CI −7.08 to 4.28;
Analysis 1.5).
1.5.2 PANSS general
Usall 2014 and Zhao 2013 reported the PANSS general subscale
for reboxetine and thesewere not consistent, with the former show-
ing no effect and the latter a large benefit for reboxetine resulting
in a combined estimate that was not significant (MD−2.90, 95%
CI −7.57 to 1.77; Analysis 1.5).
1.5.3 PANSS total
Three studies reported this outcome (n = 219) with a large benefit
of reboxetine without statistical significance (MD−3.67, 95%CI
−10.07 to 2.72; Analysis 1.5) and substantial heterogeneity (I² =
94%).
There were only three trials for medium-term outcomes so we
did not perform a full subgroup and sensitivity analysis but we
did look for sources of heterogeneity. The large study by Zhao
2013, which was the only one to look at patients taking clozapine,
showed a much greater benefit of reboxetine than the other two
studies and could be considered an outlier visually: excluding this
both abolished heterogeneity and attenuated the benefit of rebox-
etine (MD −1.07, 95% CI −2.59 to 0.46). A fixed-effect model
makes little difference to the estimated effect size but narrows the
confidence intervals to become statistically significant (see Table
3).
1.6 Mental state: 3a. Specific: average symptoms score
(various scales, high = worse) - short term (2 to 12 weeks)
1.6.1 mood (BPRS)
Kelly 2009 reported BPRS anxiety/depression subscale endpoint
completer scores at 8 weeks but these were skewed. We entered
them into Analysis 1.8 and calculated change scores and estimated
SD.
There was no difference between atomoxetine and placebo (MD
0.20, 95% CI −2.60 to 3.00; Analysis 1.6).
1.6.2 mood (HRSD)
Hinkelmann 2013 reported LOCF HRSD endpoint scores at 4
weeks but these were skewed and entered into Analysis 1.8 and we
calculated change scores and imputed the SD. Poyurovsky 2003
reported endpoint scores at 6 weeks but these were skewed and
entered into Analysis 1.8 and we calculated change scores and
imputed the SD. Poyurovsky 2007 reported endpoint scores at
6 weeks from cognitive testing completers only but these were
skewed and entered into Analysis 1.8. They also reported ITT
change scores. Schutz 2001 reported endpoint scores for com-
pleters at 6 weeks but these were skewed and entered into Analysis
1.8. We could not calculate change scores but there was no differ-
ence between the groups in mean scores.
Combining the three studies (n = 114) reporting change scores for
theHRSD showed a significant benefit of reboxetine (MD−2.37,
95% CI −4.29 to −0.45; Analysis 1.6). As there were only three
trials we did not perform a full subgroup and sensitivity analysis
but a fixed-effect model made little difference (MD −2.53, 95%
CI −4.03 to −1.03).
1.6.3 negative (PANSS negative)
Friedman 2008 reported observed PANSS negative change scores
at 8 weeks and we calculated LOCF endpoint scores with imputed
SDwhichwere skewed and entered intoAnalysis 1.8.Hinkelmann
2013 reported LOCF endpoint scores at 4 weeks which were
skewed and entered into Analysis 1.8 and we calculated change
scores with imputed SD. Li 2008 reported endpoint scores at 12
weeks. Schutz 2001 reported endpoint scores for completers at 6
weeks which were skewed and entered into Analysis 1.8 and we
derived change scores with imputed SD. Yu 2012 and Zhao 2013
reported endpoint scores at 8 weeks.
Together, these six (n = 359) studies showed no statistically sig-
nificant benefit of NRIs (MD −0.99, 95% CI −2.53 to 0.56;
Analysis 1.6) with significant heterogeneity (I² = 71%).
We performed subgroup and sensitivity analysis (see Table 4). Vi-
sually there was no clear individual outlier and excluding any indi-
vidual study did not markedly reduce the heterogeneity. Friedman
2008 was the only study reporting outcomes for atomoxetine and
this showed no benefit. Excluding Friedman 2008 to analyse the
effect of reboxetine slightly increased the overall benefit which re-
mained non-significant (MD−1.20, 95%CI−2.80 to 0.40). The
two studies that enrolled only patients on clozapine were inconsis-
tent but magnified the benefit when combined, although this re-
mained non-significant (MD−1.60, 95% CI −3.96 to 0.76) (Li
2008; Zhao 2013). Adding Hinkelmann 2013 (which included
some patients on clozapine) attenuated the overall effect further
(MD −0.75, 95% CI −3.25 to 1.75). Four trials specifically re-
cruited patients with negative symptoms which inflated the ben-
efit of NRIs but remained non-significant (MD −1.47, 95% CI
−3.04 to 0.09).
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Only three studies did not have associated skew and combin-
ing these inflated the benefit of reboxetine which became statisti-
cally significant (MD−1.92; 95% CI−3.28 to−0.55) (Li 2008;
Yu 2012; Zhao 2013). We imputed the SD for two studies and
excluding these inflated the benefit of reboxetine which became
statistically significant (MD −1.68, 95% CI −3.04 to −0.32)
(Hinkelmann 2013; Schutz 2001). Using a fixed-effect model in-
flated the benefit of NRIs which became statistically significant
(MD −1.82, 95% CI −2.46 to −1.18).
We did not determine that any of these studies were at high risk of
bias for randomisation. Only two studies described their randomi-
sation methods in any detail and we considered these at low risk of
bias. Combining these two studies showed a large non-significant
benefit for placebo over reboxetine (MD 3.55, 95% CI −0.43 to
7.54) (Hinkelmann 2013; Schutz 2001). We classified Yu 2012
as high risk of bias for allocation concealment, blinding of par-
ticipants and outcomes, selective reporting, and other sources of
bias and excluding this study largely abolished the benefit of NRIs
(MD −0.12, 95% CI −2.31 to 2.08). Most sensitivity analyses
made little impact on the high overall heterogeneity.
1.6.4 negative (SANS)
Poyurovsky 2003 reported SANS endpoint scores at 6weekswhich
were skewed and entered into Analysis 1.8 and we calculated
change scores with estimated SD. Poyurovsky 2007 reported ITT
change scores at 6 weeks and we derived endpoint data and im-
puted SD. Shafti 2015 reported endpoint scores at 12 weeks.
Combined together these three (n = 129) studies showed a non-
significant benefit of reboxetine (MD −2.47, 95% CI −6.22 to
1.28; Analysis 1.6) and substantial heterogeneity (I² = 71%).
As there were only three trials we did not perform a full subgroup
and sensitivity analysis but we looked for sources of heterogeneity.
There was no one clear outlier when we inspected visually. A fixed-
effect model attenuates the effect size but becomes statistically
significant (MD −1.66, 95% CI −3.09 to −0.22).
1.6.5 negative (SANS - modified)
Kelly 2009 reported modified SANS endpoint completer scores
at 8 weeks. As this has been modified from the original SANS
instrument it was not combined directly with other SANS results.
This showed a large benefit of atomoxetine thatwas not statistically
significant (MD −5.70, 95% CI −18.01 to 6.61; Analysis 1.6).
1.6.6 positive (BPRS)
Kelly 2009 reported completer BPRS positive endscores at 8weeks
whichwere skewed and entered intoAnalysis 1.8 andwe calculated
change scores and imputed SD.
This study produced a non-significant benefit for placebo over
atomoxetine (MD 1.60, 95% CI −2.59 to 5.79; Analysis 1.6).
1.6.7 positive (PANSS positive)
Friedman 2008 reported PANSS positive change scores for com-
pleters at 8 weeks and we calculated endpoint LOCF scores
with imputed SDs which were skewed and we entered these into
Analysis 1.8. Hinkelmann 2013 reported LOCF endscores at 4
weeks but these were skewed and we entered them into Analysis
1.8 calculating change scores with estimated SD. Li 2008 re-
port endscores at 12 weeks which were skewed and entered into
Analysis 1.8 and we calculated change scores and estimated the
SD. Schutz 2001 report endscores for completers at 6 weeks which
were skewed and entered into Analysis 1.8 and we derived change
scores with estimated SD. Zhao 2013 report endscores at 8 weeks
which were skewed and entered into Analysis 1.8 and we calcu-
lated change scores with SD imputed.
Five studies (n = 294) reported outcomes with no benefit or harm
from NRIs (MD −0.16, 95% CI −0.96 to 0.63; Analysis 1.6).
We performed subgroup and sensitivity analysis for short-term
outcomes (see Table 5). There was only one study of atomoxe-
tine which showed a non-significant tendency to favour placebo
(Friedman 2008); and looking only at studies of reboxetine made
little difference to the outcome. The two studies looking at pa-
tients taking clozapine only did not show a benefit of reboxetine
(Li 2008; Zhao 2013); and looking only at those studies including
patients on clozapine (Hinkelmann 2013; Li 2008; Zhao 2013),
which were also the studies recruiting patients specifically with
negative symptoms, made minimal difference. All studies had im-
puted SDs except Friedman 2008 and all change scores were as-
sociated with skewed endscores. A fixed-effect model made no
difference. We determined that none of the studies were at high
risk of bias for randomisation but only two studies reported these
methods in any detail and they did not show a benefit for rebox-
etine (Hinkelmann 2013; Schutz 2001). We did not classify any
studies at high risk of bias for any domain.
1.6.8 positive (SAPS)
Poyurovsky 2003 report SAPS endscores at 6 weeks which are
skewed and entered into Analysis 1.11 and we calculated the
change scores and imputed the SD. Poyurovsky 2007 report ITT
change scores at 6 weeks and we derived endscores using an im-
puted SD which were skewed and entered into Analysis 1.11.
Shafti 2015 report endscores at 12 weeks.
We combined three studies (n =129)which showedno overall ben-
efit from reboxetine (MD 0.73, 95% CI −1.29 to 2.74; Analysis
1.6). There were only three trials so a full subgroup and sensitivity
analysis was not performed but a fixed-effect model made little
difference (MD 0.59, 95% CI −1.16 to 2.33).
1.7 Mental state: 3b. Specific: Average symptoms score
(various scales, high = worse) - medium term (13 to 26
weeks)
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1.7.1 negative (PANSS negative)
Usall 2014 reported PANSS negative endpoint scores at 24 weeks
which were skewed and entered into Analysis 1.9 and we calcu-
lated change scores with imputed SDs. Yu 2012 reported end-
point scores at 16 weeks. Zhao 2013 reported endpoint scores at
24 weeks.
These three studies (n = 219) showed a significant benefit for
reboxetine (MD −3.25, 95% CI −4.04 to −2.47; Analysis 1.7)
without heterogeneity.
There were only three trials so we did not perform a full subgroup
and sensitivity analysis but a fixed-effectmodel made no difference
to the result (MD −3.25, 95% CI −4.04 to −2.47).
1.7.2 negative (SANS)
Usall 2014 reported SANS endpoint scores at 24weekswhichwere
skewed and entered into Analysis 1.9 and we calculated change
scores with imputed SDs.
This showed a large benefit for reboxetine that was not significant
(MD −7.12, 95% CI −19.39 to 5.15; Analysis 1.7)
1.7.3 positive (PANSS positive)
Usall 2014 reported PANSS positive endscores at 24 weeks which
were skewed and entered into Analysis 1.9 with change scores cal-
culated and SD imputed. Zhao 2013 report endscores at 24 weeks
which were skewed and entered into Analysis 1.9 with change
scores calculated and SD imputed.
The reboxetine studies by Usall 2014 and Zhao 2013 showed no
benefit overall (MD−0.14, 95% CI−1.30 to 1.02; Analysis 1.7).
1.8 Mental state: 4a. General and specific: Average score
(various scales, high = worse) - skewed results - short term
(2 - 12 weeks)
Data for this outcome were skewed and are presented as ’other
data’ .
1.9 Mental state: 4b. General and specific: Average score
(various scales, high = worse) - skewed results - medium
term (13 - 26 weeks)
Data for this outcome were skewed and are presented as ’other
data’ .
1.10 Cognitive functioning: 1. General - average composite
cognitive functioning score (SMD)
1.10.1 short term (2 to 12 weeks)
Eli Lilly 2006 reported a LOCF composite cognitive change score
at 8 weeks. Friedman 2008 reported composite cognitive change
scores for completers at 8 weeks. Kelly 2009 reported composite
cognitive endscores and change scores for completers at 8 weeks.
Poyurovsky 2007 did not report composite cognitive scores but
we were able to calculate a composite score at 6 weeks using mean
SMD from individual cognitive scale endscores (excluding those
that were skewed) with estimated SD.
When combined these four (n = 180) studies showed no overall
benefit from NRIs (SMD 0.04, 95% CI −0.28 to 0.36; Analysis
1.10).
We performed subgroup and sensitivity analysis for short-term
outcomes (see Table 6). There was only one reboxetine trial which
showed no benefit and this was the one study where we calculated
the composite effect size ourselves (Poyurovsky 2007). Excluding
this to look only at studies of atomoxetine also showed no benefit.
No study specifically recruited patients with negative symptoms.
Using a fixed-effect model made little difference. No study was
at high risk of bias for randomisation but only Kelly 2009 and
Poyurovsky 2007 reported their methods in detail and their results
were not consistent but combined they showed a non-significant
benefit forNRIs (MD−0.18, 95%CI−1.06 to 0.69). Two studies
were considered at high risk for other sources of bias and excluding
them showed a slight benefit for placebo (MD 0.14, 95% −0.42
to 0.71) (Eli Lilly 2006; Kelly 2009); while excluding only Eli
Lilly 2006 which was also considered at high risk of attrition and
reporting bias, had little effect.
1.10.2 medium term (13 to 26 weeks)
Ball 2011 reported a composite cognitive change score at 24weeks.
This showed a large benefit of atomoxetine thatwas not statistically
significant (SMD−0.66, 95% CI −1.46 to 0.13; Analysis 1.16).
1.11 Cognitive functioning: 2. Specific - average individual
scores (SMD) - short term (2 to 12 weeks)
1.11.1 working memory
Kelly 2009 reported endscores from three working memory scales
(WAIS-III letter-number sequencing, Woodcock-Johnson plan-
ning test, number sequencing test) for atomoxetine completers at
8 weeks and we used these to calculate a composite working mem-
ory SMD. Poyurovsky 2007 reported endscores from two working
memory scales (matching to sample, mental rotation) with reac-
tion time and percentage correct scores for each at 6 weeks for
reboxetine. Mental rotation reaction times were skewed and we
calculated a composite working memory SMD excluding this.
These showed little benefit of NRIs when combined (MD−0.11,
95% CI −0.89 to 0.67; Analysis 1.11) and a fixed-effect model
made little difference (MD −0.06, 95% CI −0.60 to 0.49).
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1.11.2 reasoning/problem solving
Eli Lilly 2006 reported ITT change scores from the Tower of Lon-
don test at 8 weeks. Friedman 2008 reported change scores from
the Tower of London test at 8 weeks for completers. Poyurovsky
2007 reported endpoint scores from the Wisconsin card sorting
task at 6 weeks with categories and percentage perseverative errors
but the latter were skewed and we excluded them.
The three studies (n = 158) showed no benefit of NRIs (SMD
0.03, 95% CI −0.28 to 0.34; Analysis 1.11). There were only
three trials so we did not perform a full subgroup and sensitivity
analysis but a fixed-effect model made no difference (MD 0.03,
95% CI −0.28 to 0.34).
1.11.3 speed of processing
Eli Lilly 2006 reported ITT change scores from three speed of pro-
cessing measures (token motor task, verbal fluency, symbol cod-
ing task) at 8 weeks and we used these to calculate a composite
speed of processing SMD. Friedman 2008 reported change scores
from four speed of processing measures (token motor task, cate-
gory instances test, controlled oral word association test, symbol
coding task) at 8 weeks for completers and we used these to calcu-
late a composite speed of processing SMD. Kelly 2009 reported
completer only endscores from three speed of processing measures
(WAIS-III digit symbol, grooved pegboard, letter fluency) at 8
weeks and we used these to calculate a composite speed of process-
ing SMD. Poyurovsky 2007 reported endpoint scores from three
speed of processing tasks (simple reaction time, code substitution,
code substitution immediate recall) with reaction time and per-
centage correct scores for each at 6 weeks. We used these to cal-
culate a composite speed of processing SMD although the simple
reaction time task was excluded due to skew and 100% correct
responses.
These four studies (n = 177) showed no benefit of NRIs (SMD
0.08, 95% CI −0.21 to 0.38; Analysis 1.11). We performed sub-
group and sensitivity analysis (see Table 7). The one study of re-
boxetine showed a non-significant benefit of placebo (Poyurovsky
2007); and excluding this to look only at studies of atomoxetine
did not change the overall lack of benefit of NRIs. We used calcu-
lated composite scores for all studies. None of the trials included
patients on clozapine or recruited specifically those with negative
symptoms. A fixed-effect model made no difference. No study was
at high risk of bias for randomisation but only Kelly 2009 and
Poyurovsky 2007 reported their methods in detail and their results
were not consistent but overall suggested a small non-significant
benefit for placebo (SMD 0.13, 95% CI−0.41 to 0.68). We con-
sidered two trials at high risk for attrition and other sources of bias
and excluding these showed a non-significant benefit of placebo
(SMD 0.23, 95% CI -.34 to 0.80) (Eli Lilly 2006; Kelly 2009);
while excluding just Eli Lilly 2006, which was also considered at
high risk of reporting bias, had little effect.
1.11.4 attention
Eli Lilly 2006 reported ITT change scores from the continuous
performance test at 8 weeks. Kelly 2009 reported completer end-
scores for the GDS continuous performance distractibility test at
8 weeks. Poyurovsky 2007 reported endpoint scores from the con-
tinuous performance test at 6 weeks with reaction time and per-
centage correct scores combined to calculate a composite attention
SMD.
These three studies (n = 161) showed no benefit of NRIs (SMD
−0.01, 95% CI −0.51 to 0.48; Analysis 1.11). There were only
three trials so we did not perform a full subgroup and sensitivity
analysis. A fixed-effect model favoured placebo but was not statis-
tically significant (SMD 0.10, 95% CI −0.21 to 0.41).
1.11.5 verbal learning/memory
Eli Lilly 2006 reported ITT change scores for two verbal learn-
ing/memory scales (verbal memory, digit sequencing) at 8 weeks
and we tcombined these into a composite verbal learning/memory
SMD. Friedman 2008 reported completer change scores for two
verbal learning/memory measures (list learning, digit sequencing)
at 8 weeks and these were combined into a composite verbal learn-
ing/memory SMD. Kelly 2009 reported completer endscores for
the California verbal learning test at 8 weeks. Poyurovsky 2007
reported endpoint scores for the code substitution delayed recall
task at 6 weeks with reaction time and percentage correct scores
combined to calculate a composite verbal learning/memory SMD.
These four studies (n = 181) showed no benefit of NRIs (SMD
0.01, 95% CI −0.31 to 0.32; Analysis 1.11). Subgroup and sen-
sitivity analysis was performed (see Table 8). Only Poyurovsky
2007 studied reboxetine which showed a non-significant benefit
of placebo and excluding this made little difference (SMD−0.08,
95% CI−0.40 to 0.25). None of the studies included patients on
clozapine or recruited specifically with negative symptoms. Only
Kelly 2009 did not use a composite score and this showed a large
but non-significant benefit of atomoxetine. Using a fixed-effect
model made little difference (SMD 0.01, 95% CI−0.28 to 0.30).
We did not classify any study as high risk of bias for randomisation
but only Kelly 2009 and Poyurovsky 2007 reported their methods
in enough detail to be considered low risk and they showed no
benefit when combined (SMD −0.06, 95% CI −1.04 to 0.93).
We determined that two studies were high risk for other sources of
bias (Eli Lilly 2006; Kelly 2009); and excluding them inflated the
benefit of placebo (SMD 0.26, 95% CI −0.31 to 0.83). Eli Lilly
2006 was also considered at high risk of attrition and reporting
bias and excluding this made little difference.
1.11.6 visual learning/memory
Kelly 2009 reported completer endscores for the brief visuospatial
memory test at 8 weeks with a benefit for atomoxetine that was
not statistically significant (SMD−0.44; 95% CI−1.29 to 0.41;
Analysis 1.11).
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1.12 Quality of life: Average quality of life score (GQOLI-74,
high = better) - short term (2 to 12 weeks)
The reboxetine study by Li 2008 reports GQOLI-74 endpoint
total scores as well as subscores from four domains of functioning
and 20 individual subscales at 12 weeks. We made a post hoc de-
cision to consider the total score but also to report scores from the
four domains. We did not report the individual subscales due to
the likelihood of a small number of statistically significant differ-
ences due to chance and the view that a benefit of NRIs on any
single subscale is unlikely to be of clinical relevance.
1.12.1 general - total
The GQOLI-74 total score (MD 9.36, 95% CI 7.89 to 10.83;
Analysis 1.12) showed a significant benefit for reboxetine.
1.12.2 specific - well-being - material
The dimension of material well-being (MD 0.21, 95% CI−2.34
to 2.76; N = 114) did not show a benefit (Analysis 1.12).
1.12.3 specific - well-being - physical
The dimension of physical well-being (MD 0.68, 95% CI −1.35
to 2.71; N = 114) did not show a benefit (Analysis 1.12).
1.12.4 specific - well-being - psychological
The dimension of psychological well-being (MD 10.00, 95% CI
8.01 to 11.99; N = 114) showed a large benefit for reboxetine over
placebo (Analysis 1.12).
1.12.5 specific - well-being - social
The dimension of social well-being (MD 10.02, 95% CI 8.03 to
12.01; N = 114) showed a large benefit for reboxetine over placebo
(Analysis 1.12).
1.13 Clinical global response: 1a. Average clinical global
status score (CGI-S, high = worse) - short term (2 to 12
weeks)
Hinkelmann 2013 reported CGI-S endscores at 4 weeks which
were skewed and entered into Analysis 1.14 and we estimated
change scores with imputed SD. Kelly 2009 reported completer-
only CGI-S endscores at 8 weeks. Poyurovsky 2003 reportedCGI-
S endscores at 6 weeks which were skewed and we entered these
intoAnalysis 1.14 and calculated change scores with estimated SD.
Poyurovsky 2007 reported ITT CGI-S change scores at 6 weeks
and we could estimate endscores and impute the SD. Schutz 2001
reported completer CGI-S and CGI-I endpoint scores at 6 weeks
and the latter were skewed and entered into Analysis 1.14.
Five studies (n = 160) provided CGI-S scores and they did not
show an overall effect of NRIs (MD −0.03, 95% CI −0.35 to
0.28; Analysis 1.13).We performed subgroup and sensitivity anal-
ysis (see Table 9). There was only one study of atomoxetine which
did not show a statistically significant benefit (Kelly 2009); and
excluding this to look at reboxetine resulted in a small benefit
for the control group which was not statistically significant (MD
0.10, 95% CI −0.23 to 0.42). Only Hinkelmann 2013 included
patients taking clozapine and specifically recruited those with neg-
ative symptoms and this showed a benefit of placebo that was not
statistically significant. Excluding imputed SDs slightly inflates the
benefit of NRIs but remains non-significant (MD−0.15; 95%CI
−0.60 to 0.29) - these were also the studies with skewed endscores
(Hinkelmann 2013; Poyurovsky 2003). A fixed-effectmodelmade
no difference. All trials were low risk of bias for randomisation. We
considered Kelly 2009 to be at high risk for other sources of bias
due to apparently changing exclusion criteria after randomisation.
1.15 Leaving the study early: 1a. Short term (2 to 12 weeks)
1.15.1 any reason
Li 2008 reported 4/115 withdrawals which could not be assigned
to a treatment arm and Sacco 2009 did not report withdrawals.
Eight trials (n = 401) reported little difference (RR 0.94, 95%
CI 0.63 to 1.39; Analysis 1.15). One of these eight trials had no
withdrawals so did not contribute to the overall estimate (Shafti
2015).
We performed subgroup and sensitivity analysis (see Table 10).
There was little difference when atomoxetine or reboxetine trials
were considered separately and the single viloxazine study showed
a similar lack of effect (Kurland 1981). No study included only
patients on clozapine and only Hinkelmann 2013 included any
patients taking clozapine and this study showed a non-significant
benefit for placebo. This was one of only two studies (the other
being Shafti 2015) recruiting patients specifically with negative
symptoms. A fixed-effect model made no difference to the rela-
tive risk. No study was at high risk of bias for randomisation and
five studies reported their methods in enough detail to be con-
sidered low risk; analysing these separately made little difference
(Hinkelmann 2013; Kelly 2009; Poyurovsky 2003; Poyurovsky
2007; Schutz 2001). We rated two studies as high risk of other
sources of bias (Eli Lilly 2006; Kelly 2009), two studies were high
risk for reporting bias (Eli Lilly 2006; Kurland 1981), and one
study (Kelly 2009) at high risk of attrition bias; but excluding
these made little difference.
1.15.2 due to adverse effects
Four studies (n = 178) showed a non-significant benefit of placebo
(RR 2.08, 95% CI 0.70 to 6.21; Analysis 1.15).
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We performed subgroup and sensitivity analysis for short-term
outcomes (see Table 11). Only Schutz 2001 looked at reboxetine
but this showed little difference from the atomoxetine studies.
None of the studies included patients taking clozapine and none
recruited specifically those with negative symptoms. A fixed-ef-
fect model made no difference. No study was at high risk of bias
for randomisation but only two studies were low risk and these
showed contrasting non-significant benefits for NRI or placebo
respectively and no overall effect when combined (RR 1.15, 95%
CI 0.15 to 8.60) (Kelly 2009; Schutz 2001). Two studies were at
high risk for other sources of bias (Eli Lilly 2006; Kelly 2009);
and excluding these magnified the benefit of placebo (RR 4.48,
95% CI 0.56 to 35.52). Eli Lilly 2006 also showed attrition and
reporting bias and excluding this slightly attenuated the benefit of
placebo which remained non-significant.
1.15.3 due to psychiatric symptoms
Eli Lilly 2006 and Kelly 2009 reported withdrawal due to psychi-
atric symptoms at 8 weeks. Poyurovsky 2007 reported withdrawal
due to lack of efficacy at 6 weeks.
Combining the three studies (n = 183) reporting withdrawal due
to psychiatric symptoms (variously described) showed no evident
difference between NRIs and placebo (RR 0.97, 95% CI 0.44 to
2.13; Analysis 1.15).
There were only three trials so we did not perform a full subgroup
and sensitivity analysis but fixed-effect analysis made no difference
(RR 1.01, 95% CI 0.47 to 2.20).
1.16 Leaving the study early: 1b. Medium term (13 to 26
weeks)
1.16.1 any reason
Zhao 2013 reported 3/110 withdrawals which could not be as-
signed to a treatment arm and Ganguli 2008 did not report with-
drawals.
Three trials (n = 169) reported medium-term (13 to 26 weeks)
outcomes (RR0.92, 95%CI0.52 to 1.62; Analysis 1.16)with little
difference (Ball 2011; Usall 2014; Yu 2012).There were only three
trials so a full subgroup and sensitivity analysis was not performed
but a fixed-effect model made little difference (RR 0.88, 95% CI
0.50 to 1.55).
1.16.2 due to adverse effects
The atomoxetine trial by Ball 2011 reported outcomes at 24 weeks
(RR 1.47, 95%CI 0.31 to 6.95; Analysis 1.16) and showed a non-
significant trend to favour controls.
1.16.3 due to psychiatric symptoms
Usall 2014 reported withdrawal due to acute exacerbation at 24
weeks.
This showed a benefit to placebo that was not statistically signifi-
cant (RR 4.44, 95% CI 0.22 to 88.04; Analysis 1.16).
1.17 Adverse effects: 1. General - short term (binary, 2 to 12
weeks)
1.17.1 any
The Eli Lilly 2006 study of atomoxetine reported treatment-emer-
gent adverse events as percentages whichwe could use to determine
the number of events in each group at 8 weeks and this showed
little difference between arms (RR 1.07, 95% CI 0.80 to 1.43;
Analysis 1.17). The Kurland 1981 trial of viloxazine reported that
there were no adverse events at 4 weeks. Shafti 2015 reported side-
effects in the reboxetine arm at 12 weeks and, assuming that there
were none in the placebo arm, this implies a very large risk of
side-effects associated with reboxetine (RR 19.00, 95% CI 1.17
to 309.77). When combined this indicates a large non-significant
benefit for placebo (RR 3.49, 95% CI 0.14 to 90.29; Analysis
1.17) with large heterogeneity (I² = 82%).
1.17.2 serious
The Eli Lilly 2006 study of atomoxetine reported serious adverse
events as percentages which we used to determine the number of
events in each group at 8 weeks. This showed an increased rate of
serious adverse events with atomoxetine that was not statistically
significant (RR 2.95, 95% CI 0.32 to 27.58). Hinkelmann 2013
reported that there were no serious adverse events at 4 weeks in
either reboxetine or placebo arms. Li 2008 reported one seizure
in the reboxetine arm of the study. Overall these showed a non-
significant benefit of placebo (RR 2.95, 95% CI 0.47 to 18.36;
Analysis 1.17). No deaths were reported in any study.
1.18 Adverse effects: 2a.i. Specific - short term (binary, 2 to
12 weeks)
Kelly 2009 reported rates of nausea, insomnia, dry mouth, consti-
pation, sedation, malaise (weakness, fatigue), dizziness, anorexia,
abdominal pain, vomiting, diarrhoea, sore throat, weight loss,
tremor, akathisia, restlessness, and stiffness over 8 weeks in com-
pleters and we calculated ITT figures. Li 2008 reported rates of
nausea, insomnia, dry mouth, constipation, dizziness, and tachy-
cardia over 12 weeks in completers and we could not calculate ITT
figures as withdrawals were not reported by study arm. Poyurovsky
2003 reported rates of daytime somnolence, akathisia, and use
of anticholinergic medication over 6 weeks in completers and
we calculated ITT figures. They also reported no gastrointestinal
29Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
side-effects (0/13 in both arms). Schutz 2001 reported rates of
nausea, dry mouth, fatigue, dizziness, impotence, rash, akathisia,
parkinsonism, acute dystonia, and hypersalivation over 6 weeks
in completers and we calculated ITT figures. Eli Lilly 2006 re-
ported percentages which we used to calculate rates of headache at
8 weeks. Poyurovsky 2003 reported that no anticholinergic med-
ication was used in either the reboxetine or placebo arms over 6
weeks. Poyurovsky 2007 and Shafti 2015 reported rates of anti-
cholinergic medication at 6 or 12 weeks respectively and we as-
sumed these to be ITT.
1.18.1 anticholinergic - constipation
One study showed a benefit for atomoxetine which was not signif-
icant (Kelly 2009); and one reboxetine study showed no effect (Li
2008). Overall there was a non-significant benefit for NRIs (RR
0.74, 95% CI 0.24 to 2.29; Analysis 1.18).
1.18.2 anticholinergic - dry mouth
Combining three studies (n = 176) showed an adverse effect of
NRIs (RR 3.46, 95% CI 1.40 to 8.53; Analysis 1.18).
As there were only three trials a full subgroup and sensitivity anal-
ysis was not performed but fixed-effect analysis made little differ-
ence (RR 3.55, 95% CI 1.45 to 8.70), nor did using completer
rather than ITT data (RR 3.35, 95% 1.35 to 8.30; N = 163).
1.18.3 anticholinergic - impotence
Schutz 2001 found no difference between reboxetine and placebo
(Analysis 1.18).
1.18.4 cardiovascular - tachycardia
For reboxetine, Li 2008 reported rates of tachycardia at 12 weeks
(RR 3.33, 95% CI 0.97 to 11.48) showing a benefit of placebo
that was not statistically significant (Analysis 1.18).
1.18.5 central nervous system - anorexia
Kelly 2009 showed no difference between atomoxetine and
placebo (Analysis 1.18).
1.18.6 central nervous system - dizziness
Combining these three studies (n = 176) did not suggest an effect
of NRIs (RR 1.52, 95% CI 0.54 to 4.31; Analysis 1.18).
There were only three trials so a full subgroup and sensitivity anal-
ysis was not performed but fixed-effect analysis made little differ-
ence (RR 1.55, 95% CI 0.55 to 4.33), nor did using completer
rather than ITT data (RR 1.60, 95% CI 0.57 to 4.52).
1.18.7 central nervous system - fatigue
One atomoxetine (Kelly 2009) and one reboxetine (Schutz 2001)
study gave no suggestion of an overall effect of NRIs (RR 1.00,
95% CI 0.12 to 8.60; Analysis 1.18).
1.18.8 central nervous system - headache
Eli Lilly 2006 found no difference between atomoxetine and
placebo (Analysis 1.18).
1.18.9 central nervous system - insomnia
One atomoxetine (Kelly 2009) and one reboxetine (Li 2008) study
showed a non-significant benefit for placebo (Analysis 1.18).
1.18.10 central nervous system - sedation
Combining one atomoxetine (Kelly 2009) and one reboxetine
(Poyurovsky 2003) study produced a non-significant benefit of
NRIs (RR 0.74, 95% CI 0.28 to 1.94; Analysis 1.18).
1.18.11 extrapyramidal - acute dystonia
Schutz 2001 reported no difference between arms (RR 1.00, 95%
CI 0.07 to 14.55; Analysis 1.18).
1.18.12 extrapyramidal - akathisia
Kelly 2009 reported rates of akathisia with a non-significant ben-
efit for atomoxetine and also rates of restlessness which were the
same in each arm. Poyurovsky 2003 reported no akathisia in either
the reboxetine or placebo arm while the rates in Schutz 2001 were
the same in each arm. Overall there was a marginal and non-sig-
nificant benefit for NRIs (RR 0.87, 95%CI 0.25 to 3.09; Analysis
1.18).
1.18.13 extrapyramidal - hypersalivation
Schutz 2001 reported a non-significant benefit for placebo on
hypersalivation (RR 0.33, 95% CI 0.01 to 7.58; Analysis 1.18).
1.18.14 extrapyramidal - parkinsonism
Schutz 2001 showed a non-significant benefit for placebo (RR
1.80, 95% CI 0.79 to 4.11; Analysis 1.18).
1.18.15 extrapyramidal - tremor
Kelly 2009 found no difference between the two arms (RR 1.00,
95% CI 0.24 to 4.23; N = 32; Analysis 1.18).
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1.18.16 extrapyramidal - stiffness
Kelly 2009 showed a non-significant benefit for atomoxetine (RR
5.00, 95% CI 0.66 to 38.15; Analysis 1.18).
1.18.17 extrapyramidal - use of antiparkinson medication
Poyurovsky 2003 reported no use in either the reboxetine or
placebo arms while combining Poyurovsky 2007 and Shafti 2015
showed little benefit of reboxetine (RR 0.80, 95%CI 0.44 to 1.45;
Analysis 1.18).
1.18.18 gastrointestinal - abdominal pain
Kelly 2009 showed no difference between atomoxetine and
placebo (Analysis 1.18).
1.18.19 gastrointestinal - nausea
Three studies (n = 176) showed a non-significant benefit for NRIs
(RR 0.49, 95% CI 0.10 to 2.41; Analysis 1.18).
As there were only three trials we did not perform a full subgroup
and sensitivity analysis but fixed-effect analysis made little differ-
ence (RR 0.63; 95% CI 0.28 to 1.43), nor did using completer
rather than ITT data (RR 0.60; 95% CI 0.15 to 2.41; N = 163).
1.18.20 gastrointestinal - vomiting
Kelly 2009 showed no difference between atomoxetine and
placebo (Analysis 1.18).
1.18.21 gastrointestinal - diarrhoea
Kelly 2009 found no difference between atomoxetine and placebo
(Analysis 1.18).
1.18.22 immune system - rash
Schutz 2001 showednodifference between reboxetine andplacebo
(Analysis 1.18).
1.18.23 immune system - sore throat
Kelly 2009 found no difference between atomoxetine and placebo
(Analysis 1.18).
1.18.24 metabolic - weight loss
Kelly 2009 showed no difference between atomoxetine and
placebo (Analysis 1.18).
1.18.25 metabolic - significant weight gain
Two reboxetine studies reported rates of weight gain, both using
the criterion of 7% or more increase in weight. Poyurovsky 2003
reported weight gain for completers at 6 weeks and we calculated
ITT rates from this while Poyurovsky 2007 reported ITT weight
gain at 6 weeks. Both studies showed a significant benefit for re-
boxetine which was demonstrated when they were combined (RR
0.38, 95% CI 0.20 to 0.73; Analysis 1.18). This benefit persists
utilising completer only rather than ITTdata for Poyurovsky 2003
(RR 0.37, 95% CI 0.19 to 0.75; N = 79).
1.19 Adverse effects: 2a.ii. Specific - extrapyramidal -
average change score (continuous, various scales, high =
worse) - short term (2 to 12 weeks)
Kelly 2009 reported SAS and AIMS endscores for atomoxe-
tine completers at 8 weeks which were skewed and entered into
Analysis 1.20 and we calculated change scores with SD imputed.
Poyurovsky 2007 reported SAS and BAS ITT change scores at 6
weeks for reboxetine: we calculated endscores with estimated SDs,
and the BAS endscore was skewed. Schutz 2001 reported SAS
endscores for reboxetine completers at 6 weeks which were skewed
and entered into Analysis 1.20 but it was not possible to calculate
change scores as baseline values were not available.
1.19.1 AIMS
AIMS change scores from Kelly 2009 showed no benefit of atom-
oxetine over placebo (MD 0.30, 95% CI−2.34 to 2.94; Analysis
1.19).
1.19.2 BAS
BAS change scores from Poyurovsky 2007 showed no benefit of
reboxetine over placebo (MD −0.18, 95% CI −0.65 to 0.29;
Analysis 1.19).
1.19.3 SAS
SAS change scores from Poyurovsky 2007 and Kelly 2009 showed
minimal benefit of NRIs (MD −0.27, 95% CI −1.79 to 1.25;
Analysis 1.19).
1.21 Adverse effects: 2b.i. Specific - medium term (binary,
13 to 26 weeks)
The reboxetine study of Zhao 2013 reported rates of nausea,
insomnia, dry mouth, constipation, dizziness, tachycardia, and
sweating over 24 weeks including all completers with no with-
drawals. Ball 2011 reported rates of tremor and QT prolongation
over 24 weeks in completers and we calculated ITT figures.
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1.21.1 anticholinergic - constipation
There was a statistically significant benefit for placebo (RR 4.58,
95% CI 1.04 to 20.23; Analysis 1.21).
1.21.2 anticholinergic - dry mouth
This showed a small but non-significant benefit for placebo (RR
1.53, 95% CI 0.27 to 8.78; Analysis 1.21).
1.21.3 anticholinergic - sweating
Zhao 2013 showed no difference between reboxetine and placebo
(Analysis 1.21).
1.21.4 cardiovascular - QT prolongation
Ball 2011 showed no difference between atomoxetine and placebo
(Analysis 1.21).
1.21.5 cardiovascular - tachycardia
There was a benefit of placebo that was not statistically significant
(RR 1.78, 95% CI 0.55 to 5.74; Analysis 1.21).
1.21.6 central nervous system - dizziness
This did not suggest an effect of reboxetine (RR 1.36, 95% CI
0.32 to 5.78; Analysis 1.21).
1.21.7 central nervous system - insomnia
We found a non-significant benefit for placebo (Analysis 1.21).
1.21.8 extrapyramidal - tremor
Ball 2011 showed a significant benefit of atomoxetine (RR 0.42;
95% CI 0.20 to 0.89; Analysis 1.21).
1.21.9 gastrointestinal - nausea
We calculated a large, but not statistically significant, benefit for
placebo (RR 5.09, 95% CI 0.62 to 42.16; Analysis 1.21).
1.22 Adverse effects: 2a.iv. Specific - metabolic - average
weight gain (continuous, increase in kg)
Ball 2011 did not report weight gain at 24 weeks directly but we
could estimate mean change from the figure and SD from the
mixed model. Poyurovsky 2003 reported weight gain at 6 weeks.
Poyurovsky 2007 reported ITT weight gain at 6 weeks. Zhao 2013
reported endpoint weight andwe calculated weight gain at 8 weeks
and 24 weeks with estimated SD. Endpoint weights were available
or could be estimated for all studies with no evidence of skew.
1.22.1 short term (2 to 12 weeks)
Three studies (n = 186) showed a significant benefit of reboxetine
(MD −2.17, 95% CI −3.19 to −1.15; Analysis 1.22).
There were only three trials so we did not perform a full subgroup
and sensitivity analysis but a fixed-effectmodel made no difference
(MD −2.17, 95% CI −3.19 to −1.15).
1.22.2 medium term (13 to 26 weeks)
We found a non-significant benefit of NRIs (MD−3.12, 95% CI
−10.67 to 4.42; Analysis 1.22) with very high heterogeneity (I² =
98%) from two studies. Ball 2011 found little effect of atomoxetine
while Zhao 2013 showed a large benefit with reboxetine.
1.23 Social or general functioning: Average social functioning
score (various subscales) - short-term (2 to 12 weeks)
The atomoxetine study of Friedman 2008 reported LOCF and
completer change scores for the six SLOF subscales at 8 weeks.
We analysed the change scores for completers but were able to
calculate LOCF endscores with estimated SD and these were not
skewed. We inverted these endscores were inverted by subtracting
from zero in order to display them in the same direction as the
SSPI scale. With the SLOF, inverted high scores are now worse.
The reboxetine study by Li 2008 reported endscores for the ten
SSPI subscales at 12 weeks. Three of these subscales were skewed
and we calculated change scores with estimated SD.
1.23.1 activity - activities (inverted SLOF, high = worse)
Friedman 2008 showednobenefit of atomoxetine (MD0.00, 95%
CI −3.30 to 3.30; Analysis 1.23).
1.23.2 activity - hospital activity (SSPI, high = worse)
Li 2008 found no benefit of reboxetine (MD −0.03, 95% CI
−0.17 to 0.11; Analysis 1.23).
1.23.3 activity - disease indoor activity (SSPI, high = worse)
This was analysed as a change score due to the subscale being
skewed and Li 2008 showed no benefit of reboxetine (MD−0.14,
95% CI −0.28 to −0.00; Analysis 1.23).
1.23.4 activity - physical functioning (inverted SLOF, high =
worse)
Friedman 2008 showed no benefit of atomoxetine (MD −0.30,
95% CI −1.12 to 0.52; Analysis 1.23).
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1.23.5 personal care - personal care skills (inverted SLOF,
high = worse)
Friedman 2008 showed no benefit of atomoxetine (MD −0.20,
95% CI −1.43 to 1.03; Analysis 1.23).
1.23.6 personal care - self-care (SSPI, high = worse)
We analysed this as a change score due to the subscale being skewed
and Li 2008 showed no benefit of reboxetine (MD −0.03, 95%
CI −0.22 to 0.16; N = 114; Analysis 1.23).
1.23.7 personal care - social acceptability (inverted SLOF,
high = worse)
Friedman 2008 showednobenefit of atomoxetine (MD0.10, 95%
CI −0.72 to 0.92; Analysis 1.23).
1.23.8 relationships - family role (SSPI, high = worse)
Li 2008 showed no benefit of reboxetine (MD −0.09, 95% CI
−0.23 to 0.05; Analysis 1.23).
1.23.9 relationships - interest and concern in the external
environment (SSPI, high = worse)
Li 2008 found a small benefit of reboxetine (MD−0.19, 95% CI
−0.37 to −0.01; N = 114; Analysis 1.23).
1.23.10 relationships - interpersonal relationships (inverted
SLOF, high = worse)
Friedman 2008 showed no benefit of atomoxetine (MD −1.20,
95% CI −5.41 to 3.01; Analysis 1.23).
1.23.11 relationships - relationships and caring for others
(SSPI, high = worse)
Li 2008 showed no benefit of reboxetine (MD −0.09, 95% CI
−0.24 to 0.06; Analysis 1.23).
1.23.12 relationships - sexual role (SSPI, high = worse)
Li 2008 showed no benefit of reboxetine (MD −0.03, 95% CI
−0.21 to 0.15; Analysis 1.23).
1.23.13 relationships - social withdrawal (SSPI, high =
worse)
We analysed this as a change score due to the subscale being skewed
and Li 2008 showed a benefit of reboxetine (MD−0.32, 95% CI
−0.49 to −0.15; Analysis 1.23).
1.23.14 work - professional skills (SSPI, high = worse)
Li 2008 showed a small benefit of reboxetine (MD −0.19, 95%
CI −0.34 to −0.04; Analysis 1.23).
1.23.15 work - responsibility and planning (SSPI, high =
worse)
Li 2008 showed no benefit of reboxetine (MD −0.03, 95% CI
−0.21 to 0.15; Analysis 1.23).
1.23.16 work - work skills (inverted SLOF, high = worse)
Friedman 2008 showed a benefit of atomoxetine (MD −3.00,
95% CI −5.48 to −0.52; Analysis 1.23).
Missing outcomes
There were no reported results from any study for two of the pri-
mary outcomes: significant response or improvement in a clinical
scale of cognitive functioning or in quality of life. While many
studies measured the PANSS positive subscale, the SAPS, and the
HRSD, none defined or reported response or relapse rates. No
studies reported scores for any other symptom scales not men-
tioned above. No studies reported rates of response or improve-
ment for composite cognitive scores or in any individual cogni-
tive domain (e.g. working memory). No studies reported occupa-
tional status, economic, or service utilisation outcomes (e.g. ad-
mission rates). No study reported ’significant’ extrapyramidal side-
effects or movement disorder but they did report rates of spe-
cific extrapyramidal symptoms and no studies reported cumula-
tive dosage of antiparkinson medication. No studies reported any
measures of satisfaction with treatment, the general impression of
carers beyond the CGI, or improvement in social functioning.
Sensitivity analysis
There was not sufficient data to combine studies in a meta-analysis
so we did not perform a subgroup and sensitivity analysis on the
primary outcome measures.
2. Comparison 2. NRI versus citalopram
Only two trials provided data to compare NRIs against an active
control - Hinkelmann 2013 and Usall 2014 - and both compared
reboxetine to citalopram, but at 4 weeks and 24 weeks respectively,
so they could not be combined in a meta-analysis.
2.1 Mental state: 1a. General: Average general/overall
symptoms score (PANSS general, high = worse) - short term
(2 to 12 weeks)
Hinkelmann 2013 reported LOCF PANSS general endpoint
scores at 4 weeks which were skewed and we entered these into
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Analysis 2.5 and calculated LOCF PANSS general change scores
with an estimated SD.
We found a a non-significant benefit of citalopram over reboxetine
(MD 2.90, 95% CI −2.85 to 8.65; Analysis 2.1).
2.2 Mental state: 1b. General: Average general/overall
symptoms score (various scales, high = worse) - medium
term (13 to 26 weeks)
Usall 2014 reported PANSS total and general endpoint scores at
24 weeks which were skewed and we entered into Analysis 2.6.
We calculated change scores with an estimated SD.
2.2.1 PANSS total
Usall 2014 found a non-significant trend for a benefit of citalo-
pramover reboxetine (MD1.62, 95%CI−6.89 to 10.13; Analysis
2.2).
2.2.2 PANSS general
Usall 2014 found little difference (MD 0.62, 95% CI −4.00 to
5.24; Analysis 2.2) at 24 weeks.
2.3 Mental state: 2a. Specific: Average symptoms score
(various scales, high = worse) - short term (2 to 12 weeks)
Hinkelmann 2013 reported LOCF PANSS negative, HRSD, and
PANSS positive endpoint scores at 4 weeks but these were skewed
and we entered them into Analysis 2.5. We calculated change
scores and imputed the SDs.
2.3.1 mood (HRSD)
This showed a fairly large but non-significant benefit of citalopram
over reboxetine (MD 3.00, 95% CI−1.24 to 7.24; Analysis 2.3).
2.3.2 negative (PANSS negative)
Hinkelmann 2013 found a non-significant benefit of citalopram
over reboxetine (MD 1.50, 95% CI−4.34 to 7.34; Analysis 2.3).
2.3.3 positive (PANSS positive)
We found a non-significant benefit of citalopram over reboxetine
(MD 1.70, 95% CI −1.52 to 4.92; Analysis 2.3).
2.4 Mental state: 2b. Specific: Average symptoms score
(various scales, high = worse) - medium term (13 to 26
weeks)
Usall 2014 reported PANSS negative and SANS endpoint scores
at 24 weeks which were skewed and entered into Analysis 2.6 and
we calculated change scores with imputed SDs.
2.4.1 negative (PANSS negative)
Usall 2014 found little difference (MD 0.26, 95% CI −3.66 to
4.18; Analysis 2.4).
2.4.2 negative (SANS)
There was minimal difference between reboxetine and citalopram
(MD −0.27, 95% CI −12.69 to 12.15; Analysis 2.4).
2.4.3 positive (PANSS positive)
Usall 2014 found little difference (MD 0.74, 95% CI −1.86 to
3.34; Analysis 2.4).
2.7 Clinical global response: Average clinical global status
score (CGI-S, high = worse) - short term (2 to 12 weeks)
Hinkelmann 2013 reported CGI-S endscores at 4 weeks which
were not skewed and showed no difference between reboxetine
and citalopram (MD 0.00, 95% CI−0.89 to 0.89; Analysis 2.7).
2.8 Leaving the study early: 1a. Short term (2 to 12 weeks)
2.8.1 any reason
In the short-termHinkelmann 2013 found a non-significant ben-
efit of reboxetine over citalopram (RR 0.63, 95% CI 0.17 to 2.41;
Analysis 2.8) at 4 weeks. Hinkelmann 2013 reported that there
were no serious adverse events at 4 weeks in either reboxetine or
citalopram arms.
2.9 Leaving the study early: 1b. Medium term (13 to 26
weeks)
2.9.1 any reason
At 24 weeks Usall 2014 found little difference (RR 1.13, 95% CI
0.48 to 2.67; Analysis 2.9). No deaths were reported.
2.9.2 due to psychiatric symptoms
Usall 2014 reported withdrawal due to acute exacerbation at 24
weeks which showed a non-significant benefit for citalopram over
reboxetine (RR 1.77, 95% CI 0.17 to 18.26; Analysis 2.9).
D I S C U S S I O N
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Summary of main results
Sixteen studies (39 articles, 919 participants) met the inclusion
criteria for this review, although only 14 studies contributed use-
able data for themeta-analysis. Belowwe discuss themain findings
outlined in the Summary of findings for themain comparison plus
selected additional adverse effects.
1. Mental state
1.1 Significant response or improvement in negative
symptoms
Only one study reported this outcome in a useable form. Shafti
2015 found a much greater response rate (20% reduction in the
SANS)with reboxetine at 12 weeks compared to placebo (Analysis
1.1) and is included in the Summary of findings for the main
comparison. Due to the limited evidence available we have rated
this finding as ’very low quality’ and it should be interpreted with
great caution. We therefore considered that it would be mislead-
ing to focus on this outcome in isolation when continuous out-
comes offer complementary and comparable information to di-
chotomous outcomes. Therefore we briefly discuss the results from
average negative symptom scores below.
1.1.1 Average negative symptom score
Three studies (N = 129) reported SANS continuous scores in the
short-term (2 to 12 weeks) and combining these we found no
benefit of reboxetine on negative symptoms compared to placebo
(Poyurovsky 2003; Poyurovsky 2007; Shafti 2015).However, there
was substantial heterogeneity and the effect was not robust with
a fixed-effect model showing a statistically significant benefit of
reboxetine. Kelly 2009 (N = 23) reported a modified version of
the SANS in the short term (2 to 12 weeks) which did not show
a significant benefit.
Six studies (N = 359) reported PANSS negative subscale contin-
uous scores in the short term (2 to 12 weeks) and we found no
benefit of NRIs over placebo (Friedman 2008;Hinkelmann 2013;
Li 2008; Schutz 2001; Yu 2012; Zhao 2013). There was again sig-
nificant heterogeneity and the effect was not robust as, for exam-
ple, a fixed-effect model showed a statistically significant benefit
of NRIs.
In themedium term (13 to 26 weeks) one study showed no benefit
of reboxetine on the SANS (Usall 2014;N =47)while three studies
(N = 219) reporting the PANSS negative subscale suggested a large
benefit of reboxetine over placebo (Usall 2014; Yu 2012; Zhao
2013). The medium term PANSS negative subscale result is not
included in the Summary of findings for the main comparison
and we consider it to be ’low quality’ by GRADE criteria due to
concerns about small sample size and the risk of bias in some of
the trials and so it should be interpreted with caution.
The more equivocal findings in the short term could represent a
correlation between duration of treatment and effect size and this
is borne out by the larger benefit of reboxetine in themedium term
compared to the short term seen in the two studies contributing
to both analyses (Yu 2012; Zhao 2013).
1.2 Significant response or improvement in positive
symptoms
No trials reported this outcome so we used average positive symp-
tom score as a surrogate and downgraded the quality of evidence
due to indirectness as per GRADE criteria.
1.2.1 Average positive symptoms score
Three studies (N = 129) reported SAPS continuous scores in the
short term (2 to 12 weeks) and we found no effect of reboxetine
(Poyurovsky 2003; Poyurovsky 2007; Shafti 2015). One study
(Kelly 2009; N = 23) reported short-term BPRS positive subscale
continuous scores and we found no difference between atomoxe-
tine and placebo.
Five studies (N = 294) reported PANSS positive subscale continu-
ous scores in the short term (2 to 12 weeks) with no effect of NRIs
over placebo (Friedman 2008;Hinkelmann 2013; Li 2008; Schutz
2001; Zhao 2013). We included this in the Summary of findings
for the main comparison and rated it as ’moderate quality’ due to
the small sample size. As a surrogate for the dichotomous outcome
we further downgraded to ’low quality’ due to the indirectness of
the measure and it should be interpreted with caution. The lack
of effect of NRIs on positive symptoms in the short term (2 to 12
weeks) was quite robust although the confidence intervals did not
completely exclude clinically significant effects.
Two further studies also reported medium-term (13 to 26 weeks)
outcomes without effect of reboxetine (Usall 2014; Zhao 2013; N
= 154).
2. Cognitive functioning
2.1 Significant response or improvement in clinical scale of
cognitive functioning
No trial reported this outcome.
2.2 Average composite cognitive functioning score
Four studies (N = 180) reported composite SMD effect sizes in the
short term (2 to 12 weeks) with no benefit for NRIs over placebo
(Eli Lilly 2006; Friedman 2008; Kelly 2009; Poyurovsky 2007).
and when we combined them there was a fairly robust lack of
benefit with confidence intervals excluding all but a small benefit
of NRIs. We included this result in the Summary of findings for
the main comparison and rated it as ’low quality’ due to the small
35Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sample size, width of the confidence intervals, and risk of bias in
some studies.
One study reported medium-term (13 to 26 weeks) outcomes for
atomoxetine without a significant benefit (Ball 2011; N = 26).
3. Quality of life
3.1 Significant response or improvement in quality of life
No trial reported this outcome so we used average quality of life
score as a surrogate and downgraded the quality of evidence due
to indirectness as per GRADE criteria.
3.1.1 Average quality of life score
One trial reported GQOLI-74 total and subscale continuous
scores in the short-term (2 to 12 weeks) and we found a benefit of
reboxetine on the total score and on two out of four subscales (psy-
chological and social wellbeing) compared to placebo (Li 2008; N
= 114). We included this result in the Summary of findings for the
main comparison and rated it as ’very low quality’ due to concerns
about the risk of bias in this trial and evidence of publication bias
and it should be interpreted with great caution.
4. Clinical global response
4.1 Significant response or improvement in clinical global
status
One study reported non-specific improvement rates which showed
no difference between placebo and viloxazine (Kurland 1981; N
= 28). We included this result in the Summary of findings for the
main comparison and rated it as ’very low quality’ due to concerns
about the quality of the trial and the risk of bias as well as evi-
dence of publication bias and it should be interpreted with great
caution. We therefore considered that it would be misleading to
focus on this outcome in isolation when continuous outcomes of-
fer complementary and comparable information to dichotomous
outcomes. Therefore we briefly discuss the results from average
clinical global status score below.
4.1.1 Average clinical global status score
Five studies (n = 160) reported CGI-S continuous scores in the
short term (2 to 12 weeks) and we found no benefit for NRIs
over placebo (Hinkelmann 2013; Kelly 2009; Poyurovsky 2003;
Poyurovsky 2007; Schutz 2001). These findings were robust al-
though the confidence intervals could not exclude a clinically sig-
nificant benefit. This result was not included in the Summary of
findings for the main comparison and we have rated it as ’moder-
ate quality’ by GRADE criteria due to the small sample size.
5. Leaving the study early
5.1 All cause withdrawals
Eight trials (n =401) reported short-term (2 to 12weeks) outcomes
and we found no difference in the rates of withdrawals between
NRIs and placebo (Eli Lilly 2006; Friedman 2008; Hinkelmann
2013; Kelly 2009; Poyurovsky 2003; Poyurovsky 2007; Schutz
2001; Shafti 2015). Three trials (n = 169) reported medium-term
(13 to 26 weeks) outcomes with similar results (Ball 2011; Usall
2014; Yu 2012). This lack of effect was robust but the confidence
intervals did not rule out clinically significant benefits or harms;
and withdrawals were poorly reported. We did not include this
result in the Summary of findings for the main comparison and
we have rated it as ’moderate quality’ using GRADE criteria due to
concerns about the small sample size andwide confidence intervals.
5.2 Withdrawal due to adverse events
Four studies (n = 178) reported results in the short term (2 to 12
weeks) and we found no difference in withdrawals due to adverse
events betweenNRIs and placebo (Eli Lilly 2006; Friedman 2008;
Kelly 2009; Schutz 2001). One medium-term (24 weeks) study
(N = 33) of atomoxetine also showed no difference (Ball 2011).
The confidence intervals did not rule out clinically significant ben-
efits or harms, and withdrawals were poorly reported. We did not
include this in the Summary of findings for the main comparison
and we have rated it as ’low quality’ using GRADE criteria due to
concerns about small sample size, wide confidence intervals, and
likely publication bias, and it should be interpreted with caution.
6. Specific adverse effects
6.1 Incidence of nausea
We were unable to include the data from one study (Hinkelmann
2013).
Three studies (n = 176) reported rates of nausea in the short term
(2 to 12 weeks) but we found no evidence of an increased rate with
NRIs over placebo (Kelly 2009; Li 2008; Schutz 2001). While
this was fairly robust the confidence intervals do not rule out clini-
cally significant benefits or harms and, overall, adverse events were
poorly reported and the number of events was low. This result is
included in the Summary of findings for the main comparison
and we have rated it as ’low quality’ due to concerns about publi-
cation bias, small sample size, and wide confidence intervals, and
it should be interpreted with caution.
One study reported rates in the medium term (13 to 26 weeks)
without a significantly increased rate with reboxetine (Zhao 2013;
N = 107).
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6.2 Average weight gain
Three studies (n = 186) reported weight gain in the short term (2
to 12weeks) andwe found that patients taking reboxetine gained 2
kg less on average than patients taking placebo (Poyurovsky 2003;
Poyurovsky 2007; Zhao 2013). This result was not included in the
Summary of findings for the main comparison and we have rated
it as ’low quality’ using GRADE criteria due to concerns about
publication bias and small sample size, and it should be interpreted
with caution.
Two studies reported medium-term (13 to 26 weeks) results, one
finding little benefit of atomoxetine (Ball 2011; N = 26), the other
a large benefit of reboxetine (Zhao 2013; N = 107).
6.3 Serious adverse events
Three studies (N = 271) reported rates of serious adverse events
in the short term (2 to 12 weeks) and we did not find evidence
of an increased rate with NRIs compared to placebo (Eli Lilly
2006; Hinkelmann 2013; Li 2008). The confidence intervals did
not rule out clinically significant harms and overall adverse events
were poorly reported. We did not include this in the Summary of
findings for the main comparison and we have rated it as ’very low
quality’ using GRADE criteria due to concerns about the small
sample size with few events and very wide confidence intervals and
also likely publication bias and it should be interpreted with great
caution.
6.4 Other specific adverse effects
We analysed other specific adverse effects, including insomnia,
dry mouth, constipation, sedation, fatigue, dizziness, tachycardia,
tremor, and akathisia. Single trials reported rates of QT-prolon-
gation, headache, vomiting, diarrhoea, anorexia, weight loss, ab-
dominal pain, sore throat, impotence, rash, sweating, parkinson-
ism, acute dystonia, and hypersalivation. Only for dry mouth did
we find rates significantly higher for NRIs over placebo in the
short term (2 to 12 weeks). In the medium term (13 to 26 weeks)
single studies suggested constipation rates were greater with rebox-
etine while rates of tremor were lower with atomoxetine. These
results were not included in the Summary of findings for the main
comparison and in general wewould rate them as ’very low quality’
using GRADE criteria due to concerns about small sample sizes,
few events, very wide confidence intervals, and likely publication
bias and they should be interpreted with great caution. The el-
evated rate of dry mouth with NRIs in the short term (2 to 12
weeks) from three studies (Kelly 2009; Li 2008; Schutz 2001; N
= 172) was rated as ’low quality’ due to concerns about the small
sample size and likely publication bias and should be interpreted
with caution.
Overall completeness and applicability of
evidence
1. Completeness
1.1 Outcomes
The majority of reported outcomes were mental state scales (e.g.
the PANSS), clinical global response (CGI-S), or cognitive tests.
However, even for these outcomes there was evidence of consid-
erable under-reporting and possible publication bias. Few studies
attempted to utilise their continuous outcome measures to de-
fine response rates and thus there were few dichotomous outcome
measures reported. Dichotomous outcomes, such as the propor-
tion of patients with a 50% reduction in scores on mental state
scales, offer complementary information to the mean scores on
symptom scales by emphasising the number of patients with clin-
ically significant improvements rather than differences in mean
symptom scores averaged across all patients. More patient-centred
outcomes (that likely are more relevant for long-term prognosis)
such as quality of life, social functioning, occupational status, or
carer or patient satisfaction, were rarely reported if at all. With-
drawal rates were around 20% overall and did not differ between
NRI and placebo arms, suggesting that the validity of outcomes
was not compromised.
The limited number of small studies included makes detection of
rare but serious adverse events highly unlikely, including those of
specific interest such as suicide or acute liver failure. For instance,
it is very difficult to interpret the finding of one patient devel-
oping seizures in the NRI arm of a single study as we found in
this review. We did not detect an increased rate of even the most
commonly reported side-effect with NRIs (nausea) and given the
low event rate it is likely that for most side-effects we did not have
the sensitivity to detect an increased rate with NRIs. As is unfor-
tunately often the case in clinical trial reporting, while side-effects
were measured by most studies they were infrequently reported in
a useable form. Therefore, although NRIs seemed generally rela-
tively well tolerated, there was certainly evidence consistent with
NRIs being associated with an increased rate of side-effects.
It is increasingly recognised that the economic costs of inter-
ventions are important to guide recommendations for treatment.
However, no studies reported on economic outcomes or possible
proxies for this, such as hospitalisation.
1.2 Duration
The majority of trials were short term (2 to 12 weeks) with some
medium term (13 to 26 weeks) and none long term (> 26 weeks).
There was some evidence that the benefits of NRIs increase with
a longer course of treatment. Therefore it is disappointing that so
few studies followed patients up longer than a few weeks when the
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natural history of schizophrenia and likely duration of treatment
would suggest much longer trials are needed to inform treatment
decisions.
2. Applicability
2.1 Patients
The majority of trials included only patients with schizophrenia
(mostly using DSM-IV criteria), limiting applicability to patients
with other schizophrenia spectrum disorders such as schizoaffec-
tive disorder. As is usually the case with clinical trials most studies
excluded patients with physical or psychiatric comorbidities, and
substance misuse in particular, which somewhat limits applicabil-
ity to real life clinical populations where comorbidity is common.
The patient populations included in each study were relatively
poorly characterised but overall it appeared that it was primarily
patients with more chronic presentations.
Trials were conducted in awide range of countries including Spain,
South Africa, China, Israel, Iran, and the United States. While
most outcomes were homogeneous it is noticeable that in those
cases where there appeared to be benefits of NRIs over placebo,
these frequently involvedChinese studies (Li 2008; Yu 2012; Zhao
2013), although this is also confounded, with studies specifically
recruiting patients with negative symptoms or taking clozapine,
and other studies recruiting patients with negative symptoms (e.g.
Shafti 2015;Usall 2014), also showing trends for a benefit ofNRIs.
2.2 Dosage
Most studies used doses of reboxetine up to 8 mg daily with the
rest using up to 4 mg daily. However, 8 mg daily is the starting
dose of reboxetine for depression and it can be increased up to 12
mg daily (BNF 2016), suggesting that it may have been under-
dosed in these trials. The more positive Chinese studies used doses
of 8 mg daily.
Most trials using atomoxetine titrated up to 80 mg daily, with one
study using doses up to 120 mg daily and one study including
an arm with 40 mg daily. When used for ADHD atomoxetine is
started at 40 mg daily, and increased to a usual maintenance dose
of 80 mg to 100 mg daily, and can be increased up to 120 mg
daily (BNF 2016), again suggesting that most trials may have used
doses at the lower end of the therapeutic range.
2.3 Setting
Where reported, most trials included only inpatients, and while
most outcomeswere not heterogeneous it is noticeable that in those
cases where there appeared to be benefits of NRIs over placebo
these frequently involved Chinese inpatients.
Quality of the evidence
For most domains of bias we judged the majority of trials to be
of unclear or low risk; however in most domains there were also
some trials at high risk of bias (see Figure 2; Figure 3). Although
we included one open trial (Yu 2012), our sensitivity analyses did
not suggest that this was driving the outcomes. We considered
the quality of the current evidence to be low or very low using
GRADE criteria, except for the findings of no effect of NRIs on
CGI-S and PANSS positive score (Summary of findings for the
main comparison); or all cause withdrawals, where we considered
the evidence to be of moderate quality. The quality of evidence
was downgraded due to small sample sizes with wide confidence
intervals, poorly described methods, and evidence of selective re-
porting of outcomes and publication bias. There was a mixture of
studies funded by pharmaceutical companies and by government
agencies with no evidence of differential outcomes depending on
funding source. There was a particular issue with skewed outcomes
and we were unable to establish whether utilising change scores
rather than endscores ameliorated this. We also made widespread
utilisation of imputed SD. In our sensitivity analyses we did not
detect evidence that skewed scores or imputed SD made a sub-
stantial difference to results.
Potential biases in the review process
1. Unpublished data
Our review has certainly identified the most studies of NRIs in
schizophrenia to date. A number of the included studies were per-
formed in China and reported in Chinese and had not previously
been identified. This suggests that there may be a considerable
literature available, published in regional non-English journals.
There were also a number of studies which did not fully report
their results or which appear to be completed but unpublished,
suggesting that there is still a substantial amount of data that we
have not been able to include in the review.
2. Poor reporting and publication bias
A number of studies did not provide useable data, often reporting
no significant effect on these outcomes, which suggests the pos-
sibility of publication bias for positive studies. However, the vast
majority of studies found no significant changes, partially due to
small effect sizes resulting in low statistical power. The NRI litera-
ture is unusual in that most published studies have found negative
results but more recently larger more positive studies have been
published. It is possible that some smaller negative studies were
not thought to warrant publication given the largely negative ex-
isting literature. Due to the limited number of studies, it was not
possible to perform funnel plots to investigate publication bias.
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3. Chinese studies
Three positive Chinese studies were major contributors to our
review, driving many significant results (Li 2008; Yu 2012; Zhao
2013). There is some evidence that trial results from non-Western
countries tend to over-report positive findings (Panagiotou 2013),
particularly Chinese studies, and the most likely explanation for
this is lower trial quality (Zhang 2011). We have not specifically
conducted sensitivity analyses excluding these trials, preferring to
rely on our assessments of risk on a trial-by-trial basis. Apart from
the unblinded study by Yu 2012, the other two Chinese trials -
Li 2008 and Zhao 2013 - were not clearly of lower quality than
the other studies in this review (Figure 3) but it is noticeable that
reported standard deviations in all three trials were smaller than
for the other trials included in this review and the random-effects
model we used will only partially compensate for this.
Agreements and disagreements with other
studies or reviews
We have reported effect sizes in terms of the underlying measure-
ment scales in order to facilitate their interpretation. Paradoxically
this makes comparisons with other studies difficult as these have
mostly used the SMD as a measure of effect size. For illustrative
purposes we have converted the short-term PANSS total scores
and medium-term PANSS negative scores to the corresponding
SMD using all change scores (as endscores and change scores can-
not be combined when calculating the SMD). The PANSS total
effect size goes from 2.8 to 2.4 points using change scores and
this corresponds to an SMD of 0.4. Similarly the PANSS negative
effect size goes from 3.3 to 3.7 points using change scores and this
corresponds to an SMD of 1.1.
Rummel-Kluge 2006 conducted aCochraneReviewof antidepres-
sants for negative symptoms in schizophrenia but did not include
any selective noradrenaline reuptake inhibitors (NRIs), specifically
excluding three studies as they did not recruit patients with pre-
dominantly negative symptoms (Kurland 1981; Poyurovsky 2003;
Schutz 2001). Another Cochrane Review by Whitehead 2002
looked at the use of antidepressants in patients with comorbid
schizophrenia and depression but the only trial of NRIs identi-
fied was Kurland 1981. Vernon 2014 conducted a review of an-
tidepressants for cognitive symptoms in schizophrenia and found
mostly non-significant or clinically unimportant effects and only
identified one NRI study (Poyurovsky 2007). Singh 2010 con-
ducted ameta-analysis looking at antidepressants for the treatment
of the negative symptoms of schizophrenia. This found an overall
benefit of antidepressants with an SMD around 0.5; but looking
at three studies - Poyurovsky 2003, Poyurovsky 2007 and Schutz
2001 - concluded there was no benefit of reboxetine. They did
not include atomoxetine as it is not considered an antidepressant.
It is interesting that studies of mirtazapine and mianserin have
found larger benefits than studies of SSRIs since the former have
noradrenergic as well as serotonergic effects (Hecht 2012; Kishi
2014). We had only limited evidence to compare NRIs directly
against SSRIs but two studies including reboxetine and citalopram
arms found no statistically significant differences between them
(Hinkelmann 2013; Usall 2014). However, neither study found a
benefit of either citalopram or reboxetine over placebo and were
not sufficiently powered to detect differences.
The most comparable study to our review is a meta-analysis by
Kishi 2013 which updates Singh 2010 to look specifically at nora-
drenaline reuptake inhibitors. They included seven studies which
are also included in our review (Ball 2011; Friedman 2008; Kelly
2009; Poyurovsky 2003; Poyurovsky 2007; Sacco 2009; Schutz
2001). They also included Poyurovsky 2013, which we excluded
from our review as the intervention was reboxetine plus betahis-
tine. In addition they included a trial of mazindol which they clas-
sified as a noradrenaline reuptake inhibitor but pointed out that
it is known to additionally inhibit dopamine and serotonin re-
uptake. As our study looked specifically at selective noradrenaline
reuptake inhibitors (NRIs) we made an a priori decision not to
include mazindol. There were nine additional studies identified
and included in our review that were not included in Kishi 2013
(Eli Lilly 2006; Ganguli 2008; Hinkelmann 2013; Kurland 1981;
Li 2008; Shafti 2015; Usall 2014; Yu 2012; Zhao 2013). They
are characterised mostly by having been published more recently
or being published in Chinese. Kishi 2013 found no benefit of
NRIs on overall, positive, or negative symptoms of schizophre-
nia with a borderline significant benefit on depressive symptoms.
They also found no greater side-effects with noradrenaline reup-
take-inhibitors except for an increased pulse rate and weight loss.
Areas of overlap include the findings of NRIs benefiting depres-
sive symptoms and decreasing weight gain and a general lack of
side-effects for NRIs. Areas of difference include our finding of a
benefit of NRIs on PANSS total scores in the short term (2 to 12
weeks) and PANSS negative scores in the medium term (13 to 26
weeks). It is notable that few of the studies contributing to these
outcomes were included in Kishi 2013. The increased rate of dry
mouth in our review was not analysed by Kishi 2013 and we did
not look specifically at heart rate as a continuous outcome. They
did not analyse cognitive outcomes, social functioning, or quality
of life. We included viloxazine in our review as the limited data
available about its pharmacological profile suggests it is selective
for noradrenaline reuptake but it contributed few measures to our
analysis.
Choi 2015 conducted a meta-analysis looking at medication for
weight control in schizophrenia and identified two out of three
studies included in our short-term analysis - Poyurovsky 2003 and
Poyurovsky 2007 - finding a similar effect size. Mizuno 2014 also
looked at medication for weight control and as well as the two
studies included in Choi 2015 they also identified the Ball 2011
study of atomoxetine which showed no benefit on weight. Neither
review identified Zhao 2013.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
People with schizophrenia should know that there is not much
evidence to draw conclusions about the effectiveness of NRIs in
schizophrenia. What evidence there is suggests that NRIs, rebox-
etine in particular, added to antipsychotic medication might help
with negative symptoms although this benefit is likely to be fairly
small and may not be noticeable in real life. The main side-effects
of NRIs are reduced weight gain, compared to taking antipsy-
chotics alone, and dry mouth.
2. For clinicians
The available evidence from RCTs of NRIs used to augment an-
tipsychotic medication provides tentative support for a benefit on
negative symptoms that is fairly small in terms of absolute im-
provements on rating scales and is largely driven by trials from
China mostly of inpatients taking clozapine. There was not suf-
ficient evidence to usefully compare NRIs to SSRIs. Findings on
individual quality of life and social functioning scales are inter-
esting but far too unreliable to guide clinical practice. One note-
worthy finding is that the positive symptoms of schizophrenia do
not appear to be exacerbated by NRIs and this is of interest if,
for example, use of atomoxetine was planned for the treatment
of comorbid ADHD. The evidence does not show any benefit of
NRIs for cognitive functioning in schizophrenia. Reboxetine re-
liably seems to attenuate antipsychotic-induced weight gain. The
benefit is relatively small (around 2 kg on average in the short term;
and 7 kg in the medium term) but does highlight that the side-
effects of reboxetine do not usually include weight gain in contrast
to many other strategies for augmenting antipsychotic treatment.
NRIs appear generally well tolerated with themain identified side-
effect being dry mouth.
3. For policy makers
Policy makers should support further trials into potential treat-
ments for the more difficult to treat, but likely more disabling,
negative and cognitive symptoms of schizophrenia. They should
also mandate where possible the comprehensive publication of re-
search findings needed to fully assess the totality of evidence for
any given treatment.
Implications for research
1. General
The quality of reporting of clinical trials remains poor and there is
evidence that many have not been published. Outcomes continue
to be reported selectively and often not in a useable form for
meta-analysis. There is also poor reporting of adverse effects and
withdrawals. We have written to the corresponding authors of
included and ongoing studies but have received few responses.
This is a significant failure in the clinical trials process which has
not been addressed by the pre-registration of trials, and represents
a waste of financial investment and clinical knowledge. Following
CONSORT standards (Moher 2001) and making data available
for future researchers (AllTrials) would go a long way to addressing
this.
2. Specific
2.1 For reviews
Several of the included and excluded studies could also be relevant
for other existing Cochrane Schizophrenia Group reviews (Table
12). In particular this suggests the need for a review of serotonergic
antidepressant augmentation in schizophrenia that does not just
focus on those with negative symptoms.
2.2 For trials
The evidence base for NRIs in schizophrenia has developed from
a series of relatively small studies showing little benefit to increas-
ingly larger studies showing more significant effects. Given the
accumulating but equivocal evidence for a benefit of NRIs in
schizophrenia, further larger RCTs are clearly needed. There was
evidence from our results that treatment in themedium term leads
to greater benefits from NRIs, suggesting that longer trials are in-
dicated. There were also hints that recruiting specifically patients
with prominent negative symptoms or on clozapine could also
magnify the benefit. Although in many ways reboxetine is a drug
looking for an indication in our review, the evidence was more
supportive of reboxetine than atomoxetine. While the results of
cognitive testing were generally negative these were all short-term
and usually involved atomoxetine rather than reboxetine. A larger
RCT (with hundreds rather than tens of patients) investigating the
benefit of reboxetine on negative symptoms and cognitive func-
tioning over a longer period (at least 3 months) would be most in-
formative, particularly if including patients with prominent neg-
ative symptoms and using higher doses (at least 8 mg daily). See
Table 13 for a suggested design for a future RCT.
A C K N OW L E D G E M E N T S
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TheCochrane SchizophreniaGroup (CSG) Editorial Base inNot-
tinghamproduces andmaintains standard text for use in theMeth-
ods section of their reviews. We have used this text as the basis
of what appears here and adapted it as required. Our thanks to
Clive Adams and Claire Irving for providing editorial support and
advice and particular thanks to Farhad Shokraneh for his help and
advice in designing the search strategy and Clive Adams for exten-
sive assistance in revising the final text.
We would like to thank Dr Qi Pei for her assistance with Chinese
translations and checking the accuracy of data extraction from
Chinese papers.
We are grateful to those authors who responded to enquiries to
provide additional data or to clarify methods.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ball 2011
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 24 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder
N = 37 (data from 36)
Age: 18 to 65 years (mean 47 years)
Sex: 11 F, 25 M
History: clinically stable outpatients, mean baseline BPRS total score 33 (mild severity),
duration of illness not reported but all patients treated for at least 6 months, participants
from Maryland Psychiatric Research Center Outpatient Program, DSM-IV diagnoses,
taking clozapine (N = 18 with 10 also taking risperidone) or olanzapine (N = 18) for at
least 6 months with weight gain greater than 7% since initiation
Exclusions: those on medication with central noradrenergic effects or associated with
weight gain (unless stable for over 6 months), other weight-loss medication, pregnancy,
DSM-IV mental retardation or alcohol or substance dependence in 6 months or abuse
in the last 1 month (excluding nicotine), uncontrolled hypertension
Interventions 1.NRI: atomoxetine titrated from40mgdaily to 120mgdaily byweek 8 (dose reductions
permitted). N = 19
2. Placebo. N = 17
Outcomes Mental state: BPRS total score†§
Cognitive functioning: composite neuropsychological z-score‡§
Leaving the study early
Adverse effects: specific side-effects (tremor, QTc prolongation)§, weight change§
Unable to use (no means or SD reported)
Mental state: BPRS subscales, SANS
Clinical global response: CGI
Cognitive functioning: Individual neuropsychological tests
Adverse effects: AIMS, SAS, SEC
Notes Given a weight loss programme (Weight Watchers) in both arms of the trial using a
token system to encourage compliance
Patient population overlaps with Kelly 2009 but each study randomised separately
Funded by Eli Lilly and NIH, no declarations of interest
Additional correspondence with author M Patricia Ball (PB) clarifying randomisation
and blinding (see below)
Date study conducted not reported but overlapping study Kelly 2009 conducted 2004
to 2006 in the United States
Risk of bias
Bias Authors’ judgement Support for judgement
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Ball 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
“Randomization was conducted separately
within those 3 strata, with an additional
stratification by site (MPRC inpatient,
MPRC outpatient or VA) within each of
the 3 trial participation strata, using a ran-
domizated block design[*]
“A permuted block design was used to as-
sign treatments within the three strata de-
scribed in my previous e-mail. The ran-
dom treatment assignments sequences were
generated in advance by the study statis-
tician, and prior to the completion of the
study the only persons with access to the
sequence were the study statistician and the
unblinded pharmacist who prepared the
study medication (identical appearing cap-
sules containing atomoxetine or placebo)
for the patients. When a treatment assign-
ment was requested for a new participant,
the statistician e-mailed a code number to
the pharmacist, who kept a list of the code
numbers and corresponding treatments in
a locked cabinet in the his/her office” PB
*The 3 strata are those participating in Ball
2011, Kelly 2009, or both
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As above
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals accounted for but evidence of
differences in reasons between treatment
and placebo arms
Selective reporting (reporting bias) High risk Selective reporting of outcome measures
evident
Other bias Low risk No other specific biases noted
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Eli Lilly 2006
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 8 weeks
Participants Diagnosis: schizophrenia
N = 121 (data from 92)
Age: 18 to 55 years (mean 41 years)
Sex: 22 F, 99 M
History: baseline severity and duration of illness not reported, multicentre study (18
centres in USA), stabilised on aripiprazole, risperidone, quetiapine, olanzapine over 2
months with a stable dose for 8 weeks and dose unchanged during study, DSM-IV
diagnoses
Exclusions: serious health problems, antidepressant for depression, insulin for diabetes,
alcohol or drug dependence (except caffeine or nicotine) in last 6 m
Interventions 1. NRI: atomoxetine titrated up to 40 mg twice daily over 2 weeks. N = 61
2. Placebo: twice daily dosing. N = 60
Outcomes Cognitive functioning: composite cognitive index‡§, Brief Assessment of Cognition in
Schizophrenia (BACS) Verbal Memory, Digit Sequencing Task, TokenMotor Task, Ver-
bal Fluency, Symbol Coding Task, Tower of London scores†§, Continuous Performance
Test (CPT) 4 digit identical pairs scores†§
Leaving the study early
Adverse effects:
Adverse events§
Unable to use (no data presented)
Mental state: PANSS, MADRS
Clinical global response: CGI-I
Cognitive functioning: Penn Emotional Recognition Test, Penn Facial Memory Test
Adverse effects: weight, BAS, SAS, AIMS
Social or general functioning: Drug Attitude Inventory (DAI-10), Social Functioning
Scale, Independent Living Scale
Notes ITT LOCF for all patients with at least 1 post-baseline observation
Data provided by Eli Lilly
Funded by Eli Lilly, no declarations of interest
Study conducted from 2003 to 2005 in the United States
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
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Eli Lilly 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
High risk More withdrawals in the atomoxetine arm
(6 vs 2) with reasons for withdrawals in the
atomoxetine arm frequently related to psy-
chiatric symptoms (e.g. hospitalisation for
acute psychosis)
Selective reporting (reporting bias) High risk Selective reporting of outcome measures
evident
Other bias Unclear risk Baseline imbalance in cognitive scores but
not statistically significant and unclear if
this has had a significant impact on the re-
sults
Friedman 2008
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 8 weeks
Participants Diagnosis: schizophrenia
N = 20 (15 completers)
Age: not reported
Sex: not reported
History: baseline severity borderline ill (mean PANSS 66), duration of illness not re-
ported, psychiatry outpatients in the New York area, DSM-IV diagnoses, taking risperi-
done, olanzapine, quetiapine, or aripiprazole on stable dose for ≥ 4 weeks, no other
psychotropics
Exclusions: not reported
Interventions 1. NRI: atomoxetine 40 mg once daily for 4 weeks then 40 mg twice daily for 4 weeks.
N = 7
2. Placebo: once daily for 4 weeks then twice daily for 4 weeks. N = 8
Outcomes Mental state: PANSS positive, negative, and general scores†§
Cognitive functioning: Brief Assessment of Cognition in Schizophrenia (BACS) com-
posite score, list learning test, digit sequencing, tokenmotor task, category instances test,
controlled oral word association test, Tower of London test, symbol coding change z-
scores†§
Leaving the study early
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Friedman 2008 (Continued)
Social or general functioning: Specific Level of Functioning (SLOF) scale physical func-
tioning, personal care skills, interpersonal relationships, social acceptability, activities,
work skills change scores†§
Unable to use (data not reported)
Cognitive functioning: N-back task
Notes FMRI study of N-back task
LOCF and completer data reported
Funding from Eli Lilly, NIH, US Dept Veterans Affairs. Reported conflicts of interest
include shares, grants, and advisory boards for Eli Lilly
Study conducted in the United States but the date was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind...matching placebo”
Non-concurrence in ratings (PM: unclear
risk; MP: low risk) and overall unclear risk
agreed after discussion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar number of withdrawals between
groups, reasons for withdrawals dissimilar
between groups but overall unlikely to im-
pact on effect sizes
Selective reporting (reporting bias) Low risk All outcomes of interest reported
Other bias Low risk No other specific biases noted
Ganguli 2008
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 26 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder
N = 60 (30 completers)
Age: 18 to 65 years
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Ganguli 2008 (Continued)
Sex: not reported
History: baseline severity mild illness (PANSS ≤ 80), duration of illness not reported,
prominent negative symptoms, 30 days stable dose of antipsychotics (and other psy-
chotropics), no hospital admission in last 30 days, DSM diagnosis of schizophrenia,
birth control, ≥ 10 on 5 SANS global ratings, ≥ 3 on 2 global items and mean score ≤
4 on General Life Satisfaction on Lehman’s QoL
Exclusions: inability to give informed consent, alcohol or substancemisuse or dependence
in last 6 months, narrow angle glaucoma or organic brain disease, history of uncontrolled
diabetes mellitus or hypertension, liver disease, cerebrovascular disease or myocardial
infarction in last 3 months, use of venlafaxine, MAOI, cytochrome p450
2d6 inhibitors (e.g. fluoxetine), salbutamol, or psychostimulant currently or last 2 weeks
Interventions 1. NRI: atomoxetine 40 mg twice daily
2. Placebo
Outcomes Unable to use (data not reported)
Mental state: SANS, PANSS, Calgary Depression Scale
Clinical global response: CGI
Cognitive functioning: Cognitive battery
Quality of life: Lehman’s quality of life scale (QoL)
Social or general functioning: General Assessment of Functioning (GAF)
Notes Funded by the Stanley Research Foundation, conflicts of interest not reported
Date conducted not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised double blind”
Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Half of all participants did not complete
the trial
Selective reporting (reporting bias) High risk No useable outcomes reported
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Ganguli 2008 (Continued)
Other bias Unclear risk Due to limited published information
about this trial it was not possible to estab-
lish other sources of bias
Hinkelmann 2013
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 4 weeks
Participants Diagnosis: schizophrenia
N = 51 (43 completers)
Age: Mean 40 years
Sex: 17 F, 34 M
History: baseline severity markedly ill (CGI 5), mean duration of illness 12 years, DSM-
IV,≥ 4 on at least 1 PANSS negative item, 2 weeks stable antipsychotic dose (olanzapine
5, quetiapine 5, clozapine 7, amisulpride 9, risperidone 13, aripiprazole 2, combined
10) kept stable throughout study
Exclusions: alcohol or substance abuse, other psychiatric or somatic disorders, abnormal
laboratory findings
Interventions 1. NRI: reboxetine 4 mg capsule once daily and increased as needed to twice daily after
1 week. N = 19
2. Placebo: 1 capsule once daily and increased as needed to twice daily after 1 week. N
= 16
3. Active control: citalopram 20 mg capsule once daily and increased as needed to twice
daily after 1 week. N = 16
Outcomes Mental state: PANSS positive, negative, general, HRSD scores†§
Clinical global response: CGI-S†§
Leaving the study early
Adverse effects: ‘Serious’ side-effects§, agitation side-effect§
Unable to use (data not reported)
Mental state: PANSS total, PANSS negative responder rate
Adverse effects: UKU side-effects rating scale, AIMS, SAS, BAS, other specific side-
effects
Notes Lorazepam (up to 2 mg daily), zolpidem (up to 10 mg daily), and zopiclone (up to 7.5
mg daily) allowed
ITT LOCF analysis for those with data after 1 week
PANSS ’global’ results reported but these appear to be the PANSS general subscale and
are treated as such
Funding from the Stanley Medical Research Institute, reported conflicts of interest in-
clude multiple honoraria, expenses, and grants from various pharmaceutical companies
including Eli Lilly and Pfizer
Study conducted from 2002 to 2008, although it is not explicitly stated it is presumed
to have been carried out in Germany
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization was organized using
the PLAN procedure from the SAS/STAT
software”
Allocation concealment (selection bias) Low risk “Allocation codes for each patient were pro-
vided in sealed envelopes through the phar-
macy”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More withdrawals in the reboxetine arm (3
vs 1) and reasons for withdrawals not given
Selective reporting (reporting bias) Unclear risk Evidence of some secondary outcome mea-
sures not reported from Stanley Founda-
tion grant abstract
Other bias Low risk Some baseline imbalance but not statisti-
cally significant and unlikely to have a ma-
jor impact
Kelly 2009
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 8 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder
N = 32 (data from 22)
Age: 18 to 60 years (mean 49 years)
Sex: 6 F, 16 M
History: baseline severity markedly ill (CGI 4.5), mean duration of illness not reported
directly but mean 24 years since first hospitalisation, inpatients and outpatients, DSM-
IV, cognitive impairment (RBANS ≤ 90), 4-week stable dose of atypical antipsychotics
(olanzapine 13, quetiapine 2, risperidone 11), 2 week stabilisation phase before ran-
domisation, psychotropics at a stable dose for 4 weeks, no medication changes during
study
Exclusions: on clozapine or aripiprazole, organic brain disease, alcohol or substance abuse
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Kelly 2009 (Continued)
in last 1 month or dependence in last 6 months, pregnancy, uncontrolled hypertension,
venlafaxine or MAOI use, anticholinergics or benzodiazepines (but see below)
Interventions 1. NRI: atomoxetine 40 mg capsule once daily for 2 weeks then 80 mg once daily for 6
weeks. N = 16
2. Placebo: 1 capsule once daily for 2 weeks then 2 capsules once daily for 6 weeks. N =
16
Outcomes Mental state: BPRS total, positive, anxiety/depression, and hostility scores, modified
SANS total score†§
Clinical global response: CGI†§
Cognitive functioning: Composite mean scores for cognitive tests‡, WAIS-III Letter-
Number Sequencing and Number-Sequencing Test, WAIS-III Digit Symbol, Grooved
Pegboard, Letter Fluency,Woodcock Johnson Planning, California Verbal Learning Test,
Brief Visuospatial Memory Test, distractibility version of the GDS Continuous Perfor-
mance Test (many scores considered to be skewed)†§
Leaving the study early
Adverse effects: SAS, AIMS, BAS ≥2*†§, side-effects checklist§, weight§
Notes Allowed benztropine or lorazepam for anxiety, agitation, or akathisia
2 patients taking aripiprazole excluded for taking aripiprazole after randomisation
Patient population overlaps with Ball 2011 but each study randomised separately
Funding from NIH, US Dept Veterans Affairs, Stanley Medical Research Institute.
Eli Lilly provided study medication. Reported conflicts of interest include multiple
honoraria, grants, and advisory boards for multiple pharmaceutical companies including
Pfizer and Eli Lilly
Study conducted from 2004 to 2006 in the United States
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”permuted block randomization system“
Allocation concealment (selection bias) Low risk Method not described but likely same as
for Ball 2011
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The central unblinded pharmacist will be
notified of the treatment assignment, and
will inform unblinded pharmacists at the
other sites about which study medication
to dispense
“All raters, investigators and other staff will
be blind to treatment assignment except for
the pharmacist”
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals accounted for but evidence of
slight differences in withdrawal reasons be-
tween treatment andplacebo armswith 2 in
placebo arm showing worsening psychosis
and 1 in atomoxetine arm ’feeling strange’
although unclear if this could significantly
influence the results
Selective reporting (reporting bias) Low risk All outcomes of interest reported
Other bias High risk 2 patients taking aripiprazole excluded
from the atomoxetine arm after randomisa-
tion on the grounds that aripiprazole is an
exclusion criterion (although it is not listed
as such in the protocol)
Kurland 1981
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 4 weeks
Participants Diagnosis: schizophrenia
N = 28 (22 completers)
Age: 19 to 53 years
Sex: not reported
History: baseline severity or duration of illness not reported, HRSD ≥ 18, stabilised for
≥ 2 weeks on constant dose of chlorpromazine or haloperidol
Exclusions: pregnancy, significant physical illness, epilepsy, mental retardation, senility,
organic brain disease, history of alcohol or drug abuse, investigational drugs in the
last 2 weeks, sensitivity to test compounds, MAOI in last 2 weeks, treatment with
antiparkinsonian medication
Interventions 1. NRI: viloxazine 50 mg tablets 3 times per day in week 1 and increased by 1 tablet
daily each week until a reduction ≥ 40% on HRSD (if HRSD subsequently increased
the titration schedule was continued) up to a maximum of 300 mg daily. N = 10
2. Placebo: tablets titrated as above. N = 12
Outcomes Mental state/clinical global response: Improvement§
Leaving the study early
Unable to use (data not reported)
Mental state: BPRS, HRSD, Zung Self Rating Depression Scale
Clinical global response: CGI
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Kurland 1981 (Continued)
Notes Funding not reported but authors acknowledge assistance from ICI, declarations of
interest not reported
Date study conducted not reported; although it is not explicitly stated it is presumed to
have been carried out in the United States
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind...identical-appearing
placebo tablets”
Non-concurrence in ratings (PM: unclear
risk; MP: low risk) and overall unclear risk
agreed after discussion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described in detail. “During
the course of the study each patient was in-
terviewed and evaluated by the same inves-
tigator”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals equal across arms and reasons
unlikely to be related to treatment
Selective reporting (reporting bias) High risk Most outcomes not reported in any detail
Other bias Unclear risk Some methodological flaws (e.g. protocol
includes excluding patients with side-ef-
fects in certain situations) but it was not
clear that this had an effect on the results
Li 2008
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 12 weeks
Participants Diagnosis: schizophrenia
N = 118 (114 completers)
Age: 18 to 65 years (mean 50 years)
Sex: All male
History: baseline severity mild (mean PANSS 75), mean duration of illness 27 years (> 3
years), inpatients inFutuijunrenHospital,Hebei Province, with chronic schizophrenia by
Chinese Classification of Mental Disorders (3rd Ed), predominantly negative symptoms
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Li 2008 (Continued)
(by criteria of Andreasen 1982), clozapine at stable dose for≥ 3months, PANSSnegative
≥ 30, PANSS total ≥ 60, no other psychotropics, duration of illness: > 3 years (mean
27 years)
Exclusions: post-schizophrenic depression, schizoaffective disorder, abnormal physical
examination or blood tests, significant physical illness, epilepsy, organic brain disease,
alcohol or drug abuse
Interventions 1. NRI: reboxetine 4 mg daily increased to 8 mg daily after the third day. N = 57
2. Placebo. N = 57
Outcomes Mental state: PANSS total, positive, negative, and general scores†
Quality of life: General Quality Of Life Inventory-74 (GQOLI-74) total and subscales
(a published quality of life scale adapted for the Chinese population)†
Adverse effects: Treatment Emergent Symptoms Scale†
Social or general functioning: Scale of Social-skills for Psychiatric Inpatients (SSPI)
subscales (a published Chinese scale for social functioning)†
Unable to use (data not reported)
Adverse effects: leaving the study early not reported by treatment arm (1 seizure and 3
discharged from hospital),
weight
Notes Translated from Chinese
Patients could receive benzodiazepines or Z-drugs for insomnia
Source of funding and conflicts of interest not reported
Study conducted in 2006 in China
Reported SDs for continuous outcomes appear significantly smaller than for other trials.
Although the paper does not explicitly report that these are SDs rather than SEs (stating
they are “x ± s”) examination of the reported t-tests confirms that these are SDs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described in detail, “unblind-
ing by pharmacy at the end of the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “unblinding by pharmacy at the end of the
study”
“the reboxetine and placebo (starch pow-
der) were placed in identical looking cap-
sules”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
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Li 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals not reported separately for
treatment arms but unlikely to have a sig-
nificant impact on outcomes
Selective reporting (reporting bias) Unclear risk Some outcomes of interest not reported
Other bias Low risk No other specific biases noted
Poyurovsky 2003
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 6 weeks
Participants Diagnosis: schizophrenia
N = 26
Age: mean 31 years
Sex: 9 F, 17 M
History: baseline severity moderately severe (mean CGI 4.7), mean duration of illness 6
years, hospitalised first episode schizophrenia in the Tirat Carmel Mental Health Center,
DSM-IV, < 4 weeks antipsychotic exposure in last 6 months, no previous olanzapine and
current recommendation for olanzapine, given 10 mg olanzapine daily for 6 weeks
Exclusions: uncooperative, aggressive or suicidal behaviour, diabetes mellitus, obesity
Interventions 1. NRI: reboxetine 4 mg daily. N = 13
2. Placebo. N = 13
Outcomes Mental state: Scale for the Assessment of Positive Symptoms (SAPS), SANS, HRSD†¥
Clinical global response: CGI†¥
Leaving the study early
Adverse effects: Weight, gaining ≥ 7% of initial weight¥
Unable to use (means and SD not reported)
Adverse effects: BAS, SAS
Notes Poyurovsky 2003 reports a reboxetine dose of 2 mg twice daily while Amrami-Weizman
2013 reports 4 mg twice daily
Trihexyphenidyl (5 to 10 mg daily) and lorazepam (1 to 3 mg daily) allowed as needed
but no other psychotropics
Funding not reported but Agis Industries Ltd. (Israel) provided medication, conflicts of
interest not reported
Study conducted in Israel but the date conducted not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Poyurovsky 2003 (Continued)
Random sequence generation (selection
bias)
Low risk “…participants were allocated according to
entries of a table of random numbers”
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All weight measurements were performed
by a research nurse who was blind to the
patients’ treatment assignment…
Clinical ratings were completed at baseline
and at week 6 by the same trained psychia-
trist… who was blind to the patients’ treat-
ment assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Equal withdrawals and reasons equally dis-
tributed
Selective reporting (reporting bias) Low risk All outcomes of interest reported
Other bias Low risk No other specific biases noted
Poyurovsky 2007
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 6 weeks
Participants Diagnosis: schizophrenia or schizophreniform disorder
N = 59
Age: 19 to 48 years (mean 30 years)
Sex: 21 F, 38 M
History: baseline severity moderately ill (mean CGI 4.2), mean duration of illness 3.5
years, inpatients with first episode of psychosis in Tirat Carmel Mental Health Center,
DSM-IV by SCID-I, under 4 weeks antipsychotic treatment, recommendation for olan-
zapine (given 10 mg daily olanzapine during study), no other antipsychotics, antidepres-
sants, or mood stabilisers were permitted
Exclusions: organic brain damage, alcohol or drug abuse, other Axis-I psychiatric disor-
ders including major mood disorders, aggressive or suicidal behaviour, medical illnesses
that could affect body weight (e.g. diabetes mellitus and hypothyroidism), obesity
Interventions 1. NRI: reboxetine 2 mg twice daily. N = 31
2. Placebo: twice daily. N = 28
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Poyurovsky 2007 (Continued)
Outcomes Mental state: SAPS, SANS, HRSD†¥
Clinical global response: CGI†¥
Cognitive functioning: Automated Neuropsychological Assessment Metrics (ANAM)
computerised battery percentage correct and reaction time for correct responses, simple
reaction time, code substitution, code substitution immediate recall, mental rotation
task, matching to sample test, Continuous Performance Test, code substitution delayed
recall†¥, Wisconsin Card Sorting Test categories completed and perseverative errors†¥
Leaving the study early
Adverse effects: BAS, SAS†¥, use of ’as needed’ medication, weight, gaining ≥ 7% of
initial weight¥
Notes Administration of trihexyphenidyl (5mg/day) or biperiden (2 to 4 mg/day) for extrapyr-
midal side-effects and lorazepam (1 to 3 mg/day) or diazepam (5 mg/day) for insomnia
or agitation were allowed as needed
Intention-to-treat analysis with imputation by regression for missing weights
The exact dosing regime of reboxetine is unclear as it is reported variously as 2 mg twice
daily (Poyurovsky et al 2007), 4 mg once daily (Poyurovsky et al 2009), and 4 mg twice
daily (Amrami-Weizman 2013).
In Poyurovsky et al 2007 under 4 weeks of antipsychotic treatment is reported but
Poyurovsky et al 2009 states that the mean duration of antipsychotic treatment prior to
the study was 6 weeks
Funded by the Stanley Medical Research Institute, conflicts of interest not reported
Study conducted from 2003 to 2006 in Israel
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The participants were allocated according
to entries on a table of random numbers”
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study medications were dispensed in
identical capsules, and patients received
two capsules per day”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical and research staff and patients
were unaware of and could not determine
the study drug assignment by appearance
or otherwise…All weight measurements
were performed by a research assistant
blinded to the patients’ treatment assign-
ment…Clinical ratings were completed at
baseline and at week 6 by the same trained
psychiatrist…who was blinded to the pa-
tients’ treatment assignment...Neuropsy-
chological assessments were performed by
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Poyurovsky 2007 (Continued)
the psychologist…who was blind to the
subjects’ treatment condition and clinical
rating scores”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appropriate imputation methods for
weight data. Similar withdrawal rates and
reasons between groups
Selective reporting (reporting bias) Low risk All outcomes of interest reported
Other bias Low risk No other specific biases noted
Sacco 2009
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 2 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder with nicotine dependence
N = 12
Age: 18 to 59 years
Sex: not reported
History: in stable remission from active psychiatric syptomatology but baseline sever-
ity and duration of illness not reported, SCID DSM-IV diagnosis of schizophrenia or
schizoaffective disorder and nicotine dependence, smoking ≥ 15 cigarettes/day, expired
breath carbon monoxide > 10 parts per million, stable remission, stable psychotropics
last 3 months, IQ > 80, VSWM, CPT, or WCST at least 1 standard deviation below
mean
Exclusions: abuse or dependence of alcohol or other substances of abuse in last 3 months,
otherAxis I disorder, unable to give informed consent,methadone, paroxetine, fluoxetine,
or quinidine, contraindications to atomoxetine, current or planning pregnancy
Interventions 1. NRI: atomoxetine 80 mg daily. N = 3
2. NRI: atomoxetine 40 mg daily. N = 4
3. Placebo. N = 5
Outcomes Unable to use (means and SD not reported)
Mental state: PANSS
Cognitive functioning: Neurocognitive battery
Notes Lower PANSS positive score in the 80 mg/day group as compared with the 40 mg/day
group
Funded by NARSAD and NIH. Reported conflicts of interest include grants and con-
sulting work with multiple pharmaceutical companies including Pfizer and Eli Lilly
Study conducted from 2005 to 2007, although not explicitly stated presumed to have
been carried out in the United States
Risk of bias
63Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sacco 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described in detail, “random-
ized in a double-blind manner”
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described in detail, “double-
blind, placebo-controlled”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Method not described
Selective reporting (reporting bias) High risk Only data for selected differences reported
Other bias Unclear risk Some baseline imbalance but significance
not clear
Schutz 2001
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 6 weeks
Participants Diagnosis: schizophrenia
N = 30 (23 completers)
Age: mean 33 years
Sex: 2 F, 28 M
History: baseline severity mild (mean PANSS total 79) and mean duration of illness 98
months, inpatients in Sterkfontein Hospital with DSM-IV schizophrenia (acute relapse
n = 13; or chronic n = 17) on haloperidol 5 mg daily with at least partial response, 4
weeks washout for depot or 2 weeks for other psychotropics
Exclusions: significant medical illness or medication; psychotropics other than benzodi-
azepines, any other major psychiatric diagnosis, substance abuse ormore than 3 alcoholic
drinks daily
Interventions 1. NRI: reboxetine 8 mg daily in divided doses. N = 12
2. Placebo. N = 11
Outcomes Mental state: Response rate (≥ 20% reduction on PANSS), PANSS total, negative,
positive, general subscales, HRSD†§
Clinical global response: CGI†§
Leaving the study early
Adverse effects: Side-effects§, SAS†§
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Schutz 2001 (Continued)
Notes Unclear total numbers in each arm prior to withdrawals but presumed to be 15 in each
Additional correspondence with author Michael Berk (MB) clarifying randomisation
and blinding (see below)
Funding and conflicts of interest not reported
Study conducted in South Africa but date study conducted not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomization was done by an exter-
nal statistician using computer generation”
MB
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “blinding was done by over encapsulation
and repackaging into identical labelled con-
tainers” MB
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals accounted for and balanced
but missing data is not clearly recorded nor
are numbers in each arm of the trial
Selective reporting (reporting bias) Low risk All outcomes of interest reported
Other bias Low risk No other specific biases noted
Shafti 2015
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 12 weeks
Participants Diagnosis: schizophrenia
N = 50
Age: mean 40 years
Sex: All male
History: baseline severity severely ill (SANS 80) and mean duration of illness 9 years,
long-term inpatients in the Razi Psychiatric Hospital with DSM-IV schizophrenia and
chronic negative symptoms, > 2 years negative symptoms, SANS≥ 66, SAPS≤ 96, SAS
≤ 10, 2 weeks wash-out then start haloperidol 5 mg/day
Exclusions: schizoaffective disorder, major depression, mental retardation, neurological
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disorders, medical complications, severe aggressiveness, medically deaf or mute, long-
acting depot in last 6 months, atypical antipsychotics, antidepressants, lithium
Interventions 1. NRI: reboxetine 4 mg daily. N = 25
2. Placebo. N = 25
Outcomes Mental state: SANS score and response rate (reduction≥ 20%), SANS subscales, subscale
response rates, SAPS†§
Leaving the study early
Adverse effects: side-effects§
Unable to use (not reported)
Mental state: HRSD
Cognitive functioning: MMSE
Adverse effects: SAS
Notes Additional correspondence with author Saeed Shoja Shafti (SS) clarifying randomisation
and blinding (see below)
Funded by Razi Psychiatric Hospital, no interests declared
Study conducted in Iran but date study conducted not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomization was based on the number
of file (bed) that had been determined for
each patient upon admission in the hospi-
tal...they had been divided or designated
one by one and by chance into two differ-
ent groups until completion of the groups
”every patient had the same chance to
be in the treatment or control arms’, and
there was no pre-determined plan for di-
viding the numbers into groups, for exam-
ple, based on ’even’ or ’odd’ , or alternately
and else“ SS
Non-concurrence in ratings (PM: unclear
risk; MP: low risk) and overall unclear risk
agreed after discussion
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The tablets were prescribed while previ-
ously inserted into empty and similar cap-
sules, which were prepared in this regard,
to make patients blind regarding the pro-
cedure. The evaluator (a psychiatrist) also
remained unaware concerning the above
mentioned panel and the type of medica-
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tions prescribed for each group
“The assessor, staff and patients were
unaware regarding the prescribed drugs,
which were arranged by an extra colleague,
whowas supervisor andmanager of the try-
out” SS
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The assessor, staff and patients were
unaware regarding the prescribed drugs,
which were arranged by an extra colleague,
whowas supervisor andmanager of the try-
out” SS
Incomplete outcome data (attrition bias)
All outcomes
Low risk “there was no dropout during the assess-
ment”
Selective reporting (reporting bias) Low risk Some selective reporting of outcomes (SAS
andMMSE in particular) but primary out-
comes reported and no significant out-
comes of interest excluded
Other bias Low risk No other specific biases noted
Usall 2014
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 6 months
Participants Diagnosis: schizophrenia
N = 90 (64 completers)
Age: 18 to 65 years (mean 42 years)
Sex: 13 F, 67 M
History: baseline severity mildly ill (mean PANSS total 73) and mean duration of illness
16 years, multicentre study (10 centres in Spain), DSM-IV, stable treatment with olan-
zapine or risperidone for 60 days, 1 or more negative symptom with severity score > 4
on PANSS negative scale
Exclusions: substance misuse or dependence in last 6 months, learning disability, an-
tidepressant or mood stabiliser use in last 4 months, use of antipsychotics other than
olanzapine or risperidone, or use of multiple antipsychotics, HRSD > 20, pregnancy or
lactation, severe renal failure, history of haemorrhagic disorders, allergy or intolerance
to citalopram or reboxetine
Interventions 1. NRI: reboxetine 4 mg daily for 1 week then 8 mg daily. N = 34
2. Placebo. N = 33
3. Active control: citalopram 15 mg daily for 1 week then 30 mg daily. N = 23
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Outcomes Mental state: PANSS total, positive, negative, and general subscales, SANS total, affec-
tive flattening/blunting, alogia, avolition/apathy, anhedonia/asociality, attentional im-
pairment subscales†§
Leaving the study early
Adverse effects: acute exacerbation of psychosis side-effect§
Unable to use
Outcomes at 12 weeks as sample size not reported
Notes Hypnotic use of levomepromazine up to 100 mg, clotiapine 40 mg, chlorpromazine 100
mg, or quetiapine 200 mg daily was allowed
Benzodiazepine andbiperidenuse permitted.No changes to antipsychotic doses through-
out trial
Statistically significant difference in baseline psychiatric comorbidity between reboxetine
and placebo arms (21% vs 47%)
Funded by Fondo de Investigación Sanitario, conflicts of interest include honoraria,
grants, and advisory boards for multiple pharmaceutical companies and funding bodies
including Eli Lilly and Pfizer
Study conducted 2008 to 2011 in Spain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly assigned…on the basis of a ran-
dom number list”
Allocation concealment (selection bias) Low risk “randomly assigned by the…trial phar-
macy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “…tablets were prepared so theywere iden-
tical in appearance. All study personnel and
participants remained blind to treatment
assignment for the duration of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All study personnel and participants re-
mained blind to treatment assignment for
the duration of the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Similar number of withdrawals between
groups but differences in reasons for with-
drawals, in particular due to exacerbation
of illness with reboxetine compared to
placebo (2 vs 0), but unclear if this is suf-
ficient to make a significant difference to
results
Selective reporting (reporting bias) Low risk All significant outcomes of interest re-
ported
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Other bias Low risk No other specific biases noted
Yu 2012
Methods Allocation: randomised
Blindness: open, parallel groups
Duration: 16 weeks
Participants Diagnosis: schizophrenia
N = 65
Age: mean 32 years
Sex: 27 F, 38 M
History: baseline severity mildly ill (mean PANSS total 76) and mean duration of illness
10 months, hospitalised patients, CCMD-3, PANSS total > 60, negative > 30, all taking
olanzapine 10 to 25mg at night
Exclusions: organic brain diseases, serious physical illness, history of drug allergies and
similar drugs, alcohol addiction
Interventions 1. NRI: reboxetine 4 mg to 8 mg once daily. N = 33
2. Control. N = 32
Outcomes Mental state: PANSS total and negative subscales†
Leaving the study early
Notes Translated from Chinese, mean PANSS total scores below 30 which should not be
possible (minimum PANSS score is 30)
Funding and declarations of interest not reported
Study conducted 2010 to 2011 in China
Reported SDs for continuous outcomes appear significantly smaller than for other trials.
Although the paper does not explicitly report that these are SDs rather than SEs (stating
they are “x ± s”) examination of the reported t-tests confirms that these are SDs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “open randomized controlled study”
Allocation concealment (selection bias) High risk “open randomized controlled study”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “open randomized controlled study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “open randomized controlled study”
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Yu 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No explanations for withdrawals
Selective reporting (reporting bias) High risk Not all outcomes reported including re-
sponse rates
Other bias High risk Methodological concerns such as PANSS
total scores below minimum of 30
Zhao 2013
Methods Allocation: randomised
Blindness: double blind, parallel groups
Duration: 24 weeks
Participants Diagnosis: schizophrenia
N = 110 (107 after withdrawals)
Age: 18 to 55 years (mean 43 years)
Sex: All male
History: baseline severity mildly ill (mean PANSS total 74), duration of illness not
reported, ICD-10, inpatients on clozapine and stable for 1 year, metabolic syndrome by
IDF 2005 criteria, clozapine dose unchanged during trial, patients discharged from trial
if they use additional psychotropics, PANSS negative ≥ 22
Exclusions: use of other antipsychotics or psychotropics in the last year, substance misuse,
abnormalities on blood tests or physical examination, treatment for metabolic syndrome,
enrolment in othermedical research, organic brain disease, severe physical illness, epilepsy
Interventions 1. NRI: reboxetine 4 mg daily increased to 8 mg daily after 1 week. N = 53
2. Placebo. N = 54
Outcomes Mental state: PANSS total, positive, negative, general scores†§
Adverse effects: Side-effects, weight
Unable to use
Leaving the study early: not reported by treatment arm
Notes Translated from Chinese. Benzodiazepine use for anxiety or insomnia
Funding and declarations of interest not reported
Study conducted 2011 to 2012 in China
Reported SDs for continuous outcomes appear significantly smaller than for other trials.
Although the paper does not explicitly report that these are SDs rather than SEs (stating
they are “x ± s”) examination of the reported t-tests confirms that these are SDs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
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Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals not reported by treatment
arm
Selective reporting (reporting bias) Low risk Reports all pre-specified outcomes
Other bias Low risk No other specific biases noted
Abbreviations: AIMS - Abnormal Involuntary Movement Scale; BAS - Barnes Akathisia Scale; BPRS - Brief Psychiatric Rating Scale;
CCMD - Chinese Classification ofMental Disorders; CGI - Clinical Global Impression; DSM -Diagnostic and Statistical Manual of
Mental Disorders; HRSD -Hamilton Rating Scale for Depression; ITT - intention to treat; LOCF - last observation carried forward;
MADRS - Montgomery-Åsberg Depression Rating Scale; MAOI - Monoamine oxidase inhibitor; MMSE - Mini-Mental State
Examination; PANSS - Positive andNegative Syndrome Scale; RBANS -Repeatable Battery for theAssessment ofNeuropsychological
Status; SAPS - Scale for the Assessment of Positive Symptoms; SANS - Scale for the Assessment of Negative Symptoms; SAS -
Simpson-Angus Scale; SCID - Structured Clinical Interview for DSM; SEC - Side-Effects Checklist
† Published outcome measures
‡ Composite score not previously published but individual scores are
§ Self-report or independence of raters not stated
¥ Independent raters
Raters not independent
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amrami-Weizman 2013 Allocation: randomised parallel group
Participants: schizophrenia or schizophreniform disorder
Intervention: reboxetine or placebo
Outcomes: data from Poyurovsky 2003 and Poyurovsky 2007 were combined to report metabolic and
hormonal measures which have not been defined as outcomes in our review
Apud 2007a Allocation: randomised cross-over trial, stratified by COMT genotype
Participants: schizophrenia
Intervention: atomoxetine or placebo
Outcomes: terminated early due to slow recruitment and low priority, only 4 patients recruited and
completed and no data collected
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Barnes 2009 Allocation: randomised parallel group
Participants: schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychosis not otherwise
specified
Intervention: citalopram or placebo
Hou 2007 Allocation: randomised parallel group
Participants: schizophrenia
Intervention: citalopram or placebo
Mueller 2005 Allocation: 2 randomised parallel group trials (1-2)
Participants:
1. schizophrenia (on risperidone)
2. depression (on reboxetine)
Intervention: celecoxib or placebo
Poyurovsky 2013 Allocation: randomised parallel group
Participants: schizophrenia
Intervention: reboxetine plus betahistine or placebo
Excluded as betahistine use was not equally distributed across treatment and control groups
Salokangas 1997 Allocation: randomised parallel group
Participants: schizophrenia
Intervention: citalopram or placebo
Shafti 2004 Allocation: 3 randomised parallel group trials (1-3)
Participants: schizophrenia
Intervention:
1. clomipramine, alprazolam, citalopram or placebo
2. bromocriptine, fluoxetine, nortriptyline or placebo
3. fluvoxamine, maprotiline or placebo
Excluded as none of the active compounds is a selective NRI
Characteristics of studies awaiting assessment [ordered by study ID]
Shekhar 2005
Methods 52 week randomised parallel group placebo-controlled trial
Participants Recruitment target of 126 patients with treatment-resistant schizophrenia on clozapine
Interventions Atomoxetine (up to 40 mg daily) or placebo
Outcomes Symptom scales (e.g. PANSS, CGI), cognitive testing (BACS), side-effect scales (e.g. AIMS), weight
Notes Trial terminated but no further information on results could be obtained
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Tamminga 2009
Methods 12 week randomised factorial design parallel group placebo-controlled trial
Participants 119 patients with schizophrenia recruited
Interventions 1. Atomoxetine (40 mg twice daily) plus cognitive remediation
2. Atomoxetine plus remediation control
3. Placebo plus cognitive remediation
4. Placebo plus remediation control
Outcomes Symptom scales (e.g. PANSS, CGI), cognitive testing, physical examination (e.g. ECG, weight), neuroimaging
(fMRI)
Notes Trial completed but no further information on results could be obtained
Characteristics of ongoing studies [ordered by study ID]
Baranchik 2006
Trial name or title Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
Methods 6 week randomised parallel group placebo-controlled trial
Participants Recruitment target of 30 patients with schizophrenia (aged 18 to 65 years)
Interventions Reboxetine (titrated up to 4 mg twice daily) or placebo
Outcomes Symptom scales (e.g. PANSS, SANS) and cognitive testing (CogScan)
Starting date March 2006
Contact information Stanislav Baranchik, Abarbanel Medical Mental Health Center, Israel
Notes No further information on the status of this trial could be obtained
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D A T A A N D A N A L Y S E S
Comparison 1. SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome - A. Mental
state: Specific - clinically
significant response or
improvement in negative
symptoms (SANS, high=worse)
- short term (12 weeks)
1 50 Risk Ratio (M-H, Random, 95% CI) 3.17 [1.52, 6.58]
2 Primary outcome - B. Clinical
global response: Clinically
significant response or
improvement in global status
(CGI-S, high=worse) - short
term (4 weeks)
1 28 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.45, 2.20]
3 Mental state: 1. General -
clinically significant response or
improvement in general/overall
symptoms as defined in each
study - short term (2-12 weeks)
2 58 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.64, 2.09]
4 Mental state: 2a. General:
Average general/overall
symptoms score (various scales,
high=worse) - short term (2 -
12 weeks)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BPRS total 1 23 Mean Difference (IV, Random, 95% CI) 1.5 [-6.64, 9.64]
4.2 PANSS general 5 294 Mean Difference (IV, Random, 95% CI) -2.17 [-3.93, -0.40]
4.3 PANSS total 4 308 Mean Difference (IV, Random, 95% CI) -2.84 [-5.28, -0.40]
5 Mental state: 2b. General:
Average general/overall
symptoms score (various scales,
high=worse) - medium term
(13 - 26 weeks)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 BPRS total 1 26 Mean Difference (IV, Random, 95% CI) -1.4 [-7.08, 4.28]
5.2 PANSS general 2 154 Mean Difference (IV, Random, 95% CI) -2.90 [-7.57, 1.77]
5.3 PANSS total 3 219 Mean Difference (IV, Random, 95% CI) -3.67 [-10.07, 2.72]
6 Mental state: 3a. Specific:
Average symptoms score
(various scales, high=worse) -
short term (2 - 12 weeks)
10 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 mood (BPRS) 1 23 Mean Difference (IV, Random, 95% CI) 0.2 [-2.60, 3.00]
6.2 mood (HRSD) 3 114 Mean Difference (IV, Random, 95% CI) -2.37 [-4.29, -0.45]
6.3 negative (PANSS negative) 6 359 Mean Difference (IV, Random, 95% CI) -0.99 [-2.53, 0.56]
6.4 negative (SANS) 3 129 Mean Difference (IV, Random, 95% CI) -2.47 [-6.22, 1.28]
6.5 negative (SANS -
modified)
1 23 Mean Difference (IV, Random, 95% CI) -5.70 [-18.01, 6.61]
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6.6 positive (BPRS) 1 23 Mean Difference (IV, Random, 95% CI) 1.60 [-2.59, 5.79]
6.7 positive (PANSS positive) 5 294 Mean Difference (IV, Random, 95% CI) -0.16 [-0.96, 0.63]
6.8 positive (SAPS) 3 129 Mean Difference (IV, Random, 95% CI) 0.73 [-1.29, 2.74]
7 Mental state: 3b. Specific:
Average symptoms score
(various scales, high=worse) -
medium term (13 - 26 weeks)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 negative (PANSS negative) 3 219 Mean Difference (IV, Random, 95% CI) -3.25 [-4.04, -2.47]
7.2 negative (SANS) 1 47 Mean Difference (IV, Random, 95% CI) -7.12 [-19.39, 5.15]
7.3 positive (PANSS positive) 2 154 Mean Difference (IV, Random, 95% CI) -0.14 [-1.30, 1.02]
8 Mental state: 4a. General and
specific: Average score (various
scales, high=worse) - skewed
results - short term (2 - 12
weeks)
Other data No numeric data
8.1 general - overall symptoms
(BPRS total)
Other data No numeric data
8.2 general - overall symptoms
(PANSS general)
Other data No numeric data
8.3 general - overall symptoms
(PANSS total)
Other data No numeric data
8.4 specific - mood (BPRS
anxiety/depression)
Other data No numeric data
8.5 specific - mood (HRSD) Other data No numeric data
8.6 specific - negative
symptoms (SANS)
Other data No numeric data
8.7 specific - negative
symptoms (PANSS negative)
Other data No numeric data
8.8 specific - positive
symptoms (BPRS positive)
Other data No numeric data
8.9 specific - positive
symptoms (PANSS positive)
Other data No numeric data
8.10 specific - positive
symptoms (SAPS)
Other data No numeric data
9 Mental state: 4b. General and
specific: Average score (various
scales, high=worse) - skewed
results - medium term (13 - 26
weeks)
Other data No numeric data
9.1 general - overall symptoms
(BPRS total)
Other data No numeric data
9.2 general - overall symptoms
(PANSS general)
Other data No numeric data
9.3 general - overall symptoms
(PANSS total)
Other data No numeric data
9.4 specific - negative
symptoms (PANSS negative)
Other data No numeric data
9.5 specific - negative
symptoms (SANS)
Other data No numeric data
9.6 specific - positive
symptoms (PANSS positive)
Other data No numeric data
75Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10 Cognitive functioning: 1.
General - average composite
cognitive functioning score
(SMD)
5 Std. Mean Difference (Random, 95% CI) Subtotals only
10.1 short term (2 - 12 weeks) 4 180 Std. Mean Difference (Random, 95% CI) 0.04 [-0.28, 0.36]
10.2 medium term (13 - 26
weeks)
1 26 Std. Mean Difference (Random, 95% CI) -0.66 [-1.46, 0.13]
11 Cognitive functioning: 2.
Specific - average individual
scores (SMD) - short term (2 -
12 weeks)
4 Std. Mean Difference (Random, 95% CI) Subtotals only
11.1 working memory 2 53 Std. Mean Difference (Random, 95% CI) -0.11 [-0.89, 0.67]
11.2 reasoning/problem
solving
3 158 Std. Mean Difference (Random, 95% CI) 0.03 [-0.28, 0.34]
11.3 speed of processing 4 177 Std. Mean Difference (Random, 95% CI) 0.08 [-0.21, 0.38]
11.4 attention 3 161 Std. Mean Difference (Random, 95% CI) -0.01 [-0.51, 0.48]
11.5 verbal learning/memory 4 181 Std. Mean Difference (Random, 95% CI) 0.01 [-0.31, 0.32]
11.6 visual learning/memory 1 22 Std. Mean Difference (Random, 95% CI) -0.44 [-1.29, 0.41]
12 Quality of life: Average quality
of life score (GQOLI-74,
high=better) - short term (2 -
12 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 general - total 1 114 Mean Difference (IV, Random, 95% CI) 9.36 [7.89, 10.83]
12.2 specific - well being -
material
1 114 Mean Difference (IV, Random, 95% CI) 0.21 [-2.34, 2.76]
12.3 specific - well being -
physical
1 114 Mean Difference (IV, Random, 95% CI) 0.68 [-1.35, 2.71]
12.4 specific - well being -
psychological
1 114 Mean Difference (IV, Random, 95% CI) 10.0 [8.01, 11.99]
12.5 specific - well being -
social
1 114 Mean Difference (IV, Random, 95% CI) 10.02 [8.03, 12.01]
13 Clinical global response: 1a.
Average clinical global status
score (CGI-S, high=worse) -
short term (2 - 12 weeks)
5 160 Mean Difference (IV, Random, 95% CI) -0.03 [-0.35, 0.28]
14 Clinical global response:
1b. Average clinical global
status score (various scales,
high=worse) - short term (2 -
12 weeks) - skewed results
Other data No numeric data
14.1 CGI-I Other data No numeric data
14.2 CGI-S Other data No numeric data
15 Leaving the study early: 1a.
Short term (2 - 12 weeks)
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 any reason 9 401 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.63, 1.39]
15.2 due to adverse effects 4 178 Risk Ratio (M-H, Random, 95% CI) 2.08 [0.70, 6.21]
15.3 due to psychiatric
symptoms
3 183 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.44, 2.13]
16 Leaving the study early: 1b.
Medium term (13 - 26 weeks)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 any reason 3 169 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.52, 1.62]
16.2 due to adverse effects 1 33 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.31, 6.95]
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16.3 due to psychiatric
symptoms
1 49 Risk Ratio (M-H, Random, 95% CI) 4.44 [0.22, 88.04]
17 Adverse effects: 1. General
- short term (binary, 2 - 12
weeks)
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 any 3 199 Risk Ratio (M-H, Random, 95% CI) 3.49 [0.14, 90.29]
17.2 serious 3 271 Risk Ratio (M-H, Random, 95% CI) 2.95 [0.47, 18.36]
18 Adverse effects: 2a.i. Specific
- short term (binary, 2 - 12
weeks)
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 anticholinergic -
constipation
2 146 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.24, 2.29]
18.2 anticholinergic - dry
mouth
3 176 Risk Ratio (M-H, Random, 95% CI) 3.46 [1.40, 8.53]
18.3 anticholinergic -
impotence
1 30 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 68.26]
18.4 cardiovascular -
tachycardia
1 114 Risk Ratio (M-H, Random, 95% CI) 3.33 [0.97, 11.48]
18.5 central nervious system -
anorexia
1 32 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.56]
18.6 central nervous system -
dizziness
3 176 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.54, 4.31]
18.7 central nervous system -
fatigue
2 62 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.12, 8.60]
18.8 central nervous system -
headache
1 121 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.52, 2.90]
18.9 central nervous system -
insomnia
2 146 Risk Ratio (M-H, Random, 95% CI) 4.79 [0.85, 26.84]
18.10 central nervous system -
sedation
2 58 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.28, 1.94]
18.11 extrapyramidal - acute
dystonia
1 30 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.55]
18.12 extrapyramidal -
akathisia
3 88 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.25, 3.09]
18.13 extrapyramidal -
hypersalivation
1 30 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.58]
18.14 extrapyramidal -
parkinsonism
1 30 Risk Ratio (M-H, Random, 95% CI) 1.8 [0.79, 4.11]
18.15 extrapyramidal - tremor 1 32 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.24, 4.23]
18.16 extrapyramidal -
stiffness
1 32 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.03, 1.53]
18.17 extrapyramidal - use of
antiparkinson medication
3 135 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.44, 1.45]
18.18 gastrointestinal -
abdominal pain
1 32 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.29, 7.81]
18.19 gastrointestinal - nausea 3 176 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.10, 2.41]
18.20 gastrointestinal -
vomiting
1 32 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.86]
18.21 gastrointestinal -
diarrhoea
1 32 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.86]
18.22 immune system - rash 1 30 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 68.26]
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18.23 immune system - sore
throat
1 32 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.86]
18.24 metabolic - weight loss 1 32 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 2.87]
18.25 metabolic - significant
weight gain
2 85 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.20, 0.73]
19 Adverse effects: 2a.ii. Specific
- extrapyramidal - average
change score (continuous,
various scales, high=worse) -
short term (2 - 12 weeks)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 AIMS 1 26 Mean Difference (IV, Random, 95% CI) 0.3 [-2.34, 2.94]
19.2 BAS 1 59 Mean Difference (IV, Random, 95% CI) -0.18 [-0.65, 0.29]
19.3 SAS 2 85 Mean Difference (IV, Random, 95% CI) -0.27 [-1.79, 1.25]
20 Adverse effects: 2a.iii. Specific
- extrapyramidal - average
change score (continuous,
various scales, high=worse) -
short term (2 - 12 weeks) -
skewed results
Other data No numeric data
20.1 AIMS Other data No numeric data
20.2 SAS Other data No numeric data
21 Adverse effects: 2b.i. Specific -
medium term (binary, 13 - 26
weeks)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 anticholinergic -
constipation
1 107 Risk Ratio (M-H, Random, 95% CI) 4.58 [1.04, 20.23]
21.2 anticholinergic - dry
mouth
1 107 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.27, 8.78]
21.3 anticholinergic - sweating 1 107 Risk Ratio (M-H, Random, 95% CI) 13.24 [0.76, 229.32]
21.4 cardiovascular - QT
prolongation
1 37 Risk Ratio (M-H, Random, 95% CI) 3.4 [0.42, 27.59]
21.5 cardiovascular -
tachycardia
1 107 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.55, 5.74]
21.6 central nervous system -
dizziness
1 107 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.32, 5.78]
21.7 central nervous system -
insomnia
1 107 Risk Ratio (M-H, Random, 95% CI) 13.24 [0.76, 229.32]
21.8 extrapyramidal - tremor 1 37 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.20, 0.89]
21.9 gastrointestinal - nausea 1 107 Risk Ratio (M-H, Random, 95% CI) 5.09 [0.62, 42.16]
22 Adverse effects: 2a.iv. Specific -
metabolic - average weight gain
(continuous, increase in kg)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 short term (2 - 12 weeks) 3 186 Mean Difference (IV, Random, 95% CI) -2.17 [-3.19, -1.15]
22.2 medium term (13 - 26
weeks)
2 133 Mean Difference (IV, Random, 95% CI) -3.12 [-10.67, 4.42]
23 Social or general functioning:
Average social functioning
score (various subscales) -
short-term (2 - 12 weeks)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 activity - activities
(inverted SLOF, high=worse)
1 15 Mean Difference (IV, Random, 95% CI) 0.0 [-3.30, 3.30]
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23.2 activity - hospital activity
(SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.03 [-0.17, 0.11]
23.3 activity - disease indoor
activity (SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.14 [-0.28, -0.00]
23.4 activity - physical
functioning (inverted SLOF,
high=worse)
1 15 Mean Difference (IV, Random, 95% CI) -0.3 [-1.12, 0.52]
23.5 personal care - personal
care skills (inverted SLOF,
high=worse)
1 15 Mean Difference (IV, Random, 95% CI) -0.20 [-1.43, 1.03]
23.6 personal care - self-care
(SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.03 [-0.22, 0.16]
23.7 personal care - social
acceptability (inverted SLOF,
high=worse)
1 15 Mean Difference (IV, Random, 95% CI) 0.1 [-0.72, 0.92]
23.8 relationships - family role
(SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.09 [-0.23, 0.05]
23.9 relationships - interest
and concern in the external
environment (SSPI, high=
worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.19 [-0.37, -0.01]
23.10 relationships -
interpersonal relationships
(inverted SLOF, high=worse)
1 15 Mean Difference (IV, Random, 95% CI) -1.20 [-5.41, 3.01]
23.11 relationships -
relationships and caring for
others (SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.09 [-0.24, 0.06]
23.12 relationships - sexual
role (SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.03 [-0.21, 0.15]
23.13 relationships - social
withdrawal (SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.32 [-0.49, -0.15]
23.14 work - professional
skills (SSPI, high=worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.19 [-0.34, -0.04]
23.15 work - responsibility
and planning (SSPI, high=
worse)
1 114 Mean Difference (IV, Random, 95% CI) -0.03 [-0.21, 0.15]
23.16 work - work skills
(inverted SLOF, high=worse)
1 15 Mean Difference (IV, Random, 95% CI) -3.0 [-5.48, -0.52]
Comparison 2. SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1a. General:
Average general/overall
symptoms score (PANSS
general, high=worse) - short
term (2 - 12 weeks)
1 35 Mean Difference (IV, Random, 95% CI) 2.90 [-2.85, 8.65]
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2 Mental state: 1b. General:
Average general/overall
symptoms score (various scales,
high=worse) - medium term
(13 - 26 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 PANSS total 1 41 Mean Difference (IV, Random, 95% CI) 1.62 [-6.89, 10.13]
2.2 PANSS general 1 41 Mean Difference (IV, Random, 95% CI) 0.62 [-2.00, 5.24]
3 Mental state: 2a. Specific:
Average symptoms score
(various scales, high=worse) -
short term (2 - 12 weeks)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 mood (HRSD) 1 35 Mean Difference (IV, Fixed, 95% CI) 3.00 [-1.24, 7.24]
3.2 negative (PANSS negative) 1 35 Mean Difference (IV, Fixed, 95% CI) 1.5 [-4.34, 7.34]
3.3 positive (PANSS positive) 1 35 Mean Difference (IV, Fixed, 95% CI) 1.7 [-1.52, 4.92]
4 Mental state: 2b. Specific:
Average symptoms score
(various scales, high=worse) -
medium term (13 - 26 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 negative (PANSS negative) 1 41 Mean Difference (IV, Random, 95% CI) 0.26 [-3.66, 4.18]
4.2 negative (SANS) 1 41 Mean Difference (IV, Random, 95% CI) -0.27 [-12.69, 12.
15]
4.3 positive (PANSS positive) 1 41 Mean Difference (IV, Random, 95% CI) 0.74 [-1.86, 3.34]
5 Mental state: 3a. General and
specific: Average score (various
scales, high=worse) - skewed
results - short term (2 - 12
weeks)
Other data No numeric data
5.1 general - overall symptoms
(PANSS general)
Other data No numeric data
5.2 specific - mood (HRSD) Other data No numeric data
5.3 specific - negative
symptoms (PANSS negative)
Other data No numeric data
5.4 specific - positive
symptoms (PANSS positive)
Other data No numeric data
6 Mental state: 3b. General and
specific: Average score (various
scales, high=worse) - skewed
results - medium term (13 - 26
weeks)
Other data No numeric data
6.1 general - overall symptoms
(PANSS general)
Other data No numeric data
6.2 general - overall symptoms
(PANSS total)
Other data No numeric data
6.3 specific - negative
symptoms (PANSS negative)
Other data No numeric data
6.4 specific - negative
symptoms (SANS)
Other data No numeric data
6.5 specific - positive
symptoms (PANSS positive)
Other data No numeric data
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7 Clinical global response: Average
clinical global status score
(CGI-S, high=worse) - short
term (2 - 12 weeks)
1 35 Mean Difference (IV, Random, 95% CI) 0.0 [-0.89, 0.89]
8 Leaving the study early: 1a.
Short term (2 - 12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 any reason 1 35 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.17, 2.41]
9 Leaving the study early: 1b.
Medium term (13 - 26 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 any reason 1 57 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.48, 2.67]
9.2 due to psychiatric
symptoms
1 49 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.17, 18.26]
Analysis 1.1. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 1 Primary outcome - A. Mental state: Specific - clinically significant response or improvement in
negative symptoms (SANS, high=worse) - short term (12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 1 Primary outcome - A. Mental state: Specific - clinically significant response or improvement in negative symptoms (SANS, high=worse) - short term (12
weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Shafti 2015 19/25 6/25 100.0 % 3.17 [ 1.52, 6.58 ]
Total (95% CI) 25 25 100.0 % 3.17 [ 1.52, 6.58 ]
Total events: 19 (NRI), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours NRI
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Analysis 1.2. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 2 Primary outcome - B. Clinical global response: Clinically significant response or improvement in
global status (CGI-S, high=worse) - short term (4 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 2 Primary outcome - B. Clinical global response: Clinically significant response or improvement in global status (CGI-S, high=worse) - short term (4 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kurland 1981 6/13 7/15 100.0 % 0.99 [ 0.45, 2.20 ]
Total (95% CI) 13 15 100.0 % 0.99 [ 0.45, 2.20 ]
Total events: 6 (NRI), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours NRI
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Analysis 1.3. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 3 Mental state: 1. General - clinically significant response or improvement in general/overall
symptoms as defined in each study - short term (2-12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 3 Mental state: 1. General - clinically significant response or improvement in general/overall symptoms as defined in each study - short term (2-12 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kurland 1981 6/13 7/15 55.8 % 0.99 [ 0.45, 2.20 ]
Schutz 2001 7/15 5/15 44.2 % 1.40 [ 0.57, 3.43 ]
Total (95% CI) 28 30 100.0 % 1.15 [ 0.64, 2.09 ]
Total events: 13 (NRI), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours placebo Favours NRI
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Analysis 1.4. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 4 Mental state: 2a. General: Average general/overall symptoms score (various scales, high=worse) -
short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 4 Mental state: 2a. General: Average general/overall symptoms score (various scales, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
Kelly 2009 11 -2.3 (9.04) 12 -3.8 (10.85) 100.0 % 1.50 [ -6.64, 9.64 ]
Subtotal (95% CI) 11 12 100.0 % 1.50 [ -6.64, 9.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 PANSS general
Friedman 2008 7 -4.7 (5.1) 8 -4.4 (8.9) 5.4 % -0.30 [ -7.53, 6.93 ]
Hinkelmann 2013 19 -3.8 (8.71) 16 -5 (9.37) 7.4 % 1.20 [ -4.83, 7.23 ]
Li 2008 57 28.02 (3.13) 57 29.7 (5.44) 38.1 % -1.68 [ -3.31, -0.05 ]
Schutz 2001 12 -3.2 (8.92) 11 -3.7 (7.44) 6.2 % 0.50 [ -6.19, 7.19 ]
Zhao 2013 53 30.3 (3) 54 34.1 (3.9) 42.9 % -3.80 [ -5.12, -2.48 ]
Subtotal (95% CI) 148 146 100.0 % -2.17 [ -3.93, -0.40 ]
Heterogeneity: Tau2 = 1.44; Chi2 = 7.09, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 2.40 (P = 0.016)
3 PANSS total
Li 2008 57 66.53 (5.93) 57 70.7 (8.71) 27.4 % -4.17 [ -6.91, -1.43 ]
Schutz 2001 12 -9.63 (20.66) 11 -9.73 (14.96) 2.6 % 0.10 [ -14.56, 14.76 ]
Yu 2012 33 50.59 (2.77) 32 51.41 (2.48) 37.6 % -0.82 [ -2.10, 0.46 ]
Zhao 2013 53 66.9 (4.6) 53 71.2 (6) 32.4 % -4.30 [ -6.34, -2.26 ]
Subtotal (95% CI) 155 153 100.0 % -2.84 [ -5.28, -0.40 ]
Heterogeneity: Tau2 = 3.70; Chi2 = 10.63, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.29 (P = 0.022)
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Analysis 1.5. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 5 Mental state: 2b. General: Average general/overall symptoms score (various scales, high=worse) -
medium term (13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 5 Mental state: 2b. General: Average general/overall symptoms score (various scales, high=worse) - medium term (13 - 26 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
Ball 2011 14 -2.4 (6.3) 12 -1 (8.18) 100.0 % -1.40 [ -7.08, 4.28 ]
Subtotal (95% CI) 14 12 100.0 % -1.40 [ -7.08, 4.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 PANSS general
Usall 2014 24 -4.93 (8.19) 23 -5.18 (9.92) 36.4 % 0.25 [ -4.96, 5.46 ]
Zhao 2013 53 27.9 (2.9) 54 32.6 (3.8) 63.6 % -4.70 [ -5.98, -3.42 ]
Subtotal (95% CI) 77 77 100.0 % -2.90 [ -7.57, 1.77 ]
Heterogeneity: Tau2 = 8.50; Chi2 = 3.27, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.22 (P = 0.22)
3 PANSS total
Usall 2014 24 -12.1 (16.7) 23 -13.02 (19.29) 19.9 % 0.92 [ -9.41, 11.25 ]
Yu 2012 33 -51.21 (3.16) 32 -50.1 (3.19) 40.5 % -1.11 [ -2.65, 0.43 ]
Zhao 2013 53 60.5 (5.3) 54 69.1 (5.9) 39.6 % -8.60 [ -10.72, -6.48 ]
Subtotal (95% CI) 110 109 100.0 % -3.67 [ -10.07, 2.72 ]
Heterogeneity: Tau2 = 25.67; Chi2 = 32.01, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 1.6. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 6 Mental state: 3a. Specific: Average symptoms score (various scales, high=worse) - short term (2 -
12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 6 Mental state: 3a. Specific: Average symptoms score (various scales, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 mood (BPRS)
Kelly 2009 11 -0.2 (2.87) 12 -0.4 (3.93) 100.0 % 0.20 [ -2.60, 3.00 ]
Subtotal (95% CI) 11 12 100.0 % 0.20 [ -2.60, 3.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 mood (HRSD)
Hinkelmann 2013 19 -5.2 (5.51) 16 -5.7 (5.6) 21.0 % 0.50 [ -3.20, 4.20 ]
Poyurovsky 2003 10 -10.2 (2.23) 10 -7.1 (3.08) 38.9 % -3.10 [ -5.46, -0.74 ]
Poyurovsky 2007 31 -4.65 (3.73) 28 -1.5 (5.07) 40.2 % -3.15 [ -5.44, -0.86 ]
Subtotal (95% CI) 60 54 100.0 % -2.37 [ -4.29, -0.45 ]
Heterogeneity: Tau2 = 1.02; Chi2 = 3.09, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 2.42 (P = 0.016)
3 negative (PANSS negative)
Friedman 2008 7 -2.6 (2.9) 8 -3.8 (5.7) 8.6 % 1.20 [ -3.30, 5.70 ]
Hinkelmann 2013 19 -4.1 (7.74) 16 -7.6 (7.01) 7.6 % 3.50 [ -1.39, 8.39 ]
Li 2008 57 29.49 (3.15) 57 32.3 (4.01) 25.5 % -2.81 [ -4.13, -1.49 ]
Schutz 2001 12 -2.07 (9.53) 11 -5.73 (7.21) 4.4 % 3.66 [ -3.21, 10.53 ]
Yu 2012 33 24.41 (2.09) 32 26.86 (1.66) 28.3 % -2.45 [ -3.37, -1.53 ]
Zhao 2013 53 27.5 (3.2) 54 27.9 (3.7) 25.6 % -0.40 [ -1.71, 0.91 ]
Subtotal (95% CI) 181 178 100.0 % -0.99 [ -2.53, 0.56 ]
Heterogeneity: Tau2 = 1.98; Chi2 = 17.20, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 1.25 (P = 0.21)
4 negative (SANS)
Poyurovsky 2003 10 -24.3 (15.19) 10 -22.1 (16.29) 6.5 % -2.20 [ -16.00, 11.60 ]
Poyurovsky 2007 31 8.38 (3.6) 28 8.86 (3) 50.5 % -0.48 [ -2.17, 1.21 ]
Shafti 2015 25 74.23 (4.07) 25 79.08 (5.83) 42.9 % -4.85 [ -7.64, -2.06 ]
Subtotal (95% CI) 66 63 100.0 % -2.47 [ -6.22, 1.28 ]
Heterogeneity: Tau2 = 6.51; Chi2 = 6.92, df = 2 (P = 0.03); I2 =71%
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(. . . Continued)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.29 (P = 0.20)
5 negative (SANS - modified)
Kelly 2009 11 32.5 (16.1) 12 38.2 (13.8) 100.0 % -5.70 [ -18.01, 6.61 ]
Subtotal (95% CI) 11 12 100.0 % -5.70 [ -18.01, 6.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
6 positive (BPRS)
Kelly 2009 11 -0.2 (4.95) 12 -1.8 (5.31) 100.0 % 1.60 [ -2.59, 5.79 ]
Subtotal (95% CI) 11 12 100.0 % 1.60 [ -2.59, 5.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
7 positive (PANSS positive)
Friedman 2008 7 0.9 (3.1) 8 -0.62 (4.5) 4.2 % 1.52 [ -2.35, 5.39 ]
Hinkelmann 2013 19 -1.4 (4.46) 16 -0.7 (2.56) 11.2 % -0.70 [ -3.07, 1.67 ]
Li 2008 57 -0.63 (3.11) 57 -0.24 (3.49) 42.5 % -0.39 [ -1.60, 0.82 ]
Schutz 2001 12 -2.9 (5.68) 11 -1.8 (7.29) 2.2 % -1.10 [ -6.47, 4.27 ]
Zhao 2013 53 -0.2 (3.3) 54 -0.3 (3.3) 40.0 % 0.10 [ -1.15, 1.35 ]
Subtotal (95% CI) 148 146 100.0 % -0.16 [ -0.96, 0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.34, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
8 positive (SAPS)
Poyurovsky 2003 10 -18.4 (16.21) 10 -19.9 (12) 2.6 % 1.50 [ -11.00, 14.00 ]
Poyurovsky 2007 31 -3.19 (3.74) 28 -3.14 (3.88) 75.9 % -0.05 [ -2.00, 1.90 ]
Shafti 2015 25 88.69 (7.41) 25 85.31 (7.59) 21.6 % 3.38 [ -0.78, 7.54 ]
Subtotal (95% CI) 66 63 100.0 % 0.73 [ -1.29, 2.74 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 2.16, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 9.04, df = 7 (P = 0.25), I2 =23%
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Analysis 1.7. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 7 Mental state: 3b. Specific: Average symptoms score (various scales, high=worse) - medium term
(13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 7 Mental state: 3b. Specific: Average symptoms score (various scales, high=worse) - medium term (13 - 26 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 negative (PANSS negative)
Usall 2014 24 -5.83 (7.72) 23 -3.56 (6) 4.0 % -2.27 [ -6.21, 1.67 ]
Yu 2012 33 18.15 (2.27) 32 21.24 (2.38) 48.3 % -3.09 [ -4.22, -1.96 ]
Zhao 2013 53 23.6 (3) 54 27.1 (3) 47.8 % -3.50 [ -4.64, -2.36 ]
Subtotal (95% CI) 110 109 100.0 % -3.25 [ -4.04, -2.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 8.11 (P < 0.00001)
2 negative (SANS)
Usall 2014 24 -14.81 (23.58) 23 -7.69 (19.19) 100.0 % -7.12 [ -19.39, 5.15 ]
Subtotal (95% CI) 24 23 100.0 % -7.12 [ -19.39, 5.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
3 positive (PANSS positive)
Usall 2014 24 -1.33 (4.75) 23 -1.57 (6.01) 14.0 % 0.24 [ -2.87, 3.35 ]
Zhao 2013 53 -0.3 (3.2) 54 -0.1 (3.4) 86.0 % -0.20 [ -1.45, 1.05 ]
Subtotal (95% CI) 77 77 100.0 % -0.14 [ -1.30, 1.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
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Analysis 1.8. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 8 Mental state: 4a. General and specific: Average score (various scales, high=worse) - skewed results
- short term (2 - 12 weeks).
Mental state: 4a. General and specific: Average score (various scales, high=worse) - skewed results - short term (2 - 12 weeks)
Study NRI NRI mean NRI SD NRI N Placebo mean Placebo SD Placebo N
general - overall symptoms (BPRS total)
Kelly 2009 Atomoxetine 30.2 8.2 11 36 11.6 12
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Mental state: 4a. General and specific: Average score (various scales, high=worse) - skewed results - short term (2 - 12 weeks)
(Continued)
general - overall symptoms (PANSS general)
Friedman
2008
Atomoxetine 26.7 4.4 10 32 8 10
Hinkelmann
2013
Reboxetine 28.7 9.4 19 28.4 10.1 16
Schutz 2001 Reboxetine 29.6 8.92 12 30.4 7.44 11
general - overall symptoms (PANSS total)
Schutz 2001 Reboxetine 67.67 20.66 12 70.67 14.96 11
specific - mood (BPRS anxiety/depression)
Kelly 2009 Atomoxetine 6.4 1.9 11 8.3 3.6 12
specific - mood (HRSD)
Hinkelmann
2013
Reboxetine 8.3 6.1 19 6.5 5.6 16
Poyurovsky
2003
Reboxetine 4.6 3.5 10 4.6 3.5 10
Poyurovsky
2007
Reboxetine 4.53 2 16 3 2 17
Schutz 2001 Reboxetine 6.93 4.95 12 6.93 3.17 11
specific - negative symptoms (SANS)
Poyurovsky
2003
Reboxetine 18.9 13.4 10 23.2 18.8 10
specific - negative symptoms (PANSS negative)
Friedman
2008
Atomoxetine 15.2 4.8 10 15.5 5.9 10
Hinkelmann
2013
Reboxetine 21.5 8.6 19 19.1 5.5 16
Schutz 2001 Reboxetine 25.13 9.53 12 23.27 7.21 11
specific - positive symptoms (BPRS positive)
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Mental state: 4a. General and specific: Average score (various scales, high=worse) - skewed results - short term (2 - 12 weeks)
(Continued)
Kelly 2009 Atomoxetine 9.8 4.9 11 10.3 5.5 12
specific - positive symptoms (PANSS positive)
Friedman
2008
Atomoxetine 13.2 4.5 10 14.6 4.5 10
Hinkelmann
2013
Reboxetine 10.6 4.6 19 8.6 2.4 16
Li 2008 Reboxetine 9.02 2.64 57 8.72 3.21 57
Schutz 2001 Reboxetine 14.1 5.68 12 15.8 7.29 11
Zhao 2013 Reboxetine 9.1 3.4 54 9.1 3.1 53
specific - positive symptoms (SAPS)
Poyurovsky
2003
Reboxetine 4.8 3.9 10 11.8 12.2 10
Poyurovsky
2007
Reboxetine 3.21 3.2 31 2.66 2.4 28
Analysis 1.9. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 9 Mental state: 4b. General and specific: Average score (various scales, high=worse) - skewed results
- medium term (13 - 26 weeks).
Mental state: 4b. General and specific: Average score (various scales, high=worse) - skewed results - medium term (13 - 26
weeks)
Study NRI NRI mean NRI SD NRI N Placebo mean Placebo SD Placebo N
general - overall symptoms (BPRS total)
Ball 2011 Atomoxetine 30.8 5.8 14 31 8.9 12
general - overall symptoms (PANSS general)
Usall 2014 Reboxetine 28.83 8.1 24 30.09 7.93 23
general - overall symptoms (PANSS total)
Usall 2014 Reboxetine 59.96 17.89 24 62.04 19.9 23
Yu 2012 Reboxetine 24.24 3.54 33 26.86 1.66 32
specific - negative symptoms (PANSS negative)
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Mental state: 4b. General and specific: Average score (various scales, high=worse) - skewed results - medium term (13 - 26
weeks) (Continued)
Usall 2014 Reboxetine 19.67 8.41 24 22.65 5.54 23
specific - negative symptoms (SANS)
Usall 2014 Reboxetine 46.75 26.12 24 54.61 19.13 23
specific - positive symptoms (PANSS positive)
Usall 2014 Reboxetine 11.46 4.14 24 12 5.68 23
Zhao 2013 Reboxetine 9 3.2 54 9.3 3.4 53
Analysis 1.10. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 10 Cognitive functioning: 1. General - average composite cognitive functioning score (SMD).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 10 Cognitive functioning: 1. General - average composite cognitive functioning score (SMD)
Study or subgroup NRI Placebo
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 short term (2 - 12 weeks)
Eli Lilly 2006 54 0.15597031 (0.19101907) 56 57.2 % 0.16 [ -0.22, 0.53 ]
Friedman 2008 7 -0.03337901 (0.51759057) 8 9.6 % -0.03 [ -1.05, 0.98 ]
Kelly 2009 10 -0.67123628 (0.44113182) 12 13.0 % -0.67 [ -1.54, 0.19 ]
Poyurovsky 2007 16 0.22510504 (0.34948652) 17 20.2 % 0.23 [ -0.46, 0.91 ]
Subtotal (95% CI) 87 93 100.0 % 0.04 [ -0.28, 0.36 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.26, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 0.27 (P = 0.79)
2 medium term (13 - 26 weeks)
Ball 2011 14 -0.66379185 (0.40489688) 12 100.0 % -0.66 [ -1.46, 0.13 ]
Subtotal (95% CI) 14 12 100.0 % -0.66 [ -1.46, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
-1 -0.5 0 0.5 1
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Analysis 1.11. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 11 Cognitive functioning: 2. Specific - average individual scores (SMD) - short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 11 Cognitive functioning: 2. Specific - average individual scores (SMD) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 working memory
Kelly 2009 8 -0.57346737 (0.46633515) 12 42.7 % -0.57 [ -1.49, 0.34 ]
Poyurovsky 2007 16 0.23427497 (0.34958371) 17 57.3 % 0.23 [ -0.45, 0.92 ]
Subtotal (95% CI) 24 29 100.0 % -0.11 [ -0.89, 0.67 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 1.92, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 0.28 (P = 0.78)
2 reasoning/problem solving
Eli Lilly 2006 54 0.05109948 (0.19075573) 56 69.8 % 0.05 [ -0.32, 0.42 ]
Friedman 2008 7 -0.37545127 (0.52276077) 8 9.3 % -0.38 [ -1.40, 0.65 ]
Poyurovsky 2007 17 0.14118037 (0.34877645) 16 20.9 % 0.14 [ -0.54, 0.82 ]
Subtotal (95% CI) 78 80 100.0 % 0.03 [ -0.28, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 speed of processing
Eli Lilly 2006 54 0.05353987 (0.19160828) 55 61.8 % 0.05 [ -0.32, 0.43 ]
Friedman 2008 7 0.13578696 (0.51823383) 8 8.5 % 0.14 [ -0.88, 1.15 ]
Kelly 2009 9 -0.10289879 (0.44979364) 11 11.2 % -0.10 [ -0.98, 0.78 ]
Poyurovsky 2007 16 0.27761259 (0.35009509) 17 18.5 % 0.28 [ -0.41, 0.96 ]
Subtotal (95% CI) 86 91 100.0 % 0.08 [ -0.21, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
4 attention
Eli Lilly 2006 55 0.26936827 (0.19431446) 52 48.5 % 0.27 [ -0.11, 0.65 ]
Kelly 2009 10 -0.68800431 (0.45096083) 11 21.6 % -0.69 [ -1.57, 0.20 ]
Poyurovsky 2007 16 17 0.0123849 (0.34831882) 29.8 % 0.01 [ -0.67, 0.70 ]
Subtotal (95% CI) 81 80 100.0 % -0.01 [ -0.51, 0.48 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 3.88, df = 2 (P = 0.14); I2 =48%
Test for overall effect: Z = 0.06 (P = 0.95)
5 verbal learning/memory
-1 -0.5 0 0.5 1
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(. . . Continued)
Study or subgroup NRI Placebo
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Eli Lilly 2006 55 56 0.01841651 (0.1898434) 58.0 % 0.02 [ -0.35, 0.39 ]
Friedman 2008 7 -0.07505166 (0.51775843) 8 9.4 % -0.08 [ -1.09, 0.94 ]
Kelly 2009 10 -0.5929726 (0.43831923) 12 13.0 % -0.59 [ -1.45, 0.27 ]
Poyurovsky 2007 16 0.41217548 (0.35222673) 17 19.6 % 0.41 [ -0.28, 1.10 ]
Subtotal (95% CI) 88 93 100.0 % 0.01 [ -0.31, 0.32 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.23, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.05 (P = 0.96)
6 visual learning/memory
Kelly 2009 10 -0.43763009 (0.43372957) 12 100.0 % -0.44 [ -1.29, 0.41 ]
Subtotal (95% CI) 10 12 100.0 % -0.44 [ -1.29, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.42, df = 5 (P = 0.92), I2 =0.0%
-1 -0.5 0 0.5 1
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Analysis 1.12. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 12 Quality of life: Average quality of life score (GQOLI-74, high=better) - short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 12 Quality of life: Average quality of life score (GQOLI-74, high=better) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 general - total
Li 2008 57 40.48 (3.28) 57 31.12 (4.63) 100.0 % 9.36 [ 7.89, 10.83 ]
Subtotal (95% CI) 57 57 100.0 % 9.36 [ 7.89, 10.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.45 (P < 0.00001)
2 specific - well being - material
Li 2008 57 45.26 (6.88) 57 45.05 (7.03) 100.0 % 0.21 [ -2.34, 2.76 ]
Subtotal (95% CI) 57 57 100.0 % 0.21 [ -2.34, 2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
3 specific - well being - physical
Li 2008 57 25.79 (5.19) 57 25.11 (5.84) 100.0 % 0.68 [ -1.35, 2.71 ]
Subtotal (95% CI) 57 57 100.0 % 0.68 [ -1.35, 2.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
4 specific - well being - psychological
Li 2008 57 40.07 (4) 57 30.07 (6.56) 100.0 % 10.00 [ 8.01, 11.99 ]
Subtotal (95% CI) 57 57 100.0 % 10.00 [ 8.01, 11.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.83 (P < 0.00001)
5 specific - well being - social
Li 2008 57 40.08 (4) 57 30.06 (6.55) 100.0 % 10.02 [ 8.03, 12.01 ]
Subtotal (95% CI) 57 57 100.0 % 10.02 [ 8.03, 12.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 91.83, df = 4 (P = 0.00), I2 =96%
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Analysis 1.13. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 13 Clinical global response: 1a. Average clinical global status score (CGI-S, high=worse) - short term
(2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 13 Clinical global response: 1a. Average clinical global status score (CGI-S, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hinkelmann 2013 19 -0.7 (1.3) 16 -1.1 (1.25) 12.9 % 0.40 [ -0.45, 1.25 ]
Kelly 2009 11 4.2 (0.9) 12 4.8 (0.8) 18.5 % -0.60 [ -1.30, 0.10 ]
Poyurovsky 2003 10 -1.6 (1.13) 10 -1.6 (0.95) 11.1 % 0.0 [ -0.91, 0.91 ]
Poyurovsky 2007 31 -0.82 (0.9) 28 -0.96 (0.84) 41.5 % 0.14 [ -0.30, 0.58 ]
Schutz 2001 12 3.2 (0.94) 11 3.4 (0.91) 16.0 % -0.20 [ -0.96, 0.56 ]
Total (95% CI) 83 77 100.0 % -0.03 [ -0.35, 0.28 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.31, df = 4 (P = 0.37); I2 =7%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 14 Clinical global response: 1b. Average clinical global status score (various scales, high=worse) -
short term (2 - 12 weeks) - skewed results.
Clinical global response: 1b. Average clinical global status score (various scales, high=worse) - short term (2 - 12 weeks) - skewed
results
Study NRI NRI mean NRI SD NRI N Placebo mean Placebo SD Placebo N
CGI-I
Schutz 2001 Reboxetine 3.4 1.35 12 3.07 1.22 11
CGI-S
Hinkelmann
2013
Reboxetine 4.2 1.5 19 3.6 1.3 16
Poyurovsky
2003
Reboxetine 3.1 1.3 10 3 1.1 10
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Analysis 1.15. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 15 Leaving the study early: 1a. Short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 15 Leaving the study early: 1a. Short term (2 - 12 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Eli Lilly 2006 11/61 13/60 30.2 % 0.83 [ 0.41, 1.71 ]
Friedman 2008 3/10 2/10 6.4 % 1.50 [ 0.32, 7.14 ]
Hinkelmann 2013 3/19 1/16 3.3 % 2.53 [ 0.29, 21.98 ]
Kelly 2009 3/16 4/16 8.9 % 0.75 [ 0.20, 2.83 ]
Kurland 1981 3/13 3/15 7.8 % 1.15 [ 0.28, 4.76 ]
Poyurovsky 2003 3/13 3/13 7.9 % 1.00 [ 0.25, 4.07 ]
Poyurovsky 2007 9/31 9/28 26.4 % 0.90 [ 0.42, 1.95 ]
Schutz 2001 3/15 4/15 9.0 % 0.75 [ 0.20, 2.79 ]
Shafti 2015 0/25 0/25 Not estimable
Subtotal (95% CI) 203 198 100.0 % 0.94 [ 0.63, 1.39 ]
Total events: 38 (NRI), 39 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.58, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 due to adverse effects
Eli Lilly 2006 6/56 2/49 49.4 % 2.63 [ 0.56, 12.41 ]
Friedman 2008 2/10 0/10 14.0 % 5.00 [ 0.27, 92.62 ]
Kelly 2009 1/14 2/14 22.9 % 0.50 [ 0.05, 4.90 ]
Schutz 2001 2/14 0/11 13.8 % 4.00 [ 0.21, 75.66 ]
Subtotal (95% CI) 94 84 100.0 % 2.08 [ 0.70, 6.21 ]
Total events: 11 (NRI), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.13, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
3 due to psychiatric symptoms
Eli Lilly 2006 3/53 1/48 12.4 % 2.72 [ 0.29, 25.25 ]
Kelly 2009 1/13 2/14 11.9 % 0.54 [ 0.06, 5.26 ]
Poyurovsky 2007 7/29 7/26 75.6 % 0.90 [ 0.36, 2.21 ]
Subtotal (95% CI) 95 88 100.0 % 0.97 [ 0.44, 2.13 ]
0.01 0.1 1 10 100
Favours NRI Favours placebo
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(. . . Continued)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 11 (NRI), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 1.84, df = 2 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
Favours NRI Favours placebo
Analysis 1.16. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 16 Leaving the study early: 1b. Medium term (13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 16 Leaving the study early: 1b. Medium term (13 - 26 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Ball 2011 6/20 5/17 32.9 % 1.02 [ 0.38, 2.76 ]
Usall 2014 10/34 10/33 60.4 % 0.97 [ 0.47, 2.02 ]
Yu 2012 1/33 3/32 6.7 % 0.32 [ 0.04, 2.95 ]
Subtotal (95% CI) 87 82 100.0 % 0.92 [ 0.52, 1.62 ]
Total events: 17 (NRI), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 due to adverse effects
Ball 2011 4/19 2/14 100.0 % 1.47 [ 0.31, 6.95 ]
Subtotal (95% CI) 19 14 100.0 % 1.47 [ 0.31, 6.95 ]
Total events: 4 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 due to psychiatric symptoms
Usall 2014 2/26 0/23 100.0 % 4.44 [ 0.22, 88.04 ]
0.01 0.1 1 10 100
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Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 26 23 100.0 % 4.44 [ 0.22, 88.04 ]
Total events: 2 (NRI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
0.01 0.1 1 10 100
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Analysis 1.17. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 17 Adverse effects: 1. General - short term (binary, 2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 17 Adverse effects: 1. General - short term (binary, 2 - 12 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any
Eli Lilly 2006 38/61 35/60 58.8 % 1.07 [ 0.80, 1.43 ]
Kurland 1981 0/13 0/15 Not estimable
Shafti 2015 9/25 0/25 41.2 % 19.00 [ 1.17, 309.77 ]
Subtotal (95% CI) 99 100 100.0 % 3.49 [ 0.14, 90.29 ]
Total events: 47 (NRI), 35 (Placebo)
Heterogeneity: Tau2 = 4.66; Chi2 = 5.54, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.75 (P = 0.45)
2 serious
Eli Lilly 2006 3/61 1/60 66.9 % 2.95 [ 0.32, 27.58 ]
Hinkelmann 2013 0/19 0/16 Not estimable
Li 2008 1/58 0/57 33.1 % 2.95 [ 0.12, 70.92 ]
Subtotal (95% CI) 138 133 100.0 % 2.95 [ 0.47, 18.36 ]
Total events: 4 (NRI), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 1.18. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 18 Adverse effects: 2a.i. Specific - short term (binary, 2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 18 Adverse effects: 2a.i. Specific - short term (binary, 2 - 12 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anticholinergic - constipation
Kelly 2009 1/16 3/16 27.8 % 0.33 [ 0.04, 2.87 ]
Li 2008 4/57 4/57 72.2 % 1.00 [ 0.26, 3.81 ]
Subtotal (95% CI) 73 73 100.0 % 0.74 [ 0.24, 2.29 ]
Total events: 5 (NRI), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
2 anticholinergic - dry mouth
Kelly 2009 6/16 1/16 20.4 % 6.00 [ 0.81, 44.35 ]
Li 2008 12/57 4/57 71.2 % 3.00 [ 1.03, 8.75 ]
Schutz 2001 1/15 0/15 8.4 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 88 88 100.0 % 3.46 [ 1.40, 8.53 ]
Total events: 19 (NRI), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
3 anticholinergic - impotence
Schutz 2001 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (NRI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 cardiovascular - tachycardia
Li 2008 10/57 3/57 100.0 % 3.33 [ 0.97, 11.48 ]
Subtotal (95% CI) 57 57 100.0 % 3.33 [ 0.97, 11.48 ]
Total events: 10 (NRI), 3 (Placebo)
Heterogeneity: not applicable
0.005 0.1 1 10 200
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(. . . Continued)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.91 (P = 0.056)
5 central nervious system - anorexia
Kelly 2009 0/16 3/16 100.0 % 0.14 [ 0.01, 2.56 ]
Subtotal (95% CI) 16 16 100.0 % 0.14 [ 0.01, 2.56 ]
Total events: 0 (NRI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
6 central nervous system - dizziness
Kelly 2009 1/16 1/16 15.0 % 1.00 [ 0.07, 14.64 ]
Li 2008 6/57 4/57 73.9 % 1.50 [ 0.45, 5.03 ]
Schutz 2001 1/15 0/15 11.1 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 88 88 100.0 % 1.52 [ 0.54, 4.31 ]
Total events: 8 (NRI), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
7 central nervous system - fatigue
Kelly 2009 3/16 1/16 49.9 % 3.00 [ 0.35, 25.87 ]
Schutz 2001 1/15 3/15 50.1 % 0.33 [ 0.04, 2.85 ]
Subtotal (95% CI) 31 31 100.0 % 1.00 [ 0.12, 8.60 ]
Total events: 4 (NRI), 4 (Placebo)
Heterogeneity: Tau2 = 1.21; Chi2 = 2.00, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.00 (P = 1.0)
8 central nervous system - headache
Eli Lilly 2006 10/61 8/60 100.0 % 1.23 [ 0.52, 2.90 ]
Subtotal (95% CI) 61 60 100.0 % 1.23 [ 0.52, 2.90 ]
Total events: 10 (NRI), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
9 central nervous system - insomnia
Kelly 2009 3/16 1/16 64.0 % 3.00 [ 0.35, 25.87 ]
Li 2008 5/57 0/57 36.0 % 11.00 [ 0.62, 194.41 ]
Subtotal (95% CI) 73 73 100.0 % 4.79 [ 0.85, 26.84 ]
Total events: 8 (NRI), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
10 central nervous system - sedation
Kelly 2009 1/16 2/16 17.7 % 0.50 [ 0.05, 4.98 ]
Poyurovsky 2003 4/13 5/13 82.3 % 0.80 [ 0.28, 2.32 ]
Subtotal (95% CI) 29 29 100.0 % 0.74 [ 0.28, 1.94 ]
0.005 0.1 1 10 200
Favours NRI Favours placebo
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Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 5 (NRI), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
11 extrapyramidal - acute dystonia
Schutz 2001 1/15 1/15 100.0 % 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 15 15 100.0 % 1.00 [ 0.07, 14.55 ]
Total events: 1 (NRI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12 extrapyramidal - akathisia
Kelly 2009 1/16 3/16 30.7 % 0.33 [ 0.04, 2.87 ]
Poyurovsky 2003 0/13 0/13 Not estimable
Schutz 2001 4/15 3/15 69.3 % 1.33 [ 0.36, 4.97 ]
Subtotal (95% CI) 44 44 100.0 % 0.87 [ 0.25, 3.09 ]
Total events: 5 (NRI), 6 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.21 (P = 0.83)
13 extrapyramidal - hypersalivation
Schutz 2001 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (NRI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
14 extrapyramidal - parkinsonism
Schutz 2001 9/15 5/15 100.0 % 1.80 [ 0.79, 4.11 ]
Subtotal (95% CI) 15 15 100.0 % 1.80 [ 0.79, 4.11 ]
Total events: 9 (NRI), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
15 extrapyramidal - tremor
Kelly 2009 3/16 3/16 100.0 % 1.00 [ 0.24, 4.23 ]
Subtotal (95% CI) 16 16 100.0 % 1.00 [ 0.24, 4.23 ]
Total events: 3 (NRI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
16 extrapyramidal - stiffness
Kelly 2009 1/16 5/16 100.0 % 0.20 [ 0.03, 1.53 ]
Subtotal (95% CI) 16 16 100.0 % 0.20 [ 0.03, 1.53 ]
0.005 0.1 1 10 200
Favours NRI Favours placebo
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Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1 (NRI), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
17 extrapyramidal - use of antiparkinson medication
Poyurovsky 2003 0/13 0/13 Not estimable
Poyurovsky 2007 2/31 3/28 11.9 % 0.60 [ 0.11, 3.34 ]
Shafti 2015 10/25 12/25 88.1 % 0.83 [ 0.44, 1.56 ]
Subtotal (95% CI) 69 66 100.0 % 0.80 [ 0.44, 1.45 ]
Total events: 12 (NRI), 15 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
18 gastrointestinal - abdominal pain
Kelly 2009 3/16 2/16 100.0 % 1.50 [ 0.29, 7.81 ]
Subtotal (95% CI) 16 16 100.0 % 1.50 [ 0.29, 7.81 ]
Total events: 3 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
19 gastrointestinal - nausea
Kelly 2009 0/16 4/16 21.0 % 0.11 [ 0.01, 1.91 ]
Li 2008 7/57 5/57 48.4 % 1.40 [ 0.47, 4.15 ]
Schutz 2001 1/15 4/15 30.5 % 0.25 [ 0.03, 1.98 ]
Subtotal (95% CI) 88 88 100.0 % 0.49 [ 0.10, 2.41 ]
Total events: 8 (NRI), 13 (Placebo)
Heterogeneity: Tau2 = 1.07; Chi2 = 4.27, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.88 (P = 0.38)
20 gastrointestinal - vomiting
Kelly 2009 0/16 2/16 100.0 % 0.20 [ 0.01, 3.86 ]
Subtotal (95% CI) 16 16 100.0 % 0.20 [ 0.01, 3.86 ]
Total events: 0 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
21 gastrointestinal - diarrhoea
Kelly 2009 0/16 2/16 100.0 % 0.20 [ 0.01, 3.86 ]
Subtotal (95% CI) 16 16 100.0 % 0.20 [ 0.01, 3.86 ]
Total events: 0 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
22 immune system - rash
0.005 0.1 1 10 200
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M-
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CI
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CI
Schutz 2001 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (NRI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
23 immune system - sore throat
Kelly 2009 0/16 2/16 100.0 % 0.20 [ 0.01, 3.86 ]
Subtotal (95% CI) 16 16 100.0 % 0.20 [ 0.01, 3.86 ]
Total events: 0 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
24 metabolic - weight loss
Kelly 2009 1/16 3/16 100.0 % 0.33 [ 0.04, 2.87 ]
Subtotal (95% CI) 16 16 100.0 % 0.33 [ 0.04, 2.87 ]
Total events: 1 (NRI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
25 metabolic - significant weight gain
Poyurovsky 2003 3/13 9/13 37.7 % 0.33 [ 0.12, 0.96 ]
Poyurovsky 2007 6/31 13/28 62.3 % 0.42 [ 0.18, 0.95 ]
Subtotal (95% CI) 44 41 100.0 % 0.38 [ 0.20, 0.73 ]
Total events: 9 (NRI), 22 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0037)
0.005 0.1 1 10 200
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Analysis 1.19. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 19 Adverse effects: 2a.ii. Specific - extrapyramidal - average change score (continuous, various
scales, high=worse) - short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 19 Adverse effects: 2a.ii. Specific - extrapyramidal - average change score (continuous, various scales, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 AIMS
Kelly 2009 11 0 (3.45) 15 -0.3 (3.31) 100.0 % 0.30 [ -2.34, 2.94 ]
Subtotal (95% CI) 11 15 100.0 % 0.30 [ -2.34, 2.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
2 BAS
Poyurovsky 2007 31 -0.68 (0.94) 28 -0.5 (0.92) 100.0 % -0.18 [ -0.65, 0.29 ]
Subtotal (95% CI) 31 28 100.0 % -0.18 [ -0.65, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
3 SAS
Kelly 2009 11 -1.6 (3.38) 15 -0.2 (2.33) 32.1 % -1.40 [ -3.72, 0.92 ]
Poyurovsky 2007 31 -2.1 (2.49) 28 -2.36 (2.45) 67.9 % 0.26 [ -1.00, 1.52 ]
Subtotal (95% CI) 42 43 100.0 % -0.27 [ -1.79, 1.25 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.35 (P = 0.72)
-4 -2 0 2 4
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Analysis 1.20. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 20 Adverse effects: 2a.iii. Specific - extrapyramidal - average change score (continuous, various
scales, high=worse) - short term (2 - 12 weeks) - skewed results.
Adverse effects: 2a.iii. Specific - extrapyramidal - average change score (continuous, various scales, high=worse) - short term (2
- 12 weeks) - skewed results
Study NRI NRI mean NRI SD NRI N Placebo mean Placebo SD Placebo N
AIMS
Kelly 2009 Atomoxetine 1.33 1.88 12 0.93 1.94 11
SAS
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Adverse effects: 2a.iii. Specific - extrapyramidal - average change score (continuous, various scales, high=worse) - short term (2
- 12 weeks) - skewed results (Continued)
Kelly 2009 Atomoxetine 0.4 0.5 11 1.9 2.6 15
Schutz 2001 Reboxetine 2.5 3.4 11 2.3 2.9 15
Analysis 1.21. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 21 Adverse effects: 2b.i. Specific - medium term (binary, 13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 21 Adverse effects: 2b.i. Specific - medium term (binary, 13 - 26 weeks)
Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anticholinergic - constipation
Zhao 2013 9/53 2/54 100.0 % 4.58 [ 1.04, 20.23 ]
Subtotal (95% CI) 53 54 100.0 % 4.58 [ 1.04, 20.23 ]
Total events: 9 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 anticholinergic - dry mouth
Zhao 2013 3/53 2/54 100.0 % 1.53 [ 0.27, 8.78 ]
Subtotal (95% CI) 53 54 100.0 % 1.53 [ 0.27, 8.78 ]
Total events: 3 (NRI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
3 anticholinergic - sweating
Zhao 2013 6/53 0/54 100.0 % 13.24 [ 0.76, 229.32 ]
Subtotal (95% CI) 53 54 100.0 % 13.24 [ 0.76, 229.32 ]
Total events: 6 (NRI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
4 cardiovascular - QT prolongation
Ball 2011 4/20 1/17 100.0 % 3.40 [ 0.42, 27.59 ]
Subtotal (95% CI) 20 17 100.0 % 3.40 [ 0.42, 27.59 ]
Total events: 4 (NRI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
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Study or subgroup NRI Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 cardiovascular - tachycardia
Zhao 2013 7/53 4/54 100.0 % 1.78 [ 0.55, 5.74 ]
Subtotal (95% CI) 53 54 100.0 % 1.78 [ 0.55, 5.74 ]
Total events: 7 (NRI), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
6 central nervous system - dizziness
Zhao 2013 4/53 3/54 100.0 % 1.36 [ 0.32, 5.78 ]
Subtotal (95% CI) 53 54 100.0 % 1.36 [ 0.32, 5.78 ]
Total events: 4 (NRI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
7 central nervous system - insomnia
Zhao 2013 6/53 0/54 100.0 % 13.24 [ 0.76, 229.32 ]
Subtotal (95% CI) 53 54 100.0 % 13.24 [ 0.76, 229.32 ]
Total events: 6 (NRI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
8 extrapyramidal - tremor
Ball 2011 6/20 12/17 100.0 % 0.43 [ 0.20, 0.89 ]
Subtotal (95% CI) 20 17 100.0 % 0.43 [ 0.20, 0.89 ]
Total events: 6 (NRI), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
9 gastrointestinal - nausea
Zhao 2013 5/53 1/54 100.0 % 5.09 [ 0.62, 42.16 ]
Subtotal (95% CI) 53 54 100.0 % 5.09 [ 0.62, 42.16 ]
Total events: 5 (NRI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 1.22. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 22 Adverse effects: 2a.iv. Specific - metabolic - average weight gain (continuous, increase in kg).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 22 Adverse effects: 2a.iv. Specific - metabolic - average weight gain (continuous, increase in kg)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (2 - 12 weeks)
Poyurovsky 2003 10 2.45 (2.72) 10 5.45 (3.09) 15.9 % -3.00 [ -5.55, -0.45 ]
Poyurovsky 2007 31 3.31 (2.73) 28 4.91 (2.45) 59.4 % -1.60 [ -2.92, -0.28 ]
Zhao 2013 53 -2 (5.6) 54 1 (5.2) 24.7 % -3.00 [ -5.05, -0.95 ]
Subtotal (95% CI) 94 92 100.0 % -2.17 [ -3.19, -1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.17 (P = 0.000030)
2 medium term (13 - 26 weeks)
Ball 2011 14 -2.4 (1.4) 12 -3.1 (1.4) 50.4 % 0.70 [ -0.38, 1.78 ]
Zhao 2013 53 -6 (4.4) 54 1 (4.4) 49.6 % -7.00 [ -8.67, -5.33 ]
Subtotal (95% CI) 67 66 100.0 % -3.12 [ -10.67, 4.42 ]
Heterogeneity: Tau2 = 29.13; Chi2 = 57.72, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 1.23. Comparison 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO,
Outcome 23 Social or general functioning: Average social functioning score (various subscales) - short-term (2
- 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 1 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus PLACEBO
Outcome: 23 Social or general functioning: Average social functioning score (various subscales) - short-term (2 - 12 weeks)
Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 activity - activities (inverted SLOF, high=worse)
Friedman 2008 7 -0.6 (3.3) 8 -0.6 (3.2) 100.0 % 0.0 [ -3.30, 3.30 ]
Subtotal (95% CI) 7 8 100.0 % 0.0 [ -3.30, 3.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 activity - hospital activity (SSPI, high=worse)
Li 2008 57 1.02 (0.4) 57 1.05 (0.35) 100.0 % -0.03 [ -0.17, 0.11 ]
Subtotal (95% CI) 57 57 100.0 % -0.03 [ -0.17, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 activity - disease indoor activity (SSPI, high=worse)
Li 2008 57 -0.16 (0.41) 57 -0.02 (0.33) 100.0 % -0.14 [ -0.28, 0.00 ]
Subtotal (95% CI) 57 57 100.0 % -0.14 [ -0.28, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
4 activity - physical functioning (inverted SLOF, high=worse)
Friedman 2008 7 0 (1) 8 0.3 (0.5) 100.0 % -0.30 [ -1.12, 0.52 ]
Subtotal (95% CI) 7 8 100.0 % -0.30 [ -1.12, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 personal care - personal care skills (inverted SLOF, high=worse)
Friedman 2008 7 -0.6 (0.9) 8 -0.4 (1.5) 100.0 % -0.20 [ -1.43, 1.03 ]
Subtotal (95% CI) 7 8 100.0 % -0.20 [ -1.43, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
6 personal care - self-care (SSPI, high=worse)
Li 2008 57 -0.04 (0.52) 57 -0.01 (0.5) 100.0 % -0.03 [ -0.22, 0.16 ]
Subtotal (95% CI) 57 57 100.0 % -0.03 [ -0.22, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
7 personal care - social acceptability (inverted SLOF, high=worse)
Friedman 2008 7 0 (0.6) 8 -0.1 (1) 100.0 % 0.10 [ -0.72, 0.92 ]
-4 -2 0 2 4
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Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 7 8 100.0 % 0.10 [ -0.72, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
8 relationships - family role (SSPI, high=worse)
Li 2008 57 0.84 (0.37) 57 0.93 (0.37) 100.0 % -0.09 [ -0.23, 0.05 ]
Subtotal (95% CI) 57 57 100.0 % -0.09 [ -0.23, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
9 relationships - interest and concern in the external environment (SSPI, high=worse)
Li 2008 57 1.09 (0.47) 57 1.28 (0.49) 100.0 % -0.19 [ -0.37, -0.01 ]
Subtotal (95% CI) 57 57 100.0 % -0.19 [ -0.37, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
10 relationships - interpersonal relationships (inverted SLOF, high=worse)
Friedman 2008 7 -3.1 (4.5) 8 -1.9 (3.7) 100.0 % -1.20 [ -5.41, 3.01 ]
Subtotal (95% CI) 7 8 100.0 % -1.20 [ -5.41, 3.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
11 relationships - relationships and caring for others (SSPI, high=worse)
Li 2008 57 1 (0.42) 57 1.09 (0.39) 100.0 % -0.09 [ -0.24, 0.06 ]
Subtotal (95% CI) 57 57 100.0 % -0.09 [ -0.24, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
12 relationships - sexual role (SSPI, high=worse)
Li 2008 57 1.39 (0.49) 57 1.42 (0.5) 100.0 % -0.03 [ -0.21, 0.15 ]
Subtotal (95% CI) 57 57 100.0 % -0.03 [ -0.21, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
13 relationships - social withdrawal (SSPI, high=worse)
Li 2008 57 -0.34 (0.45) 57 -0.02 (0.47) 100.0 % -0.32 [ -0.49, -0.15 ]
Subtotal (95% CI) 57 57 100.0 % -0.32 [ -0.49, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00020)
14 work - professional skills (SSPI, high=worse)
Li 2008 57 0.95 (0.4) 57 1.14 (0.4) 100.0 % -0.19 [ -0.34, -0.04 ]
Subtotal (95% CI) 57 57 100.0 % -0.19 [ -0.34, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
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Study or subgroup NRI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
15 work - responsibility and planning (SSPI, high=worse)
Li 2008 57 1.39 (0.49) 57 1.42 (0.5) 100.0 % -0.03 [ -0.21, 0.15 ]
Subtotal (95% CI) 57 57 100.0 % -0.03 [ -0.21, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
16 work - work skills (inverted SLOF, high=worse)
Friedman 2008 7 -2.9 (3.3) 8 0.1 (0.6) 100.0 % -3.00 [ -5.48, -0.52 ]
Subtotal (95% CI) 7 8 100.0 % -3.00 [ -5.48, -0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 2.1. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 1 Mental state: 1a. General: Average general/overall symptoms score (PANSS general,
high=worse) - short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 1 Mental state: 1a. General: Average general/overall symptoms score (PANSS general, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hinkelmann 2013 19 -3.8 (8.71) 16 -6.7 (8.59) 100.0 % 2.90 [ -2.85, 8.65 ]
Total (95% CI) 19 16 100.0 % 2.90 [ -2.85, 8.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 2 Mental state: 1b. General: Average general/overall symptoms score (various scales,
high=worse) - medium term (13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 2 Mental state: 1b. General: Average general/overall symptoms score (various scales, high=worse) - medium term (13 - 26 weeks)
Study or subgroup NRI Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS total
Usall 2014 24 -12.1 (16.7) 17 -13.72 (11.08) 100.0 % 1.62 [ -6.89, 10.13 ]
Subtotal (95% CI) 24 17 100.0 % 1.62 [ -6.89, 10.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 PANSS general
Usall 2014 24 -4.93 (8.19) 17 -5.55 (6.85) 100.0 % 0.62 [ -4.00, 5.24 ]
Subtotal (95% CI) 24 17 100.0 % 0.62 [ -4.00, 5.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
-10 -5 0 5 10
Favours NRI Favours control
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Analysis 2.3. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 3 Mental state: 2a. Specific: Average symptoms score (various scales, high=worse) -
short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 3 Mental state: 2a. Specific: Average symptoms score (various scales, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 mood (HRSD)
Hinkelmann 2013 19 -5.2 (5.51) 16 -8.2 (7.02) 100.0 % 3.00 [ -1.24, 7.24 ]
Subtotal (95% CI) 19 16 100.0 % 3.00 [ -1.24, 7.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
2 negative (PANSS negative)
Hinkelmann 2013 19 -4.1 (7.74) 16 -5.6 (9.58) 100.0 % 1.50 [ -4.34, 7.34 ]
Subtotal (95% CI) 19 16 100.0 % 1.50 [ -4.34, 7.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
3 positive (PANSS positive)
Hinkelmann 2013 19 -1.4 (4.46) 16 -3.1 (5.13) 100.0 % 1.70 [ -1.52, 4.92 ]
Subtotal (95% CI) 19 16 100.0 % 1.70 [ -1.52, 4.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.27, df = 2 (P = 0.87), I2 =0.0%
-20 -10 0 10 20
Favours NRI Favours control
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Analysis 2.4. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 4 Mental state: 2b. Specific: Average symptoms score (various scales, high=worse) -
medium term (13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 4 Mental state: 2b. Specific: Average symptoms score (various scales, high=worse) - medium term (13 - 26 weeks)
Study or subgroup NRI Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 negative (PANSS negative)
Usall 2014 24 -5.83 (7.72) 17 -6.09 (5.07) 100.0 % 0.26 [ -3.66, 4.18 ]
Subtotal (95% CI) 24 17 100.0 % 0.26 [ -3.66, 4.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 negative (SANS)
Usall 2014 24 -14.81 (23.58) 17 -14.54 (16.99) 100.0 % -0.27 [ -12.69, 12.15 ]
Subtotal (95% CI) 24 17 100.0 % -0.27 [ -12.69, 12.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
3 positive (PANSS positive)
Usall 2014 24 -1.33 (4.75) 17 -2.07 (3.74) 100.0 % 0.74 [ -1.86, 3.34 ]
Subtotal (95% CI) 24 17 100.0 % 0.74 [ -1.86, 3.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
-10 -5 0 5 10
Favours NRI Favours control
Analysis 2.5. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 5 Mental state: 3a. General and specific: Average score (various scales, high=worse) -
skewed results - short term (2 - 12 weeks).
Mental state: 3a. General and specific: Average score (various scales, high=worse) - skewed results - short term (2 - 12 weeks)
Study NRI NRI mean NRI SD NRI N Active control Control mean Control SD Control N
general - overall symptoms (PANSS general)
Hinkel-
mann 2013
Reboxetine 28.7 9.4 19 Citalopram 26.5 6.2 16
specific - mood (HRSD)
Hinkel-
mann 2013
Reboxetine 8.3 6.1 19 Citalopram 9.6 5.8 16
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Mental state: 3a. General and specific: Average score (various scales, high=worse) - skewed results - short term (2 - 12 weeks)
(Continued)
specific - negative symptoms (PANSS negative)
Hinkel-
mann 2013
Reboxetine 21.5 8.6 19 Citalopram 19.1 8.8 16
specific - positive symptoms (PANSS positive)
Hinkel-
mann 2013
Reboxetine 10.6 4.6 19 Citalopram 11.1 4.8 16
Analysis 2.6. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 6 Mental state: 3b. General and specific: Average score (various scales, high=worse) -
skewed results - medium term (13 - 26 weeks).
Mental state: 3b. General and specific: Average score (various scales, high=worse) - skewed results - medium term (13 - 26
weeks)
Study NRI NRI mean NRI SD NRI N Active control Control mean Control SD Control N
general - overall symptoms (PANSS general)
Usall 2014 Reboxetine 28.83 8.1 24 Citalopram 28.88 5.32 17
general - overall symptoms (PANSS total)
Usall 2014 Reboxetine 59.96 17.89 24 Citalopram 59.41 11.72 17
specific - negative symptoms (PANSS negative)
Usall 2014 Reboxetine 19.67 8.41 24 Citalopram 19.82 4.99 17
specific - negative symptoms (SANS)
Usall 2014 Reboxetine 46.75 26.12 24 Citalopram 46.63 15.84 17
specific - positive symptoms (PANSS positive)
Usall 2014 Reboxetine 11.46 4.14 24 Citalopram 10.71 3.58 17
114Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 7 Clinical global response: Average clinical global status score (CGI-S, high=worse) -
short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 7 Clinical global response: Average clinical global status score (CGI-S, high=worse) - short term (2 - 12 weeks)
Study or subgroup NRI Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hinkelmann 2013 19 4.2 (1.5) 16 4.2 (1.2) 100.0 % 0.0 [ -0.89, 0.89 ]
Total (95% CI) 19 16 100.0 % 0.0 [ -0.89, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours NRI Favours control
Analysis 2.8. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 8 Leaving the study early: 1a. Short term (2 - 12 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 8 Leaving the study early: 1a. Short term (2 - 12 weeks)
Study or subgroup NRI Active control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Hinkelmann 2013 3/19 4/16 100.0 % 0.63 [ 0.17, 2.41 ]
Subtotal (95% CI) 19 16 100.0 % 0.63 [ 0.17, 2.41 ]
Total events: 3 (NRI), 4 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours NRI Favours control
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Analysis 2.9. Comparison 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE
CONTROL, Outcome 9 Leaving the study early: 1b. Medium term (13 - 26 weeks).
Review: Selective noradrenaline reuptake inhibitors for schizophrenia
Comparison: 2 SELECTIVE NORADRENALINE REUPTAKE INHIBITORS versus ACTIVE CONTROL
Outcome: 9 Leaving the study early: 1b. Medium term (13 - 26 weeks)
Study or subgroup NRI Active control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Usall 2014 10/34 6/23 100.0 % 1.13 [ 0.48, 2.67 ]
Subtotal (95% CI) 34 23 100.0 % 1.13 [ 0.48, 2.67 ]
Total events: 10 (NRI), 6 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 due to psychiatric symptoms
Usall 2014 2/26 1/23 100.0 % 1.77 [ 0.17, 18.26 ]
Subtotal (95% CI) 26 23 100.0 % 1.77 [ 0.17, 18.26 ]
Total events: 2 (NRI), 1 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
0.05 0.2 1 5 20
Favours NRI Favours control
A D D I T I O N A L T A B L E S
Table 1. Mental state: 1.2 General - Average general/overall symptoms score (PANSS general, negative MD favours NRI) -
short-term (2-12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 5 294 -2.17 -3.93 to -0.40* 44%
Reboxetine 4 279 -2.20 -4.15 to -0.25* 55%
Clozapine-
only studies; exclud-
ing skewed change-
scores
2 221 -2.80 -4.87 to -0.72* 75%
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Table 1. Mental state: 1.2 General - Average general/overall symptoms score (PANSS general, negative MD favours NRI) -
short-term (2-12wks) - Subgroup and sensitivity analysis (Continued)
Excluding stud-
ies without clozap-
ine; negative symp-
toms
3 256 -2.40 -4.48 to -0.31* 65%
Excluding studies
with imputed SD
3 236 -2.66 -4.50 to -0.82* 55%
Fixed-effect model 5 294 -2.73 -3.71 to -1.74* 44%
Low risk of ran-
domisation bias
2 58 0.89 -3.60 to 5.37 0%
* Statistically significant at p<0.05
Table 2. Mental state: 1.2 General - Average general/overall symptoms score (PANSS total, negative MD favours NRI) - short-
term (2-12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 4 309 -2.84 -5.28 to -0.40* 72%
Clozapine-only
studies
2 220 -4.25 -5.89 to -2.62* 0%
Excluding out-
lier; excluding high
risk of bias
3 244 -4.20 -5.82 to -2.58* 0%
Negative symp-
toms; excluding im-
puted SD
3 186 -2.94 -5.54 to -0.34* 81%
Fixed-effect model 4 309 -2.12 -3.12 to -1.11* 72%
* Statistically significant at p<0.05
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Table 3. Mental state: 1.2 General - Average general/overall symptoms score (PANSS total, negative MD favours NRI) -
medium-term (13-26wks) - Exploration of heterogeneity
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 3 219 -3.67 -10.07 to 2.72 94%
Excluding outlier;
excluding clozapine
study
2 112 -1.07 -2.59 to 0.46 0%
Fixed-effect model 3 219 -3.63 -4.87 to -2.39* 94%
* Statistically significant at p<0.05
Table 4. Mental state: 1.5 Specific - Average negative symptoms score (PANSS negative, negative MD favours NRI) - short-
term (2-12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 6 359 -0.99 -2.53 to 0.56 71%
Reboxetine 5 341 -1.20 -2.80 to 0.40 74%
Clozapine-only
studies
2 221 -1.60 -3.96 to 0.76 84%
Excluding studies
without clozapine
3 256 -0.75 -3.25 to 1.75 81%
Negative symptoms 4 321 -1.47 -3.04 to 0.09 77%
Excluding imputed
SD
4 301 -1.68 -3.04 to -0.32* 70%
Excluding skewed
change scores
3 286 -1.92 -3.28 to -0.55* 75%
Fixed-effect model 6 259 -1.82 -2.46 to -1.18* 71%
Low risk of ran-
domisation bias
2 58 3.55 -0.43 to 7.54 0%
Excluding high risk
of bias
5 294 -0.12 -2.31 to 2.07 71%
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* Statistically significant at p<0.05
Table 5. Mental state: 1.4 Specific - Average positive symptoms score (PANSS positive, negative MD favours NRI) - short-term
(2-12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 5 294 -0.16 -0.96 to 0.63 0%
Reboxetine 4 279 -0.24 -1.05 to 0.57 0%
Clozapine-only
studies
2 221 -0.15 -1.02 to 0.72 0%
Excluding stud-
ies without clozap-
ine; negative symp-
toms
3 256 -0.22 -1.04 to 0.60 0%
Fixed-effect model 5 294 -0.16 -0.96 to 0.63 0%
Low risk of ran-
domisation bias
2 58 -0.76 -2.93 to 1.40 0%
Table 6. Cognitive functioning: 2.3 Average composite cognitive functioning score (SMD, negative favours NRI) - short-term
(2-12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 4 180 0.04 -0.28 to 0.36 8%
Atomoxetine 3 147 -0.07 -0.55 to 0.41 33%
Fixed-effect model 4 180 0.06 -0.24 to 0.35 8%
Low risk of ran-
domisation bias
2 55 -0.18 -1.06 to 0.69 61%
Excluding high risk
of other bias
2 48 0.14 -0.42 to 0.71 0%
Excluding high risk
of attrition and re-
porting bias
3 70 -0.12 -0.66 to 0.43 22%
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Table 7. Cognitive functioning: 2.9 Average speed of processing score (SMD, negative favours NRI) - short-term (2-12wks) -
Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 4 177 0.08 -0.21 to 0.38 0%
Atomoxetine 3 144 0.04 -0.29 to 0.37 0%
Fixed-effect model 4 177 0.08 -0.21 to 0.38 0%
Low risk of ran-
domisation bias
2 53 0.13 -0.41 to 0.68 0%
Excluding high
risk of attrition and
other bias
2 48 0.23 -0.34 to 0.80 0%
Excluding high risk
of reporting bias
3 68 0.13 -0.34 to 0.61 0%
Table 8. Cognitive functioning: 2.13 Average verbal learning/memory score (SMD, negative favours NRI) - short-term (2-
12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 4 181 0.01 -0.31 to 0.32 7%
Atomoxetine 3 148 -0.08 -0.40 to 0.25 0%
Fixed-effect model 4 181 0.01 -0.28 to 0.30 7%
Low risk of ran-
domisation bias
2 55 -0.06 -1.04 to 0.93 69%
Excluding high risk
of other bias
2 48 0.26 -0.31 to 0.83 0%
Excluding high risk
of attrition and re-
porting bias
3 70 -0.04 -0.66 to 0.58 38%
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Table 9. Clinical global response: 4.1 Average clinical global status score (CGI-S, negative MD favours NRI) - short-term (2-
12wks) - Subgroup and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Mean difference 95% Confidence interval I²
Overall outcome 5 160 -0.03 -0.35 to 0.28 7%
Reboxetine; exclud-
ing high risk of bias
4 137 0.10 -0.23 to 0.42 0%
Excluding imputed
SD; exclud-
ing skewed change
scores
3 105 -0.15 -0.60 to 0.29 37%
Fixed-effect model 5 160 -0.03 -0.32 to 0.27 7%
Table 10. Adverse effects: 6.2.1 All cause withdrawals (lower RR favours NRI) - short-term (2-12wks) - Subgroup and sensitivity
analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Relative risk 95% Confidence interval I²
Overall outcome 8 401 0.94 0.63 to 1.39 0%
Atomoxetine 3 173 0.89 0.49 to 1.59 0%
Reboxetine 5 200 0.95 0.54 to 1.70 0%
Fixed-effect model 8 401 0.95 0.64 to 1.41 0%
Low risk of bias in
randomisation
5 182 0.92 0.54 to 1.56 0%
Excluding high risk
of other bias
7 248 1.03 0.62 to 1.70 0%
Excluding high risk
of reporting bias
7 252 0.97 0.58 to 1.60 0%
Excluding high risk
of attrition bias
8 369 0.96 0.63 to 1.45 0%
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Table 11. Adverse effects: 6.2.2 Withdrawal due to adverse events (lower RR favours NRI) - short-term (2-12wks) - Subgroup
and sensitivity analysis
Subgroup or sensi-
tivity analysis (see
text for details)
Number of trials N Relative risk 95% Confidence interval I²
Overall outcome 4 178 2.08 0.70 to 6.21 0%
Atomoxetine 3 153 1.88 0.58 to 6.08 0%
Fixed-effect model 4 178 2.18 0.79 to 6.02 0%
Low risk of bias in
randomisation
2 53 1.15 0.15 to 8.60 18%
Excluding high risk
of other bias
2 45 4.48 0.56 to 35.52 0%
Excluding high risk
of reporting bias
3 73 1.66 0.36 to 7.72 0%
Table 12. Included and excluded studies and relevant Cochrane Reviews
Study tag Specific patient charac-
teristics
Intervention Control Relevant Cochrane Reviews
Barnes 2009 Negative symptoms Citalopram Placebo Rummel-Kluge 2006
Hou 2007 Negative symptoms Citalopram Placebo Rummel-Kluge 2006
Mueller 2005 Celecoxib Placebo Akhondzadeh 2011
Salokangas 1997 Citalopram Placebo -
Shafti 2004 Clomipramine Placebo -
Citalopram -
Fluoxetine Placebo -
Nortiptyline -
Fluvoxamine Placebo -
Maprotiline -
Hinkelmann 2013 Negative symptoms Reboxetine Placebo Rummel-Kluge 2006
Li 2008 Negative symptoms Reboxetine Placebo Rummel-Kluge 2006
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Table 12. Included and excluded studies and relevant Cochrane Reviews (Continued)
Shafti 2015 Negative symptoms Reboxetine Placebo Rummel-Kluge 2006
Usall 2014 Negative symptoms Reboxetine Placebo Rummel-Kluge 2006
Yu 2012 Negative symptoms Reboxetine Control Rummel-Kluge 2006
Zhao 2013 Negative symptoms Reboxetine Placebo Rummel-Kluge 2006
Table 13. Suggested design for a future NRI trial
Methods Allocation: randomised (with sequence generation and allocation concealment clearly described)
Blinding: double blind (participants, clinicians, and outcome assessors) and blinding tested
Duration: at least 3 months
Design: parallel group
Setting: inpatient and outpatient
Participants Diagnosis: people with schizophrenia (duration > 6m) and prominent negative symptoms (e.g. PANSS negative >
30)
N=300
Age: Any, but with recruitment focused on those aged 18-65yrs
Sex: Men and women
Interventions 1. Reboxetine (8-12mg daily) in combination with any antipsychotic treatment including clozapine
2. Placebo in combination with any antipsychotic treatment including clozapine
Outcomes Mental state: significant improvement in negative symptoms defined as 20% reduction in the PANSS negative scale*,
average scores on the PANSS negative scale, significant improvement and average scores on the PANSS total, general,
and positive scales and the HRSD
Cognitive functioning: significant improvement in a clinical scale of cognitive functioning such as the Schizophrenia
Cognition Rating Scale (SCoRS) total score, average scores on neurocognitive testing such as the MATRICS Con-
sensus Cognitive Battery (MCCB) overall composite T-score and individual domain scores
Quality of life: significant improvement in a quality of life scale, average scores on a quality of life scale
Clinical global response: significant improvment in clinical global status defined as CGI-I scores of 1 or 2, average
scores on the CGI-S
Service utilisation
Adverse effects: leaving the study early (for any reason), serious adverse effects, average weight gain
Satisfaction with treatment
Social or general functioning
Notes * recommended primary outcome, other outcomes listed are suggestions rather than an exhaustive list
123Selective noradrenaline reuptake inhibitors for schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Previous Searches
1. November 2012
Electronic searches
1. Cochrane Schizophrenia Group Trials Register (November 2012)
We searched the register using the phrase:
[(*atomoxetine* or *attentin* or *beloxepin* or *davedax* or *edonax* or *edronax* or *esreboxetine* or *FCE 20124* or*FCE 21684*
or *LY 139602 * or *LY 139603* or *nisoxetine* or *norebox* or *Org 4428* or *prolift* or *reboxetine* or *solvex* or *SPN 812*
or *strattera* or *talopram* or *talsupram* or *tomoxetin* or *vestra* or * NRI* or *noradrenaline reuptake* or *norepinephrine
reuptake* in interventions of STUDY) or (*norepinephrine reuptake* or *noradrenaline reuptake* in title, abstract or index terms of
REFERENCE)]
This register is compiled by systematic searches of major databases, handsearches and conference proceedings (see group module).
Searching other resources
1. Reference searching
We will inspect references of all identified studies for further relevant studies.
2. Personal contact
We will contact the first author of each included study for information regarding unpublished trials.
H I S T O R Y
Protocol first published: Issue 11, 2012
Review first published: Issue 1, 2018
Date Event Description
17 November 2015 Amended Search was updated and 4 studies were added to ’Classification pending references’ section of the
review
20 August 2014 Amended Searchwas updated and six new references were added to ’Classification pending references’ section
of the the review
Note: References from previous search are still in ’Studies awaiting classification’ section of the
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(Continued)
review
C O N T R I B U T I O N S O F A U T H O R S
Paul Matthews: screening retrieved papers against eligibility criteria, appraising the quality of papers, extracting data, contacting authors
for additional information, handsearching references, calculating additional useable data from reported values, entering data into
RevMan 5, analysis of data, interpretation of data, writing the protocol and review, liaison with the Cochrane Schizophrenia Group.
Mike Pearce: appraising the quality of papers, extracting data, interpretation of data, writing the review.
Jamie Horder: screening retrieved papers against eligibility criteria, writing the protocol and review.
D E C L A R A T I O N S O F I N T E R E S T
Paul Matthews: had a short clinical attachment to the Schizophrenia Research Program at NIMH in 2009 during the period that Apud
2007a was conducted there, but did not have direct involvement in the trial. From 2011 to 2016 PM has attended a total of two days
of educational meetings organised by Lundbeck and one day organised by Eli Lilly in the UK and received travel expenses on two of
these occasions.
Jamie Horder: none known.
Michael Pearce: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Oxford Health NHS Foundation Trust, Oxford, UK.
Previously employed lead author Paul RL Matthews and employs review author Michael Pearce.
• King’s College London, UK.
Employs review author Jamie Horder.
• Berkshire Healthcare NHS Foundation Trust (Bracknell), UK.
Previously employed review authors Paul Matthews and Michael Pearce.
External sources
• No sources of support supplied
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol for this review was published as Matthews 2012.
1. Inclusion criteria
We decided to broaden the inclusion criteria of the review beyond placebo-controlled trials to better reflect the title of the review and
identified two trials using citalopram as an active comparator that were also included in the placebo-controlled analysis.
2. Search methods
After discussion with the Cochrane Schizophrenia Group TSC we broadened the search terms in order to include more potential
selective NRIs. One additional study was identified utilising viloxazine.
In the protocol we stated that we would contact the first author of each study but due to the practicalities involved we made the
pragmatic decision to contact the corresponding author for each study instead as contact details were more readily accessible and we
considered they would be more likely to have relevant data available.
3. Data collection and analysis
We specified in the protocol that PM and JH would extract data and analyse risk of bias but PM and MP carried out this role when
MP joined the final review.
In the protocol we stated that we would use the equation from the Cochrane manual for relating baseline, change, and endpoint
SD in order to impute the SD for endpoint data where we only have baseline and change scores. However, this was mathematically
underdetermined and we instead substituted the baseline SD as advised in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We continued to utilise the assumption of a 0.5 correlation between baseline and endpoint scores to estimate the SD of change scores
as outlined in the protocol but we were unable to validate this assumption by deriving empirical estimates of the correlation from other
studies as none reported all the relevant values.
It was not clear in the original protocol that we would analyse outcomes based on the duration of the trial as we had also listed these
under subgroup analyses, so we clarified this in the Methods and specified how to handle multiple outcomes within the same duration.
Wemade the post hoc decision to perform subgroup and sensitivity analyses for secondary outcomes as well as for the primary outcomes.
This was because there was limited data available for our primary outcome measures and interpretation of secondary outcomes of
significant interest (e.g. negative symptom scores) was difficult without this.
In the original protocol we had specified that we would only produce a meta-analytic outcome when there were at least three trials
available to combine; however this restriction is the not the usual practice of the Cochrane Schizophrenia Group and after discussions
we agreed to remove this requirement. As a consequence of this decision we added the clarification that subgroup and sensitivity analyses
would only be conducted when there were more than three studies as sensitivity analysis is not meaningful if there are only one or two
trials.
Although we could not determine whether change scores were skewed we were often able to calculate endpoint scores from these and
to estimate the SD which frequently suggested skew. While using the change scores rather than endpoint scores could correct this skew
it was not possible to test this so we made a post hoc decision to perform a sensitivity analysis where we excluded those change scores
which were associated with skewed endpoint scores.
In the protocol we stated that we would produce a ’Summary of findings’ table listing an important specific adverse effect but did not
define what this adverse effect would be. Prior to performing the analysis of adverse effects, we selected ’nausea’ based on the most
common adverse effects listed for reboxetine and atomoxetine in the British National Formulary (BNF 2016).
As we had not specified in advance the duration of studies to include in the ’Summary of findings’ table we made a post hoc decision
to use the analysis with the longest period of follow-up providing there were more than three studies to include for that time period;
otherwise we used the duration which included the most studies. Where there was more than one outcome measure for a time point,
we used the one with the most studies.
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